
































In this thesis I examined the role of circulating monocytes and lung macrophages in the 
pathogenesis of the early fibrotic, progressive fibrotic and resolution phases of 
pulmonary fibrosis. 
 
Pulmonary fibrosis with destruction of lung architecture and consequent respiratory 
failure and death represents a massive worldwide health burden.  Although idiopathic 
pulmonary fibrosis (IPF) is the archetypal and most common cause of lung fibrosis, 
numerous respiratory diseases can progress to pulmonary fibrosis, and this usually 
signifies a worse prognosis.  Importantly, the incidence and prevalence of IPF continue 
to rise and it remains one of the few respiratory conditions for which there are no 
effective therapies. 
 
The mechanisms resulting in pulmonary fibrosis are controversial.  Early work in the 
1980s and 1990s suggested that lung macrophages were important.  However, at the turn 
of the 21st century there was a shift to a belief that pulmonary fibrosis resulted from 
aberrant wound healing as a consequence of repetitive epithelial injury from an as yet 
unknown cause.  However, with the ever expanding knowledge of the importance of 
macrophages in other fibrotic conditions such as the kidney and liver, the potential 
importance of macrophages in pulmonary fibrosis has become more pertinent. 
 
Using an in vivo depletional strategy in several murine models of lung fibrosis, in 
conjunction with human studies, I sought to characterise the role of circulating 
monocytes and lung macrophages in the pathogenesis of pulmonary fibrosis.   
 
I have established that circulating monocytes and lung macrophages are not critical for 
the development of early lung fibrosis.  In contrast, circulating monocytes and lung 
macrophages are important during the progressive fibrotic phase of lung fibrosis.   
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Furthermore, my data suggest that the pro-fibrotic alternatively activated macrophages 
may be the sub-class of macrophages that mediate this fibrogenic effect.  In addition and 
in contrast, I have established that lung macrophages are required for the resolution of 
fibrosis.  This finding is in keeping with important work performed in the field of liver 
fibrosis. 
 
There is an ever increasing literature examining the role of matrix metalloproteinases 
(MMPs) during tissue fibrosis and repair.  My work has suggested that during lung 
fibrosis there may be compartmental specific functions of MMPs that regulate lung 
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AIMS & HYPOTHESIS 
 
It is my hypothesis that circulating monocytes and lung macrophages have an important 
role in the pathogenesis of pulmonary fibrosis.  Using in vivo depletional, add-back and 
add-in experiments I wish to establish whether this is indeed the case.  I aim to use the 
above strategies to investigate at which stages during lung fibrogenesis and fibrosis 
resolution circulating monocytes and lung macrophages may be important.  
Furthermore, I wish to establish whether potentially pro-fibrotic alternatively activated 
macrophages play a role in disease pathogenesis, and by focusing on matrix 
metalloproteinase biology I aim to gain some mechanistic insights.  Finally, by using 
samples from patients with fibrotic lung diseases I aim to establish whether this 
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Fibrotic lung diseases 
 
The human fibrotic lung diseases encompass a variety of specific diseases of different 
underlying aetiologies.  Pulmonary fibrosis affects over 5 million people worldwide 
(Maher et al., 2009) and as such is an enormous health burden.  In 2002 the American 
Thoracic Society (ATS) and European Respiratory Society (ERS) published a consensus 
classification on the idiopathic interstitial pneumonias (IIPs) which they defined within 
the family of diffuse parenchymal lung diseases (DPLDs).  It is within this family of 
DPLDs that the various forms of fibrotic lung disease may be found (American Thoracic 
Society/European Respiratory Society International Multidisciplinary Consensus 
Classification of the Idiopathic Interstitial Pneumonias, 2002) (Figure1.1).  The causes 
of fibrotic lung disease include those associated with collagen vascular disease – 
rheumatoid arthritis, systemic lupus erythematosis (SLE) and systemic sclerosis – the 
granulomatous lung diseases which may progress to lung fibrosis such as sarcoidosis, 
chronic hypersensitivity pneumonitis, occupational lung diseases such as asbestosis and 
silicosis, the adult respiratory distress syndrome (ARDS) and chronic lung infections 
such as tuberculosis.  Within the family of DPLDs the largest subgroup is the IIPs, the 
commonest of which is idiopathic pulmonary fibrosis (IPF).  IPF is the archetypal 


















Figure 1.1.  Classification of the diffuse parenchymal lung diseases.   
 
From:  American Thoracic Society/European Respiratory Society International 
Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.  
Am J Respir Crit Care Med 2002; 165:277-304. 
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Idiopathic Pulmonary Fibrosis  
 
Background 
Idiopathic pulmonary fibrosis is a devastating disease of unknown aetiology.  It has been 
defined as “a specific form of chronic fibrosing interstitial pneumonia limited to the lung 
and associated with the histological appearance of usual interstitial pneumonia (UIP) on 
surgical (thoracoscopic or open) lung biopsy” (American Thoracic Society/European 
Respiratory Society International Multidisciplinary Consensus Classification of the 
Idiopathic Interstitial Pneumonias, 2002).  The term IPF was previously applied to all 
cases of pulmonary fibrosis that did not have a recognised cause. However, as stated in 
its definition, above, it is currently reserved for, and is synonymous with, the 
pathological diagnosis of UIP following lung biopsy (in the absence of another known 
cause of UIP).  The prevalence has been classically quoted as 20.2 cases per 100,000 for 
males and 13.2 cases per 100,000 for females (Coultas et al., 1994), however, this 
appears to be rising and may be as high as 227 per 100,000 among patients aged 75 
years and over (Raghu et al., 2006).  Interestingly and alarmingly the mortality appeared 
to rise by approximately 5% per year between 1993 and 2002 (Olson et al., 2007).  The 
overall prognosis is poor, with a median survival of 3 to 5 years after diagnosis (Khalil 




Accurate diagnosis of IPF is essential in light of the prognostic differences that exist 
between it and the other IIPs.  Clinical diagnosis is currently based on a detailed medical 
history and physical examination.  Most respiratory physicians will be adept at 
recognising the typical symptoms and signs even before proceeding to further 
investigation.  Further investigation is in the form of a chest X-ray, lung function and 
high-resolution computed tomography (HRCT) scanning.  Clinically, IPF is usually 
suspected in any patient over 50 years of age presenting with unexplained dyspnoea on 
exertion that has been present for over 3 months, together with evidence of bibasilar, 
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inspiratory “velcro” crackles on auscultation of the chest.  In addition to at least three of 
these minor diagnostic criteria, patients must meet all four of the major criteria which 
include: 1.) exclusion of other known forms of DPLD; 2.) abnormal lung function tests 
that demonstrate evidence of a restrictive pattern together with reduced gas transfer; 3.) 
bibasilar reticular opacities on HRCT with minimal ground-glass changes; 4.) 
bronchoalveolar lavage (BAL) or transbronchial lung biopsy which does not suggest an 
alternative diagnosis (American Thoracic Society.  Idiopathic pulmonary fibrosis: 
diagnosis and treatment: international consensus statement, 2000).  It is important to 
note that while a normal chest X-ray does not exclude the presence of IPF, radiographic 
evidence of reduced lung volumes, reticular opacities and honeycombing is extremely 
suggestive.  An alternative diagnosis to IPF is usually suggested when there is 
radiographic evidence of lymphadenopathy, alveolar opacification or pleural disease.   
 
IPF typically occurs in people aged over 50 years.  It usually has an insidious onset 
characterised, as already discussed, by unexplained dyspnoea on exertion.  It is often 
accompanied by a non-productive cough that develops over a period of about 3 months 
(Turner-Warwick et al., 1980a).  In most patients IPF will follow a progressive course 
which may lead to peripheral oedema and right heart failure.  The prognosis is poor, 
with mortality approaching 70% at 5 years (du Bois et al., 2007), which is considerably 
worse than the other DPLDs. (American Thoracic Society.  Idiopathic pulmonary 
fibrosis: diagnosis and treatment: international consensus statement, 2000).   
 
Acute Exacerbations of IPF 
The prognosis appears to be significantly worse in patients who develop an exacerbation 
of IPF, defined as “an acute, clinically significant deterioration of unidentifiable cause in 
a patient with underlying IPF” (Collard et al., 2007).  In this group of patients increasing 
dyspnoea usually occurs within a period of 30 days (Akira et al., 1997).  Cough, fever 
and “’flu-like” symptoms may be present (Ambrosini et al., 2003; Kim DS et al., 2006).  
Patients often present with severe hypoxia and discussions regarding the need for 
mechanical ventilation are common.  Increased plasma or serum levels of interleukin 
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(IL)-8 (Ziegenhagen et al., 1998), α-defensins (Mukae et al., 2002) and soluble ST2 
protein (Tajima et al., 2003) suggest that activated T-cells and neutrophils may be 
important during this stage of disease.  In keeping with this an increase in BAL fluid 
(BALF) neutrophils has been reported (Ambrosini et al., 2003; Kim DS et al., 2006).  
Analysis of the data from these studies confirm that there is an increase in neutrophils 
compared with healthy controls, however there is usually also an increase in lymhocytes, 
and moreover it should be noted that macrophages still remain the most populous cell-
type within BAL during exacerbations of IPF.  In addition, as will be discussed later, 




 circulating blood monocytes have been found in 
patients with exacerbations of IPF highlighting the potential importance of this cell 
population (Murray et al., 2010).  In terms of biomarkers, serum neutrophil elastase, 
KL-6 and lactate dehydrogenase have been suggested as possible candidates (Yokoyama 
et al., 1998).  Radiologically, early reports described diffuse ground-glass abnormalities 
on chest X-ray (Kondoh et al., 1993).  HRCT scanning generally demonstrates bilateral 
ground-glass changes with or without areas of consolidation superimposed on the typical 
bibasilar sub-pleural reticular changes, traction bronchiectasis and honeycomb 
abnormalities characteristic of IPF (Akira et al., 1997; Ambrosini et al., 2003; Kim DS 
et al., 2006).  Three HRCT patterns of abnormality have been suggested: peripheral, 
multi-focal and diffuse ground-glass (Akira et al., 1997).  The diffuse and multi-focal 
patterns have been associated with diffuse alveolar damage (DAD) superimposed on 
UIP on surgical lung biopsy.  Degree of CT involvement may be a predictor of survival 
(Akira et al., 1997; Ambrosini et al., 2003; Kim DS et al., 2006).  Treatment has 
generally been in the form of high-dose corticosteroids but no randomised controlled 
trials have been performed.  Cyclosporin A has been used, but no convincing evidence 
of efficacy has come out of those studies (Homma et al., 2005; Okamoto et al., 2006).  If 
an effect on reducing exacerbations of IPF is analysed in patients undergoing treatment 
for IPF per se, then anti-coagulant therapy (with warfarin in the out-patient setting or 
low molecular weight heparin for patients re-hospitalised with severe respiratory failure) 
or anti-fibrotic with pirfenidone have been shown to have the effect of reducing 
exacerbation rate; patients treated with anti-coagulant therapy over a 3 year period had a 
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lower mortality from acute exacerbations than untreated patients (18% versus 71%) 
(Kubo et al., 2005).  Patients treated with pirfenidone had no exacerbations compared 
with untreated patients (Azuma et al., 2005).  It should be noted that the anti-coagulant 
trial was not blinded and had a large differential drop-out rate in the treatment arm, and 




The lack of an efficacious treatment is one of the reasons why the mortality for IPF is so 
dreadful.  It is my belief that this may reflect a fundamental lack of understanding of not 
only the history and course of the disease but the pathogenesis.  A number of completed 
and ongoing trials for patients with IPF have been and are being performed and they are 
summarised in Table 1.1 and Table 1.2, respectively.  A brief run-through of some of the 
trials is now discussed. 
 
As IPF was originally thought to be an inflammatory alveolitis, most of the original 
trials used “anti-inflammatory” agents.  Corticosteroids were one of the first groups of 
drugs to be used.  Many retrospective reviews and case series have been published.  In 
some studies transient objective clinical response was found in a minority of patients, 
but with no survival benefit relative to untreated patients (Turner-Warwick et al., 1980b; 
Mapel et al., 1996; Flaherty et al., 2001a).  However most of the studies were performed 
at a time that pre-dated the 2002 classification statement (American Thoracic 
Society/European Respiratory Society International Multidisciplinary Consensus 
Classification of the Idiopathic Interstitial Pneumonias, 2002) and as such many patients 
who today would not be considered to have IPF would likely have been included in the 
studies.  The data is therefore of dubious quality and a recent systematic review found 
no high-quality prospective trials on which to base any recommendations (Richeldi et 








Table 1.1.  Completed randomised studies of treatment for IPF 
 
From:  du Bois RM.  Strategies for treating idiopathic pulmonary fibrosis. 




Table 1.2.  Ongoing and planned clinical trials for IPF 
 
From:  du Bois RM.  Strategies for treating idiopathic pulmonary fibrosis. 
Nat Rev Drug Discovery. 2010;9(2):129-40. 
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Azathioprine is a purine analogue, converted to mercaptopurine in body tissues, which 
inhibits adenine deaminase.  It is a typical steroid-sparing anti-inflammatory agent.  A  
Cochrane review (Davies et al., 2003) identified two case-controlled or randomised 
controlled trials that evaluated azathioprine (Winterbauer et al., 1978; Raghu et al., 
1991).  Raghu and colleagues compared 13 patients treated with high-dose prednisolone 
and placebo versus 14 patients treated with an identical prednisolone regimen and 
azathioprine. These cases were not explicitly identified as having IPF as currently 
defined; however, the inclusion criteria were similar to what is used today (American 
Thoracic Society.  Idiopathic pulmonary fibrosis: diagnosis and treatment: international 
consensus statement, 2000).  At 1 year, there was no significant difference in clinical 
measures or mortality.  In a secondary analysis adjusted for age, the authors found that 
there was a marginally significant mortality benefit with azathioprine. Of two lesser 
quality, earlier randomised controlled trials performed in a heterogeneous population, 
the study by Winterbauer, mentioned above, showed a marginal benefit of azathioprine.  
They performed a prospective open label uncontrolled trial that followed 20 patients 
with variable forms of IIP that were treated initially with prednisolone followed by 
azathioprine.  Twelve out of the 20 patients had improved their vital capacity (VC) by 
more than 20%, and in the 16 who survived for more than a year there were statistical 
improvements in forced vital capacity (FVC), resting and exercise PaO2.  However, this 
was a heterogeneous cohort of patients and it was an uncontrolled, open label trial.  The 
results must therefore be interpreted with caution.  The study by Fulmer and colleagues 
(Fulmer et al., 1978) was only ever reported in abstract form; they evaluated the effects 
of addition of azathioprine to prednisolone in a randomised, double-blinded, placebo 
controlled fashion.  They concluded that there were no differences in outcome and 
considered azathioprine of no benefit, however there was limited data provided in the 
abstract and again interpretation of results must be with caution.  A limitation of the data 
on azathioprine is the lack of a no-treatment arm.  When the decline in FVC in the 
European Idiopathic Pulmonary Fibrosis International Group Exploring N-acetyl 
cysteine I Annual (IFIGENIA) trial (prednisolone plus azathioprine) is compared to the 
decline in FVC in the placebo arm of the GIPF-001 trial (Raghu et al., 2004), there is no 
 23 
obvious difference.  This suggests that prednisolone plus azathioprine may be no better 
than placebo.  However, comparison between studies has inherent problems, and 
examination of FVC is but one outcome measure.  However, it is an important point to 
highlight and raises many potential questions.   
 
Cyclophosphamide is a cytotoxic agent that has been studied.  The Cochrane review 
referred to earlier (Davies et al., 2003) only included one study assessing the effects of 
cyclophosphamide as worthy of further review.  This study by Johnson and colleagues 
(Johnson et al., 1989), which was only provisionally included, compared prednisolone 
alone with a combination of cyclophosphamide plus low-dose prednisolone in a 
randomised study.  In total 43 patients with previously untreated “fibrosing alveolitis” 
were included.  No distinction was made between patients with UIP/IPF and those with 
other forms of IIP, of which at least 20% were associated with connective tissue disease.  
Among this heterogeneous group, no differences in clinical markers or mortality rates 
were seen, although in a secondary analysis, when time to death or “failure of first 
treatment regimen” was analysed as a single variable, a significant mortality benefit 
emerged.   
 
A number of other novel therapies have also been assessed for effectiveness in treating 
IPF.  The IFIGENIA trial alluded to earlier compared acetylcysteine, an anti-oxidant and 
cellular detoxifying agent, with azathioprine and high-dose prednisolone, to azathioprine 
plus prednisolone.  The rate of decline in FVC (9% relative reduction) and DLco (24% 
relative reduction) at 12 months was significantly reduced in the groups receiving 
acetylcysteine.  No mortality benefit was seen.  These effects, whilst encouraging, are of 
uncertain clinical significance.  Furthermore, as acetylcysteine was added to 
prednisolone and azathioprine, it is difficult to know whether the effects were due to 
acetylcysteine alone, the combination, or in fact whether prednisolone and azathioprine 
may have masked acetylcysteine’s true effects.  The reasons for this assertion will 
become clear later in relation to the potential effects of corticosteroids on macrophage 
activation state.   
 24 
There have now been two large double-blind, placebo-controlled trials assessing the 
effects of interferon-γ-1b on IPF (Raghu et al., 2004; King et al., 2009).  The GIPF-001 
trial (Raghu et al., 2004) assessed the effects of interferon-γ-1b on progression-free 
survival, defined as the time-to-disease-progression, or death, as well as pulmonary 
function and quality-of-life (QoL) in 330 patients with IPF.  Over a median of 58 weeks 
there was a trend towards improvement in the primary-end point of improved survival in 
the interferon group, however among patients with less severe lung impairment at 
baseline there was a significant survival benefit in the interferon group (4% mortality in 
the interferon group versus 12% in the placebo group).  There were however no 
treatment beneficial effects on lung function, gas exchange, or QoL.  As a result of these 
promising effects, the second interferon-γ-1b trial, the (effect of)  interferon-γ-1b on 
survival in patients with idiopathic pulmonary fibrosis (INSPIRE) trial was designed.  
However, this study was stopped prematurely following a planned interim analysis; the 
results showed that after a median duration of 64 weeks on treatment, 80 (of 826 
randomised) (15%) patients on interferon-γ-1b and 35 (13%) on placebo had died.  The 
authors concluded that treatment with interferon-γ-1b cannot be recommended as it 
refuted the sub-group analyses of survival from the GIPF-001 trial.   
 
Etanercept is a soluble tumour necrosis factor (TNF) receptor antagonist that has been 
used to effectively treat rheumatoid arthritis (Moreland et al., 1999).  The trial of 
etanercept was an international randomised, double-blind, placebo-controlled study in 
which 88 patients received etanercept or placebo, and were assessed after 48 weeks for 
change in FVC, DLco, and alveolar-arterial oxygen gradient (Raghu et al., 2008).  No 
changes in the efficacy end-points were observed between the groups.  A non-significant 
reduction in disease progression was seen in several physiologic, functional and QoL 
end-points among patients who received etanercept.  The authors concluded that the 




Colchicine has been shown to block alveolar macrophage release of fibronectin and 
insulin-like growth factor-1 (IGF-1) (Rennard et al., 1988).  It has been utilised in a 
number of clinical studies in patients with IPF, but none have shown a significant 
difference in the rate of decline of lung function or improvement in survival when 
patients were treated with colchicine, with or without corticosteroids (Peters et al., 1993; 
Addrizzo-Harris et al., 1997; Douglas et al., 1997; Selman et al., 1998; Douglas et al., 
1998; Douglas et al., 2000).  The best prospective controlled clinical trial (Douglas et 
al., 1998) demonstrated that colchicine was no more effective than prednisolone when 
the outcomes of survival and pulmonary function were analysed.   
 
Two novel therapies have recently shown some promise.  Bosentan is a dual endothelin 
receptor antagonist (Clozel et al., 1994).  In the randomised, double-blind, placebo-
controlled bosentan use in interstitial lung disease (BUILD-1) trial 158 patients were 
enrolled and received either bosentan or placebo for 12 months (King et al., 2008).  
There was no change in the primary efficacy end-point of 6 minute-walk test between 
the 2 groups.  However, a post-hoc analysis of the data showed that in the patients who 
had a surgical lung biopsy because of atypical HRCT findings and who exhibited very 
limited honeycomb changes, the difference between the 2 groups did reach statistical 
difference.  In addition there was a trend to a reduction in the rate of decline in the 
dyspnoea scores of baseline dyspnoea index and transitional dyspnoea index, as well as 
a trend to reduction in the heath-related QoL index of Medical Outcomes Study Short-
Form 36-instrument and respiratory-specific QoL St. George’s Respiratory 
Questionnaire in the sub-group of patients who required a biopsy.  In the light of these 
results the BUILD-3 trial has just finished enrolling.  This trial will look at the effects of 
bosentan versus placebo in patients with less than 5% honeycombing in at least four of 
six pre-defined lung regions on CT scanning and who required a surgical biopsy to 
confirm the diagnosis.   
 
Pirfenidone is a pyridone compound (Margolin & Lefkowitz 1994) that has come 
through the entire bench-to-bedside process, having been previously investigated in 
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animal models (discussed in more detail in the later section: Models of Pulmonary 
Fibrosis: Bleomycin).  The first report of its possible efficacy in humans was from a 
Phase II study in 1999 in patients with relatively advanced IPF in whom pirfenidone 
appeared to slow decline in lung function and allowed for a reduction and eventual 
discontinuation of corticosteroids in most patients (Raghu et al., 1999).  It has already 
been discussed that in the study by Azuma and colleagues (Azuma et al., 2005) patients 
treated with pirfenidone did not have an exacerbation of their IPF.  It was also shown in 
that study that in a pre-specified subset of patients who maintained an SpO2 of greater 
than 80% during a 6 minute walk test at baseline, the lowest SpO2 improved during a 
repeat test in the pirfenidone group at 6 and 9 months.  Moreover, the rate of decline in 
VC at 9 months was significantly lower in the pirfenidone group.  More recently, the 
study by Taniguchi and colleagues (Taniguchi et al., 2010) demonstrated a reduction in 
the rate of decline in VC in the pirfenidone group.  In addition progression-free survival 
also showed a significant difference between the groups, favouring pirfenidone.  The 
results are compelling; the data from the 2 studies suggests that pirfenidone may slow 
the progression of IPF.  Furthermore, two multi-centre, randomised, double-blind, 
placebo-controlled studies (CAPACITY 1 and CAPACITY 2) have just been completed 
and presented at an international meeting.  As demonstrated in the study by Taniguchi 
and colleagues, the CAPACITY 2 trial confirmed a reduction in the rate of decline of 
FVC in patients treated with pirfenidone after a 72 week treatment period.  There was a 
trend to reduction in the CAPACITY 1 trial.  These trials are encouraging, and it will be 
interesting to see the full results when these trials come to publication. 
 
In summary therefore, a plethora of studies and clinical trials have been performed in 
patients with IPF.  Treatment with broadly acting anti-inflammatory type drugs has 
really shown no benefit, nor has treatment with drugs that have targeted particular 
inflammatory- or fibrosis-related molecules.  Promising results have been shown for 
bosentan whose effects may manifest on the pulmonary vasculature.  It is interesting to 
appreciate that pirfenidone has appeared as an agent with some promise.  As will be 
discussed in more detail later pirfenidone’s mode of action is unclear, but it leads to a 
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reduction in expression of pro-collagen I and pro-collagen III (Iyer et al., 1999a), 
decreases TGFβ  expression in lung and in BALF (Iyer et al., 1999b) and likely has 
effects on alveolar macrophage driven secretion of platelet derived growth factor 
(PDGF) (Gurujeyalakshmi et al., 1999).  It is therefore possibly surprising that 
colchicine has not had any promising effect as its mode of action is to reduce the 
production of fibronectin and IGF-1 from alveolar macrophages (Rennard et al., 1988).  
However it should be pointed out that studies with colchicine were performed prior to 
2002 and therefore pre-date the change in classification of the IIPs.  
 
 It is very possible that the lack of effect of drug therapy reflects our poor understanding 
of the natural history and pathogenesis of this increasingly common disease.  As we 
better understand its process and realise the potential of cell therapy, we may soon be in 




The hallmark of UIP/IPF is temporal heterogeneity (that is, areas of established fibrosis 
interspersed with areas of relatively normal lung, and gradations between these two 
extremes), architectural loss and chronic scarring accompanied by microscopic 
honeycomb-like structural change in the sub-visceral pleural region.  The fibrosis is 
present in the interstitial space (the space between the endothelium and the basement 
membrane, beneath the epithelium), which includes the alveolar walls. Other 
distinguishing features of UIP/IPF include the relative paucity of inflammation, a 
hyperplastic epithelium, and the presence of focal collections of fibroblasts, referred to 
as fibroblastic foci.  This has led some investigators to hypothesise that IPF is a disease 
characterised by repetitive epithelial injury and abnormal repair (Selman et al., 2001). 
The absence of marked inflammatory infiltrates has led to substantial controversy as to 
the role of inflammation in IPF. This absence of inflammation does not, however, 
exclude a role for inflammation in the initiation of the injury that subsequently leads to 
fibrosis (Gauldie 2002; Strieter 2002).   
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Furthermore, the origin and importance of fibroblastic foci is controversial.  Some 
investigators believe that fibroblastic foci are the areas where active early aberrant 
wound repair and matrix deposition occur (Katzenstein 1998), and they have been 
shown to be independent predictors of lung function and mortality in IPF (King et al., 
2001).  It has recently been suggested that they are not discrete foci but in fact represent 
an organised reticulum that courses through the lung (Cool et al., 2006).  Interestingly, 
this reticulum is surrounded by an extensive capillary network, which suggests that 
vascular remodeling is an important component of pulmonary fibrosis (Cool et al., 
2006). 
 
Within these foci are fibroblasts and myofibroblasts.  Whatever the initial insult that 
results in the generation of these foci, many investigators believe that it is predominantly 
these cells that are responsible for the deposition of matrix and remodelling that is seen 
in the lungs.  These cells are believed to arise from at least three potential sources 
(Figure 1.2): Trans-differentiation of resident fibroblasts into myofibroblasts (Zhang et 
al., 1994), recruitment of blood-borne fibrocytes (Abe et al., 2001; Phillips et al., 2004) 
or bone-marrow derived progenitor cells (Hashimoto et al., 2004), or trans-
differentiation of resident epithelial or endothelial cells to fibroblasts/myofibroblasts, so 
called epithelial-mesenchymal transition (EMT) (Willis et al., 2005; Kim et al., 2006) 
and endothelial-mesenchymal transition (Hashimoto et al., 2009), respectively.  This 
will be discussed in more detail later in this section.  Interestingly, fibrocytes may be an 
independent predictor of early mortality in IPF (Moeller et al., 2009). 
 
The predominant hypothesis regarding the pathogenesis of pulmonary fibrosis centres 
around the epithelial injury hypothesis in which fibrosis is believed to result from 
epithelial injury, activation and/or apoptosis, with subsequent abnormal wound healing 
(in the absence of chronic inflammation) (Selman et al., 2001; Selman et al., 2004).  
This hypothesis suggests that recurrent unknown injuries to distal lung causes repeated 
epithelial injury and apoptosis.  There is a consequential loss of alveolar epithelial cells 
which exposes the basement membrane to oxidative damage and degradation.  Evidence 
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for this theory has been established using the bleomycin model of pulmonary fibrosis 
which results in alveolar epithelial cell injury, apoptosis and necrosis (Hagimoto et al., 
1997; Li et al., 2003).  Inhibiting apoptosis reduces collagen deposition and fibrosis 
(Wang et al., 2000).  Furthermore in response to bleomycin-induced injury, fibrosis is 
reduced in the absence of the pro-apoptotic protein Bcl-2 homology (BH3) interacting 
domain death agonist (BID) despite similar levels of inflammation, injury and active 
transforming growth factor-β1 (TGFβ) in BALF (Budinger et al., 2006).  Moreover, 
there is immunohistochemical evidence of increased expression of pro-apoptotic 
proteins in the alveolar epithelium of patients with IPF (Plataki et al., 2005).    
 
The precise process by which alveolar epithelial cells become activated and 
communicate with fibroblasts to induce collagen deposition and fibrosis is poorly 
understood.  However, various explanations have been suggested.  The first involves the 
production of fibroblast chemotactic factors by activated alveolar epithelial cells and the 
release of growth factors involved in re-epithelialisation.  Candidate growth factors 
include TGFβ1, PDGF, IGF-1 and endothelin.  Alveolar epithelial cells may regulate the 
activity of TGFβ1 via the effects of the αvβ6 integrin; Munger and colleagues 
demonstrated that the integrin αvβ6 binds to the TGFβ latency associated peptide with 
resultant activation of TGFβ (Munger et al., 1999).  In addition they showed that β6 null 
mice display exaggerated inflammation but are protected from pulmonary fibrosis in 
response to bleomycin.  This suggests that when the alveolar epithelium becomes injured 
and the basement membrane loses its integrity, it will attempt to re-epithelialise with 
release of growth factors that may recruit fibroblasts or myofibroblasts.  If there is no 
way of regulating the process, then myofibroblast proliferation and extra-cellular matrix 
deposition may continue unabated. 
 
Another potential explanation is that the epithelium trans-differentiates into 
fibroblasts/myofibroblasts, effectively bypassing the need to release fibroblast mitogens, 







Figure 1.2.  Origins of myofibroblasts in pulmonary fibrosis.   
 
From:  Scotton CJ & Chambers RC.  Molecular Targets in Pulmonary Fibrosis: The 
Myofibroblast in Focus.  Chest 2007;132:1311-21. 
 
Abbreviations: IL-13=interleukin-13; FIZZ1=Found in inflammatory zone 1 (RELM-α, resistin-like molecule-α); 
TGFβ=transforming growth factor-β; CTGF=connective tissue growth factor; PDGF=platelet-derived growth factor; 
CXCL12=chemokine (C-X-C motif) ligand 12; GC1008=human anti-TGFβ monoclonal antibody (MAb); FG-
3019=anti-CTGF MAb; SD208=TGFβ receptor 1 kinase inhibitor; gleevec=imatinib, a tyrosine kinase inhibitor. 
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Interestingly the main inducers of EMT can also promote apoptosis, suggesting that 
EMT could potentially serve as a pathway for escape from cell death depending on the 
particular cytokine milieu (Anderson et al., 1994; Nicolás et al., 2003).  EMT is 
supported by data from several studies.  Willis and colleagues analysed the effects of 
chronic exposure to TGFβ1 on the phenotype of isolated rat alveolar epithelial cells.  In 
addition, tissue samples from patients with IPF were evaluated for cells co-expressing 
epithelial (thyroid transcription factor (TTF)-1 and pro-surfactant protein-B (pro-SP-B)) 
and mesenchymal (α-smooth muscle actin (α-SMA)) markers.  Cells exposed to TGFβ1 
for 6 days demonstrated increased expression of mesenchymal cell markers with a 
fibroblast-like morphology.  In addition TGFβ1 resulted in increased expression of α-
SMA, type I collagen, vimentin, and desmin, with associated transition to a fibroblast-
like morphology and decreased expression of TTF-1.  Cells co-expressing epithelial and 
mesenchymal markers were abundant in lung tissue from patients with IPF.  These 
results suggested that alveolar epithelial cells undergo EMT when chronically exposed 
to TGFβ1, raising the possibility that epithelial cells may serve as a novel source of 
myofibroblasts in IPF.  These results were somewhat corroborated and taken further by 
the study by Kim and colleagues (Kim KK et al., 2006).  They generated mice 
expressing β-galactosidase exclusively in lung epithelial cells and followed their fates in 
the adenoviral transforming growth factor-β (AdTGFβ) model of pulmonary fibrosis.  β-
galactosidase-positive cells expressing mesenchymal markers accumulated within 3 
weeks of lung injury. Furthermore, the increase in vimentin-positive cells within injured 
lungs was nearly all due to β-galactosidase-positive cells, implicating epithelial cells as 
the main source of mesenchymal expansion in this model.  Ex vivo, primary alveolar 
epithelial cells cultured on provisional matrix components, fibronectin or fibrin, 
underwent EMT via integrin-dependent activation of endogenous latent TGFβ1.  In 
contrast, primary cells cultured on laminin-collagen mixtures did not activate the TGFβ1 
pathway and when exposed to active TGFβ1 underwent apoptosis rather than EMT. 
These data provide further evidence for the role of EMT during lung fibrosis and 
implicate the provisional extracellular matrix as a key regulator of epithelial 
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transdifferentiation during this process.  The same group has since gone on to 
demonstrate that the α3β1 integrin appears to link β-catenin and Smad signaling to 
promote myofibroblast formation and pulmonary fibrosis (Kim KK et al., 2009).   
 
While EMT may provide an explanation for epithelial-mediated production of 
fibroblasts/myofibroblasts, it does not complete the story in terms of myofibroblast 
genesis.  Endothelial-mesenchymal transition has been proposed as another mechanism 
for the generation of myofibroblasts (Arciniegas et al., 2005).  The study by Hashimoto 
and colleagues (Hashimoto et al., 2009) has suggested that endothelial-mesenchymal 
transition may occur in pulmonary fibrosis.  Using Tie2-Cre/CAG-CAT-LacZ double-
transgenic mice, in which LacZ was stably expressed in pan-endothelial cells, 
pulmonary fibrosis was induced by bleomycin administration.  Combined X-gal staining 
and immunocytochemical staining for type I collagen and α-smooth muscle actin 
revealed the presence of X-gal positive cells in lung fibroblast cultures from bleomycin-
treated mice.  These findings are the first to show that lung capillary endothelial cells 
could give rise to significant numbers of fibroblasts through an endothelial-
mesenchymal transition in the bleomycin-induced model of lung fibrosis. 
 
The other major source of myofibroblasts, as briefly mentioned previously, is 
differentiation from pre-existing peri-vascular and peri-bronchial adventitial fibroblasts 
as well as from submesothelial regions (Figure 1.2).  Zhang and colleagues 
demonstrated that mature fibrotic foci had expanded from their initial localisation within 
these areas (Zhang et al., 1994).  The ability, per se, of fibroblasts to differentiate into 
myofibroblasts has been shown in vitro; Oda and colleagues established that 
myofibroblasts and dermal fibroblasts secret similar types of pro-collagen into culture 
media and that these were predominantly pro-collagen I and pro-collagen III (Oda et al., 
1988).  As a result they proposed that while a myofibroblast has properties of both 
fibroblasts and smooth muscle cells, it is likely that they are produced by differentiation 
of fibroblasts.  Desmouliere and colleagues subsequently demonstrated that a population 
of rat and human fibroblasts expressed α-SMA (Desmoulière et al., 1992a).  Even after 
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cloning they never found a population of cells that were negative for α-SMA, 
confirming that the myofibroblasts were indeed differentiated from fibroblasts, rather 
than arising as a result of contamination.  Furthermore they demonstrated that interferon-
γ (IFN-γ ) lead to a reduction in α-SMA expression as determined by sodium-dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting.  The 
same group confirmed that myofibroblasts can be produced from fibroblasts in further 
studies where they showed that heparin induces the differentiation of fibroblasts into 
myofibroblasts (Desmoulière et al., 1992b). 
 
Circulating fibrocytes are believed to be the other major source of myofibroblasts during 
pulmonary fibrosis (Figure 1.2).  They were originally identified by Bucala and 
colleagues (Bucala et al., 1994) as cells likely derived from hematopoietic stem cells 






.  A potential pathogenic role for 
fibrocytes in IPF has been postulated from experimental models in which blockade of 
fibrocyte recruitment is protective following experimental induction of lung fibrosis 







.  They demonstrated that fibrocytes migrate to the 
lung following bleomycin administration to mice, and in response to CXCL12.  
Furthermore, they established that administration of specific CXCL12 neutralising 
antibodies reduced pulmonary fibrosis, implicating circulating fibrocytes as contributors 





 fibrocytes express CCR2, that lung fibrocytes migrate in culture in 
response to CCL2, and that CCR2-null mice have less recruitment of these cells in 
response to fluorescein isothiocyanate (FITC)-induced pulmonary fibrosis.  Moreover, 
adoptive transfer of bone-marrow from wild-type mice to CCR2-null mice exposed to 
lethal irradiation, followed by FITC-induced pulmonary fibrosis, demonstrated that the 
fibrotic phenotype was restored.  The potential importance of fibrocytes in IPF in 
predicting outcome has recently (and previously) been described (Moeller et al., 2009).  
However, evidence that fibrocytes are capable of differentiating into fully activated 
myofibroblasts, especially in patients with IPF, is still lacking. 
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More recently, however, classical descriptions of the sources of myofibroblasts have 
been questioned.  Tanjore and colleagues have recently attempted to quantify the relative 
contribution of EMT and bone-marrow-derived circulating precursors to the production 
of fibroblasts and myofibroblasts (Tanjore et al., 2009).  Using cell fate reporter mice 
that had pulmonary fibrosis induced by bleomycin they established that approximately 
one-third and one-fifth of fibroblasts had arisen as a result of EMT or were derived from 
bone-marrow precursors, respectively.  However they established that EMT and 
circulating bone-marrow derived precursors were a minor source of lung myofibroblasts.  
The role of fibroblasts/myofibroblasts in the promotion of pulmonary fibrosis continues 
to be elucidated, but it is clear that much work will be required before a clear 
understanding of the sources, function and interactions of these interesting cells is 




















Models of pulmonary fibrosis 
 
Bleomycin 
The bleomycin model of pulmonary fibrosis is the best characterised model of lung 
fibrosis.  Bleomycin sulphate is a mixture of glycopeptide antibiotics isolated from a 
strain of Streptomyces verticillus, and is comprised primarily of A2 (approximately 70%) 
and B2 (approximately 30%) (Kross et al., 1982) sub-types.  It causes oxidant-mediated 
DNA damage (Chen et al., 2008) leading to pulmonary fibrosis (Adamson & Bowden 
1974).  Pulmonary toxicity is dose dependent but there is minimal myelosuppression or 
immunosuppression (Cooper et al., 1986).   
 
Bleomycin was first given to animals in experimental form by Robert Fleischman and 
colleagues (Fleischman et al., 1971).  They administered bleomycin intravenously to 
dogs (beagles) every fourth day for 11 or 31 treatments depending on the dose 
administered.  A high and a low dose regimen were employed.  Ten dogs were treated.  
Three became moribund; two treated with the higher dosing schedule became unwell on 
day 38 and 70, and one treated with the lower dosing schedule became unwell on day 
137.  All dogs developed microscopic evidence of a focal and confluent interstitial 
pneumonia with a sub-pleural localisation.  Gross pulmonary lesions were only apparent 
in dogs treated for more than 70 days.  Additional histopathological features were 
interstitial fibrosis, marked hyperplasia and metaplasia of type II pneumocytes, focal 
hyperplasia of pleural mesothelium and a pleomorphic inflammatory infiltrate.  Deeper 
parenchymal areas had no evidence of lung injury or fibrosis.  Adamson and Bowden 
went on administer bleomycin intra-peritoneally to mice, with the aim of using it as a 
model of pulmonary fibrosis: “The consistency and rapidity with which pulmonary 
fibrosis is induced by bleomycin administration to animals suggests that this 
experimental method provides a suitable model for the investigation of pulmonary 
fibrosis in man” (Adamson & Bowden 1974).  As a dose finding experiment they gave 
between 0.01mg and 1mg.  Mortality was 10% for doses of 0.02mg and 0.04mg, 60% 
for 0.1mg, 30% for 0.5mg and 100% for 1mg.  As a result of the dose finding 
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experiment they subsequently went on to give thirty mice 0.5mg twice weekly for four 
weeks.  Groups of three mice were culled weekly during the injection period and at two-
weekly intervals thereafter up to a total of twelve weeks.  The earliest microscopic 
abnormality was detected at two weeks and involved the endothelium and the pulmonary 
vasculature.  The first alveolar abnormalities were detected at four weeks and included 
necrosis of type I pneumocytes (with no effect on type II pneumocytes).  Intra-alveolar 
and septal fibrosis were also present at four weeks and became more severe and 
progressive with increasing time.  The changes became extensive by eight to twelve 
weeks.  Bleomycin was subsequently given to pheasants (Bedrossian et al., 1977), 
baboons (McCullough et al., 1978), hamsters (Snider GL et al., 1978a; Snider GL et al., 
1978b), rats (Thrall et al., 1979), guinea pigs (Upreti et al., 1979) and rabbits (Laurent et 
al., 1981). 
 
An advantage of the bleomycin model is that it causes inflammatory and fibrotic 
reactions within a short period of time, this being more pronounced for the intra-tracheal 
method of administration.  The “first” phase of bleomycin lung injury is that of 
inflammation and this is followed by the “progressive fibrotic” phase.  In a 21 day 
model in rats this switch from inflammation to fibrosis has been scrutinised in some 
detail (Chaudhary et al., 2006).  The authors established that during the inflammatory 
phase there is up-regulation in gene expression of pro-inflammatory cytokines such as 
IL-1, TNF-α, IFN-γ and IL-6.  This is followed by up-regulation in gene expression of 
the markers of fibrosis TGFβ, pro-collagen I and fibronectin.  In their 21 day model the 
switch from inflammation to fibrosis occurs around day 9.   
 
The bleomycin model has contributed significantly to our understanding of aspects of 
the pathogenesis of pulmonary fibrosis.  Notably, it has allowed for better understanding 
of the role played by TGFβ during pulmonary fibrosis (Zhao et al., 2002).  In their 
paper, Zhao and colleagues established that there was reduced pulmonary fibrosis, 
following bleomycin administration, in Smad3-null mutant mice as determined by 
histology and hydroxyproline content (hydroxyproline content being a quantifiable 
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indicator of the degree of pulmonary fibrosis).  Furthermore there was a reduction in 
gene expression of pro-collagen I and fibronectin in the null mutants compared to wild-
type.  Smad3 is known to be an intra-cellular mediator of TGFβ signalling (Zhang et al., 
1996).  Other groups have shown using the bleomycin model that inhibition of the 
activity of TGFβ by antibodies (Giri et al., 1993), endogenous antagonists (Giri et al., 
1997; Kolb et al., 2001) or soluble TGFβ receptors (Wang et al., 1999) results in a 
reduction in pulmonary fibrosis.  The bleomycin model has also been used to elucidate 
mechanisms of TGFβ activation in vivo; within the extra-cellular matrix TGFβ often 
exists as part of the large latent complex (LLC), which is composed of TGFβ  its 
inhibitory molecule the latency associated peptide (LAP), and the latent TGFβ-binding 
protein.  As part of this complex, TGFβ is rendered latent, or inactive (Munger et al., 
1999).  As mentioned earlier, Munger and colleagues demonstrated that the TGFβ-LAP 
is a ligand for the integrin αvβ6, that αvβ6 activates TGFβ, and that β6 null mice are 
protected from bleomycin-induced pulmonary fibrosis.  Horan and colleagues 
subsequently showed that bleomycin-induced pulmonary fibrosis is reduced, as 
measured by hydroxyproline quantification, when a monoclonal antibody against the 
αvβ6 integrin is given during the progressive fibrotic phase of bleomycin injury (Horan 
et al., 2008). 
 
Pirfenidone has “recently” emerged as a potentially promising drug for treatment of IPF 
(Raghu et al., 1999; Taniguchi et al., 2010; Collard 2010).  Its therapeutic potential has 
been discussed earlier.  The promising effects of pirfenidone were initially identified 
using the bleomycin model.  Work from Shri Giri’s group established that feeding 
pirfenidone to hamsters during bleomycin-induced pulmonary fibrosis lead to a 
reduction in fibrosis as measured by hydroxyproline quantity (Iyer et al., 1995; Iyer et 
al., 1998) or pulmonary function (Schelegle et al., 1997).  They demonstrated that its 
effects were partly due to down-regulation in gene expression of pro-collagen I and pro-
collagen III (Iyer et al., 1999a), and partly due to effects on TGFβ; hamsters given 
bleomycin and subsequently fed pirfenidone demonstrated a reduction in lung gene 
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expression of TGFβ and reduction in TGFβ in the BALF (Iyer et al., 1999b).  Further 
work established that pirfenidone inhibited synthesis of the PDGF A-and B- isoforms as 
measured in BALF of hamsters treated with bleomycin (Gurujeyalakshmi et al., 1999).  
Interestingly, alveolar macrophages secrete more PDGF in patients with IPF compared 
to normal controls (Martinet et al., 1987).  More recent work suggests that pirfenidone 
may also work by inhibition of TGFβ-stimulated production of heat-shock protein 47 
(HSP47), a collagen-specific molecular chaperone (Nakayama et al., 2008). 
 
It is recognized that there exists strain variability in response to bleomycin (Schrier et 
al., 1983) and that this is likely due to strain-specific differences in expression of the 
inactivating enzyme bleomycin hydrolase (Sebti et al., 1989).  Depending on the source, 
dose given, age and strain of mice, fibrosis may peak as much as 2 months after initial 
bleomycin instillation (Chua et al., 2007; Cabrera et al., 2007).  Although some studies 
have suggested the presence of differences between the late chronic stages of animal 
pulmonary fibrosis and features of the human disease (Borzone et al., 2001), the 
bleomycin model undoubtedly represents an invaluable tool to dissect out the 
mechanisms of pulmonary fibrosis and with which to test in vivo molecular agents 
involved in the pathogenesis of pulmonary fibrosis (Chua et al., 2005; Moeller et al., 
2008; Moore & Hogaboam 2008).  It is well characterised, reproducible and has clinical 
relevance. 
 
 Adenoviral transforming growth factor-β model of lung fibrosis 
Over-expression of TGFβ by use of an adenovirus construct containing porcine TGFβ1 
(AdTGFβ) has been shown to induce pulmonary fibrosis in mice and rats (Sime et al., 
1997; Warshamana et al., 2002).  The recombinant adenovirus vector is deleted in the 
E1 and E3 regions.  E1 is indispensable for viral propagation; E1-deleted adenoviruses 
are therefore replication incompetent (Graham et al., 1977).  E1-deleted adenoviruses 
can be grown in 293 cell lines that have been transformed by the E1 region such that 
they supply the required replication proteins (Bramson et al., 1995).  The E3 region is 
required for viral persistence as a result of interactions with major histocompatiability 
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complex (MHC) class I proteins (Routes & Cook 1990).  It is non-essential for viral 
growth, and as a result can be removed from E1-deleted adenoviral constructs to allow 
for the insertion of large inserts (Bett et al., 1994).  The TGFβ insert contains a mutation 
of cysteine to serine at positions 223 and 225, rendering the expressed TGFβ1 
biologically active (Sime et al., 1997).  Control virus (AdDL70-3) was constructed as 
previously described (Bett et al., 1994); it is deleted in E1 and E3, with no additional 
insert, and thus is an “empty” vector.  In this model transgene expression is not 
significant after day 14 and as such the fibrogenic process initiated by TGFβ over-
expression becomes self-perpetuating, a feature of IPF.  Furthermore the 
histopathological characteristics of this model are extensive and persistent fibrosis, 
beginning in the peri-vascular and peri-bronchial areas, but quickly becoming 
widespread throughout the lung interstitium, extending up to the pleural surface (Sime et 
al., 1997).  There is less inflammation than in the bleomycin model and some 
researchers believe that this model may mirror more closely the human form of the 
disease, IPF, and as a result may warrant further use as a model of lung fibrosis.  
 
Silica 
Administration of silica to induce experimental lung fibrosis has been used in rats (King 
et al., 1953; Goldstein & Webster 1966), guinea pigs (Schepers et al., 1957; Dauber et 
al., 1980) and mice (Hatch et al., 1984).  Silica has the advantage that it induces lung 
fibrosis that has associated fibrotic nodules resemblant of those seen in humans exposed 
to occupational dusts, and the model is of a more persistent nature than other models of 
lung fibrosis (Davis et al., 1998).  However, fibrosis can take 12-16 weeks to develop 
(Davis et al., 1998) and probably needs at least 8 weeks (Barbarin et al., 2005).  
Different strains of mice exhibit variable responses to silica with BALB/c mice being 
resistant (Davis et al., 1998) and if aerisolisation is needed then special equipment is 
required due to the potential toxicity to humans.  Furthermore, in specific relation to my 
studies, silica is known to be toxic to macrophages (Heppleston 1969; Civil & 
Heppleston 1979).  If I had used silica as my model of lung fibrosis, then the mere act of 
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producing the model would have confounded any interpretation of the results, and for 
this reason this model was not used in this thesis. 
 
Fluorescein isothiocyanate (FITC) 
The FITC model of lung fibrosis was first described by Roberts and colleagues (Roberts 
et al., 1995).  FITC induces lung fibrosis that typically develops around 14-28 days 
(Christensen et al., 1999) but may occur over several months (Roberts et al., 1995), and 
does not appear to be self-limiting (Fisher et al., 2005); it has clinical relevance (Roberts 
et al., 1995) and there appear to be no strain-resistant mice (Christensen et al., 1999).  In 
addition it allows direct visualisation of the areas of the lung where collagen deposition 
occurs when immunofluorescence imaging for the characteristic green color of FITC is 
performed.  However, the effective dose of FITC required to induce lung fibrosis is 
particularly LOT dependent (Moore et al., 2008), and as such there is much variability 
and no consistent reproducibility when using this model.  Furthermore, from a practical 
point of view the solution of FITC to be administered has to be made fresh each day and 
must be vortexed before each instillation.  This raises concern as to the consistency of 
fibrosis induced by each administration; add to this the variability of lung fibrosis that 
arises due to LOT variability and there appear several reasons to be wary of the 
consistency and reproducibility of this model.  This is compounded by the fact that this 
model has no direct clinical relevance to human pulmonary fibrosis, and for these 
reasons this model was not used. 
 
Irradiation-induced lung fibrosis 
Pulmonary fibrosis may be induced by irradiation of mice either in the form of total 
body irradiation which takes at least 20 weeks to develop (McDonald et al., 1993), or by 
using lead-shielding techniques that ensure that only the thoracic cavity is exposed to 
irradiation; in this form of injury fibrosis takes at least 24 weeks to develop (Johnston et 
al., 1998; Rube et al., 2000).  This model has the advantage that there is some clinical 
relevance.  However, there are obvious draw-backs to the length of time it takes for 
fibrosis to develop and in using a protocol that irradiates the whole body there will 
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undoubtedly be confounding effects on other parts of the body, in particular on the bone 
marrow.  Furthermore, there is strain-variability in the response to injury (Franko et al., 
1996; Sharplin & Franko 1989), C3H/HeJ and CBA/J mice being fibrosis resistant and 
C57Bl/6 mice being fibrosis-prone.  Moreover, in C57Bl/6 mice fibrosis may take up to 
33 weeks to develop (Haston & Travis 1997) incurring extremely large costs even before 
any interventions or analysis are performed, and with all of these considerations in mind 
I did not use this model in any of my studies. 
 
Miscellaneous 
Many other models of “lung fibrosis” have been employed which include the Fas ligand- 
induced model (Matute-Bello et al., 2001), haptenic antigens (such as immune induced 
by a recall cell-mediated immune response against the hapten 2,4,6-trinitrobenzene 
sulphonic acid (TNBS)) (Zhang-Hoover et al., 2000), murine γ-herpes virus 68-induced, 
vanadium pentoxide-induced (Bonner et al., 1998) and many more.  However, their 
mechanism of action is often poorly understood, they are generally not as well 
characterised as the bleomycin and AdTGFβ models, and they have questionable clinical 
relevance: for these reasons they were not used. 
 
Reversibility of lung fibrosis 
Attempts have been made to produce “new” reversible models of pulmonary fibrosis.  
For example, administration of adenoviral-connective tissue growth factor (AdCTGF) 
induces a reversible lung injury when given to mice (Bonniaud et al., 2003; Bonniaud et 
al., 2004).  This model has the advantage that fibrogenesis is indeed transient, however 
uncertainty has been raised as to whether this is genuine model of lung fibrosis as there 
is no up-regulation of TIMP1, a characteristic marker of fibrosis activity.  The 
bleomycin model of pulmonary fibrosis, as has already been discussed, is the best 
characterised model of lung fibrosis.  It has been known for some time that this model 
may be self-limiting (Izbicki et al., 2002), and indeed previous studies have 
demonstrated that fibrosis is starting to reverse after 6 weeks and has resolved by 9 
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weeks (Lawson et al., 2005) making it a good model in which to interrogate the 
resolution phase of pulmonary fibrosis.  
 
In summary, therefore, there exist many models of pulmonary fibrosis, each of which 
has advantages and disadvantages.  It is clear that some models are more reproducible 
and of better clinical relevance.  In examining all of the differences that exist, I aimed to 
use models with direct clinical relevance, that are clearly practical and reproducible, and 
that have been well characterised so as to ensure that any criticism of the results would 
focus on the results per se, rather than any inherent problem with the model itself.  For 
this reason I decided to use the bleomycin and AdTGFβ models to investigate the role of 
monocytes and macrophages during lung fibrogenesis, and the bleomycin model to 





The alveolar macrophage stands as the “guardian” of the alveolar–blood interface, 
serving as the front line of cellular defence against respiratory pathogens (Sibille & 
Reynolds 1990). Alveolar macrophages are the primary phagocytes of the innate 
immune system, clearing the alveoli of infectious, toxic, or allergic particles that have 
evaded the mechanical defences of the respiratory tract.  Alveolar macrophages function 
as regulators of alveolar defence against respiratory infection (Dockrell et al., 2003; 
Dockrell & Whyte 2006) and have an equally important role in resolving inflammation 
within the airspace (Haslett 1999; Gilroy et al., 2004; Marriott et al., 2006). 
 
Alveolar macrophages attempt to keep their environment relatively quiescent by down-
regulating immune responses (Holt 1986).  It is believed they can subsequently adapt 
their activity to mount an immune response when required (Lambrecht 2006).   
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Initial studies suggested that local proliferation of precursors was the main source of 
alveolar macrophages under normal conditions; studies in radiation bone-marrow 
transplant chimera mice found that if a radiation protocol that is less toxic to lungs was 
used (while having the same effect on bone marrow), then most alveolar macrophages 
were of host origin almost 1 year after treatment (Tarling et al., 1987).  More recently 
studies using bone marrow chimeric CD45.2 mice that were generated by lethal 
irradiation of CD45.2 alloantigen-expressing recipient mice and bone marrow 
transplantation from CD45.1 alloantigen-expressing donor mice, confirmed that in 
resting steady state conditions resident alveolar macrophages (of untreated chimeric 
CD45.2 mice) are very slowly replaced, however in this instance by constitutively 
immigrating CD45.1 positive monocytes.  Replacement occurred at a rate of 40% by 1 
year (Maus et al., 2006).  However, after treatment with Escherichia coli endotoxin 
lipopolysaccharide (LPS) more than 85% of the resident CD45.2 positive alveolar and 
interstitial macrophages were exchanged by donor CD45.1-expressing macrophages 
within 2 months (Maus et al., 2006).   The same group showed using similar techniques 
that following infection with Streptococcus pneumoniae, 80% of alveolar macrophages 
were replaced by donor cells after 7 days (Taut et al., 2008).  Another study 
demonstrated that in the resting steady state after whole-body irradiation and transfer of 
green fluorescent protein (GFP)-labelled bone marrow, host alveolar macrophages were 
replaced with cells of donor origin (74.5% of total bronchoalveolar lavage cells were of 
donor origin by 60 days and 80.4% by 90 days) (Matute-Bello et al., 2004).  The 
differences in the studies likely reflect differences in methodology with respect to the 
quantity and dosing schedule of radiation, the radiation type, and the methods employed 
to detect cellular turnover.  It is likely that alveolar macrophage turnover is stimulus 
dependent, and it is clear that alveolar macrophages can be replaced by recruited 
macrophage precursors.  A possible mechanism by which this occurs is highlighted by 
work suggesting that alveolar macrophages originate from blood monocytes and that the 
process requires a lung-resident intermediate (Landsman & Jung 2007). This idea was 
originally proposed by Bowden and colleagues (Bowden et al., 1969); they suggested 
that alveolar macrophages originate from a pulmonary interstitial cell precursor 
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(Bowden et al., 1972). Landsman and Jung proposed that the generation of alveolar 
macrophages involves the differentiation of blood monocytes into macrophages in the 
lung parenchyma, proliferative expansion of these cells, and their emigration into the 
alveolar space. In such a scenario, lung interstitial macrophages may serve as a local 
reservoir from which alveolar macrophages can be generated when needed. 
 
Several studies have attempted to phenotype the different sub-populations of pulmonary 







 (Strauss-Ayali et al., 2007).  Depletion of lung CD11c
+
 cells 
(macrophages and dendritic cells) results in subsequent repopulation of the murine 




Ly6Clo (CD14+CD16+ in humans) blood monocyte subpopulation (Landsman et al., 




 lung macrophages has also been 
described (Kirby et al., 2006), and as such the distinction between lung macrophages 
and dendritic cells may not be as straightforward as at first glance. 
 
 
Macrophage activation states 
 
Recent work by many groups has shown the heterogeneity that macrophages exhibit, 
culminating in an attempt to categorise macrophages into subtypes, or activation states, 
according to protein and RNA expression patterns, function, and the stimuli required to 
induce these activation states (Wynn 2004; Gordon & Taylor 2005). 
 
Several activation states have been described: 
 
Classically activated or M1 macrophages develop in response to stimulation with IFN-γ 
and LPS (Adams 1989).  IFN-γ is predominantly secreted by CD8+ cytotoxic T-
lymphocytes, antigen-presenting cells, natural killer (NK) cells, and to a lesser extent by 
B cells.  LPS is the major component of the outer membrane of Gram negative bacteria.  
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It binds to the serum protein LPS-binding protein (LBP) and is transferred to the 
myeloid marker antigen, CD14, at the cell surface.  LPS then interacts with toll-like 
receptor 4 and its accessory protein MD2 (Guha & Mackman 2001) and stimulates the 
activation of various mitogen-activated protein kinase (MAPK) pathways such as the 
extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 
pathways.  M1 macrophages display widespread morphology depending on their tissue 
location, but are typified by the production of pro-inflammatory cytokines such as IL-
1β, TNFα and IL-12 (Trinchieri et al., 2003).  They also secrete the chemokines CCL15, 
CCL20 (macrophage inhibitory protein-3α (MIP-3α)), CXCL13, and the angiostatic 
IFN-γ-responsive chemokines CXCL9, CXCL10/IP-10, and CXCL11 that are known to 
co-ordinate NK and T-helper 1 cell recruitment in type I immune responses through their 
activity on CXCR3 (Mantovani et al., 2004; Strieter et al., 2005a; Strieter et al., 2005b; 
Martinez et al., 2006).  Furthermore, M1 macrophages display elevated levels of 
expression of MHC class II and co-stimulatory molecules CD80 and CD86, as well as 
low levels of Fcγ RII (Boehm et al., 1997).  Functionally, M1 cells are characterised by 
enhanced endocytosis and an enhanced ability to kill intracellular pathogens (Mosser & 
Handman 1992).  This increased microbicidal activity is mediated by different 
mechanisms such as restriction of iron and other nutrients, acidification of the 
phagosome (Carlin et al., 1989; Gruenheid & Gros 2000), and release of nitric oxide 
(NO) from L-arginine by virtue of iNOS activity, a macrophage specific IFN-γ-inducible 
isoform of NO synthase (MacMicking et al., 1997), and a marker of M1 macrophage 
activation.  
 
Macrophages can also be activated by direct recognition of microbial pathogen-
associated molecular patterns, such as LPS, through germ-line encoded pattern 
recognition receptors (PRR) (Janeway & Medzhitov 2002), such as toll-like receptors 
(TLRs) and nucleotide oligomerisation domain (NOD) receptors (Mukhopadhyay & 
Gordon 2004).  This activation phenotype has been referred to as innate activation 
(Mukhopadhyay et al., 2006) and resembles M1 activation to a certain extent, as it is 
characterised by secretion of pro-inflammatory cytokines, such as IL-1β and TNFα, and 
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increased expression of co-stimulatory molecules.  However, innate activated 
macrophages do not show the same level of phagocytosis.  They express a different 
pattern of membrane receptors for pathogens, which includes the macrophage receptor 
with collagenous structure (MARCO), a novel marker of innate activated macrophages 
(Mukhopadhyay et al., 2006). Innate activation is usually unable to fully develop into an 
M1 profile because TLR ligation typically induces expression of only low levels of p40 
and is therefore insufficient to trigger production of the M1 biologically-active IL-12 
(Trinchieri et al., 2003).  However, complete pathogens can induce functional IL-12 
heterodimers, indicating that microbial stimulation can be considered a subgroup within 
the M1 macrophage group (Skeen et al., 1996).  
 
The M2b activation state is produced in culture by ligation of receptors such as the 
TLRs, most of which are expressed by cells of monocyte–macrophage lineage and are 
associated with microbicidal activity and pro-inflammatory cytokine production 
(Gordon and Taylor, 2005).  M2b cells are the functional converse of M1 cells, 
characterised by low IL-12 and high IL-10 production, a cytokine profile which favours 
the development of type II adaptive immune responses (Anderson & Mosser 2002).  
M2b macrophages are distinct from M2a macrophages as they produce much higher 
levels of IL-10, but also produce significant amounts of TNFα, IL-1β, and IL-6, 
suggesting that these cells are not anti-inflammatory per se.   
 
The M2c group includes cells stimulated with IL-10, TGFβ, or glucocorticoids.  It is a 
functionally heterogeneous group of cells that hints at an over-simplification of 
macrophage activation state classification.  M2c macrophages are usually regarded as 
deactivated macrophages as they are characterised by down-regulation of pro-
inflammatory cytokines and increased debris scavenging activity.  IL-10 is produced by 
macrophages, T cells, B cells, and a variety of other cell types including mast cells and 
keratinocytes, as part of the homeostatic response to infection and inflammation.  It 
plays a critical role in limiting the duration and intensity of immune and inflammatory 
responses.  In macrophages, IL-10 inhibits production of pro-inflammatory cytokines 
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such as TNFα, IL-6, IL-12 and antigen presentation by monocytes or macrophages via 
down-regulation of MHC class II and co-stimulatory molecules (de Waal Malefyt et al., 
1991).  TGFβ is a pleiotropic cytokine which mediates a wide variety of effects on 
cellular differentiation, activation, and proliferation.  On macrophages and monocytes 
TGFβ regulates activation, cytokine production, host defence, and chemotaxis.  It 
inhibits LPS-induced macrophage production of the pro-inflammatory cytokines TNFα, 
IL-lα and IL-18 (Bogdan et al., 1992).  Glucocorticoids are released in response to a 
variety of stressors such as infection and trauma and are essential for the maintenance of 
homeostatic functions (Valledor et al., 2004). They are recognised by the glucocorticoid 
receptor, which strongly suppresses pro-inflammatory cytokines such as TNFα, IL-1, 
IL-6, IL-8, IL-12, and pro-inflammatory mediators such as iNOS and cyclo-oxygenase 2 
(Valledor et al., 2004). Glucocorticoids also inhibit the inflammatory response by 
increasing the expression of IL-10 (Ehrchen et al., 2007) and other molecules with anti-
inflammatory functions such as the scavenger receptor CD163 (Högger et al., 1998), and 
by interfering with the IL-1 system as a result of increasing expression of the decoy 
receptor IL-1RII (Ehrchen et al., 2007).  Glucocorticoids also down-regulate a number 
of genes known to be up-regulated by IFN-γ, such as the chemokines CXCL10, 
CXCL11, CCL5 and the chemokine receptor CX3CR1 (Ehrchen et al., 2007). 
 
Of particular interest to fibrotic conditions are the alternatively activated macrophages 
(M2a) which are induced following stimulation with IL-4 or IL-13.  IL-4 and IL-13 
appear to be predominantly produced by Th2 cells, mast cells, and basophils (Stein et 
al., 1992). IL-4 binds two receptor complexes: the high-affinity receptor complex 
composed of the IL-4 receptor-α (IL-4Rα) chain and the IL-2 receptor common γ-chain 
(Martinez et al., 2009), both of which are expressed to varying degrees by macrophages, 
T cells, B cells and mast cells; and the low-affinity receptor complex composed of the 
IL-4Rα/IL-13Rα1 heterodimer (Martinez et al., 2009) and which is expressed on 
monocytes, fibroblasts, B cells and endothelial cells.   IL-13 binds to three receptor 
complexes: the low-affinity IL-13Rα1 monomer, the high-affinity IL-13Rα2 monomer, 
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and the IL-13Rα/IL-4Rα heterodimer (Mueller et al., 2002). The biological actions of 
IL-4 and IL-13 on monocytes and macrophages were for a long time considered to be 
purely anti-inflammatory, based on their down-regulation of pro-inflammatory 
mediators such as IL-1β and TNFα (D'Andrea et al., 1995), IFN-γ  (Mosmann et al., 
1989) , IL-8 (Standiford et al., 1990) and superoxide anion production (Abramson et al., 
1990).  In addition, IL-4 decreases the expression of important membrane molecules 
including CD14 (Lauener et al., 1990) and CCR5 (Wang et al., 1998).  In recent years a 
number of studies have shown that IL-4/IL-13 also regulate key molecules such as MHC 
class II (Cao et al., 1989; Morga & Heuschling 1996), β2 integrins (McNally et al., 
2007), the chemokines CCL22 (macrophage-derived chemokines (MDC)) (Bonecchi et 
al., 1998) and CCL18/AMAC-1 (Kodelja et al., 1998), tissue-type plasminogen activator 
(Hart et al., 1989a) and matrix metalloproteinase 1 (Chizzolini et al., 2000).  In a recent 
genome-wide M1/M2a transcriptional comparison study it was demonstrated that IL-4 
induces up-regulation of several scavenger receptors and C-type membrane lectins, 
including MRC1, SR-A, Dectin-1, DC-SIGN, DCIR (CLECSF6), DCL-1, and 
CLECSF13 (Martinez et al., 2006).  Alternatively activated macrophages also express 
fibronectin 1 and matrix associated protein betaIG-H3 (Gratchev et al., 2001), which 
promote fibrogenesis, the coagulation factor XIII (Töröcsik et al., 2005) and IGF-1 
(Kodelja et al., 1997), which provide signals for tissue repair and proliferation.  IL-4/IL-
13 also affect the IL-1β system by enhancing the production of IL-1 receptor antagonist 
and the decoy IL-1β type II receptor (Hart et al., 1989b) which synergistically interfere 
with IL-1β biological activity (Mantovani et al., 2001).  From murine studies it is 
recognised that, in contrast to M1 macrophages, M2a macrophages do not express iNOS, 
but express high levels of arginase 1 (Arg1), which skews the metabolic pathway of NO 
to the production of proline (Gordon 2003). Consequently, these cells fail to produce NO 
and are significantly compromised in their microbicidal ability for intracellular 
pathogens (Modolell et al., 1995; Hesse et al., 2001), but they synthesise polyamine and 
proline that stimulate cell growth, collagen formation, and tissue repair and fibrosis 
(Hesse et al., 2001; Gordon 2003).  In human in vitro activated macrophages this 
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metabolic signature is absent (Scotton et al., 2005).  M2a macrophages express high 
levels of the chemokines CCL13/MCP-4, CCL8/MCP-2, and CCL26/eotaxin-3, which 
coordinate the recruitment of eosinophils, basophils and some polarised Th2 cells, 
through the activity on CCR3 (Mantovani et al., 2004) and are involved in pro-
angiogenic networks (Strieter et al., 2005a; Rosenkilde et al., 2004).  In vitro 
alternatively activated macrophages also express the extracellular matrix-remodelling 
enzyme matrix metalloproteinase (MMP)-12, which has been demonstrated to be 
selectively expressed in the late, but not early stages of tuberculosis (Kahnert et al., 
2006). 
 
It is likely that there is a large degree of overlap within the various groups of 
macrophage activation, and it is possible that M1 and M2 macrophages represent the 
activation state of macrophages across a spectrum of activation states (Mantovani et al., 




















Figure 1.3. “M1 and M2 macrophages, the extremes of a continuum” 
 
From:  Mantovani et al..  Macrophage polarization: tumor-associated macrophages as a 
paradigm for polarized M2 mononuclear phagocytes.  Trends Immunol 2002; 23(11): 
549-55. 
 
























Despite this wealth of knowledge regarding macrophage activation states there remain 
many unanswered questions.  Molecular mechanisms underlying macrophage activation 
states remain largely undefined.  Tuning of nuclear factor-κB (NF-κB) activation by p50 
homodimers has been shown to be associated with M2 differentiation (Biswas et al., 
2006).  Peroxisome proliferator-activated receptor-γ (PPARγ ) agonists are known to 
induce M2-like differentiation (Bouhlel et al., 2007) and the phosphatase SH2 domain-
containing inositol 5’-phosphatase (SHIP) has been shown to play a key role in 
balancing macrophage activation, although recent evidence suggests that it acts 
indirectly through the regulation of IL-4 production by basophils (Kuroda et al., 2009).  
Ishii and colleagues recently identified a molecular pathway responsible for epigenetic 
regulation of important murine M2-associated genes (Ishii et al., 2009).  IL-4 up-
regulates the histone demethylase Jmjd3 via the transcription factor STAT6.  Jmjd3 
contributes to demethylation of histone H3 at lysine 27, thus unleashing promoters of 
M2 marker genes (arginase 1, Ym1, mannose receptor and FIZZ-1).  These findings 
offer a novel mechanistic insight into macrophage activation and may pave the way to 
its manipulation and targeting. 
 
 
Macrophages and tissue fibrosis 
 
It is well recognised that monocytes and macrophages are important modulators of 
fibrosis in other organs.  Duffield and colleagues highlighted the importance of 
macrophages in the pathogenesis of liver fibrosis (Duffield et al., 2005a).  Using the 
CD11b-DTR transgenic mouse in which administration of diphtheria toxin (DT) 
conditionally and specifically depletes macrophages (as will be discussed in more detail 
later), they demonstrated that depletion of macrophages during liver fibrogenesis 
reduced fibrosis as quantified by sirius red staining and immunohistochemistry for 
collagen III and α-SMA.  In contrast, depletion of macrophages during the resolution 
phase of experimental liver fibrosis demonstrated that macrophages were required for 
this resolution as animals treated with DT showed a slowing of resolution as quantified 
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by sirius red staining and immunohistochemistry for collagen III and α-SMA.  Work 
from the same group has since established that scar associated macrophages are the 
major source of MMP13 which is responsible in part for the resolution of liver fibrosis 
(Fallowfield et al., 2007).  Research from another group has recently established the 
importance of the Ly6hi population of monocytes in the pathogenesis of liver fibrosis 
(Karlmark et al., 2009).  They showed that Ly6
hi
 monocytes are massively recruited into 
the liver upon liver fibrogenesis, as induced by carbon tetrachloride, and can be 






 phenotype.  In addition, liver fibrosis was 
exacerbated following adoptive transfer of bone-marrow derived Ly6C
hi
 monocytes and 
CCR2-null mice had reduced liver fibrosis, suggesting that CCR2-mediated recruitment 
of Ly6C
hi
 monocytes was crucial to the development of liver fibrosis. 
 
Having established the importance of macrophages in liver fibrosis, Duffield and 
colleagues went on to assess the importance of macrophages in renal fibrosis (Duffield 
et al., 2005b).  Using CD11b-DTR transgenic mice they established that depletion of 
macrophages reduced kidney injury as assessed histologically and by analysis of renal 
function.  Furthermore immunohistochemical analysis revealed a reduction in collagen 
III and α-SMA staining following macrophage depletion, and a reduction in both 
myofibroblast proliferation and apoptosis, suggesting that macrophages support a 
population of renal myofibroblasts in a highly dynamic state during renal fibrogenesis.  
Duffield’s group has since gone on to show that Ly6hi monocytes are recruited to the 
kidney during fibrogenesis and are important for promoting fibrosis (Lin et al., 2009).   
 
 
Macrophages and pulmonary fibrosis 
 
Previous studies have attempted to ascertain the role of macrophages in lung fibrosis but 
they have all used models with questionable direct relevance to lung fibrosis (Zhang-
Hoover et al., 2000; Misson et al., 2004; Bem et al., 2004).   
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Interest in the role of macrophages in lung fibrosis is not new.  Several papers in the 
1980s highlighted their potential importance (Rennard et al., 1981; Bitterman et al., 
1983; Bitterman et al., 1984; Lacronique et al., 1984; Bitterman et al., 1986; Rennard et 
al., 1988; Nagaoka et al., 1990).  Bitterman and colleagues (Bitterman et al., 1983) 
demonstrated that alveolar macrophages from patients with IPF release a soluble factor 
that stimulates fibroblast growth and proliferation.  They cultured non-cycling 
fibroblasts with the supernatants of unstimulated macrophages from patients with IPF 
and normal controls and discovered that there was a marked increase in fibroblast 
replication rate when the source of the supernatants were patients with IPF.  
Interestingly this growth factor, which they initially termed alveolar macrophage derived 
growth factor (AMDGF), was subsequently discovered to be IGF-1 (Rom et al., 1988).  
Work from the same group demonstrated that fibronectin was produced by human 
alveolar macrophages, and that the rate of production of fibronectin was ten times 
greater in patients with IPF compared to normal controls (Rennard et al., 1981).  In 
addition they established that this macrophage-derived fibronectin was chemotactic for 
fibroblasts.  Bitterman and colleagues then showed using a variety of techniques that 
alveolar macrophage replication is increased in patients with IPF as compared with 
controls and suggested that this expansion of mononuclear phagocytes may be important 
in effecting the surrounding molecular and cellular microenvironment (Bitterman et al., 
1984).   
 
At the time of these studies there was, as there still is now, debate about the role of 
macrophages in pulmonary fibrosis.  Much of the uncertainty arises as a result of the 
lack of benefit of corticosteroids in treating patients with IPF (Turner-Warwick 1980b).  
Lacronique and colleagues demonstrated that corticosteroids do not affect the secretion 
of either fibronectin or AMDGF (IGF-1) by alveolar macrophages in normal patients or 
patients with IPF (Lacronique et al., 1984).  Furthermore they established that this effect 
was not due to a lack of corticosteroid receptors, as patients with IPF bound 
corticosteroids similarly to normal volunteers.  One other growth factor secreted by 
alveolar macrophages that has been investigated is PDGF.  There are two human PDGF 
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genes, A and B (Collins et al., 1985; Rorsman et al., 1988).  Martinet and colleagues 
discovered that alveolar macrophages from patients with IPF spontaneously released 
four times as much PDGF as alveolar macrophages from normal controls (Martinet et 
al., 1987).  In addition PDGF was found to be chemotactic for smooth muscle cells and 
acted as a “competence factor for fibroblast growth”.  Subsequently it was shown that 
there is up-regulation in gene expression of PDGF A and B in patients with IPF as 
compared to normal controls (Nagaoka et al., 1990).   
 
The first paper suggesting that an alternatively activated type of macrophage may be 
important in the pathogenesis of pulmonary fibrosis was published by Ann Millar’s 
group (Hancock et al., 1998).  They performed RT-PCR for IL-13 on RNA extracted 
from alveolar macrophages of 13 patients with various forms of fibrotic lung disease and 
8 healthy controls.  They also performed enzyme-linked immunosorbent assay (ELISA) 
for IL-13 on BALF, and culture supernatants from alveolar macrophages treated with 
LPS.  They established that IL-13 message and protein were increased in patients with 
fibrotic lung disease, and moreover IL-13 production by alveolar macrophages cultured 
in the presence of LPS was increased in patients with fibrotic lung disease compared to 
controls.  
 
However research in this area has not progressed, in part as a consequence of the lack of 
benefit of corticosteroids in treating fibrotic lung diseases.  As discussed previously, 
investigation into the pathogenesis of pulmonary fibrosis has focused on the aberrant 
wound healing model (Selman et al., 2001; Selman et al., 2006).  This hypothesis 
however does not take into account the natural history of the disease but rather reflects a 
single “snapshot” view, and does not recognise the fact that injury to any tissue is often 
followed by an inflammatory response and subsequent repair. While a poor response to 
conventional anti-inflammatory therapy at the end stage of fibrosis has been cited in 
support of this hypothesis, this negative finding should not rule out the possibility of a 
pathogenic role for early-stage inflammation.  Zuo and colleagues (Zuo et al., 2002) 
used oligonucleotide microarray analysis to compare gene expression patterns in lung 
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samples from patients with histologically proven IPF to those of healthy control 
subjects. The expression of four categories of genes was markedly increased. These 
included genes that were associated with cell contraction, including those that encode 
smooth muscle proteins.  Particularly up-regulated contractility genes included actin, 
myosin, and tropomyosin.  The expression of genes that encode proteins involved in 
signalling (cell adhesion kinase), extra-cellular matrix (ECM) formation (collagen I and 
III, fibronectin), and ECM degradation (MMP-1, MMP-2, MMP-7, and MMP-9) were 
also increased.  Interestingly and importantly, a third set of genes demonstrated the 
expression of a number of pro-inflammatory cytokines, chemokines, and antioxidants.  
Furthermore, there was up-regulation in expression of a fourth set of genes, encoding 
amyloid and immunoglobulins, genes that would normally be associated with chronic 
inflammatory disorders.   
 
Another study by Hunninghake and colleagues (Hunninghake et al., 2003) which was 
designed to identify clinical and radiologic findings associated with a pathologic 
diagnosis of UIP, found that chest radiographic findings consistent with UIP and two 
high-resolution CT scan findings (lower lobe honeycombing and irregular lines in the 
upper lobes) were positively associated with a diagnosis of UIP.  Unexpectedly, there 
was significant mediastinal adenopathy in the majority (55%) of patients with a 
diagnosis of IPF.  This finding may suggest that the majority of IPF patients have an 
ongoing immune lympho-proliferative process, presumably in response to some 
unknown antigen. Taken together, the studies of Zuo and colleagues and Hunninghake 
and colleagues demonstrate that inflammatory-associated genes are up-regulated in 
patients with IPF and that the host responds with immune-mediated lympho-
proliferation.  An interesting study by Flaherty and colleagues (Flaherty et al., 2001b) 
sheds some light on the natural history of UIP and may hint at the association between 
inflammation and UIP.  This prospective study evaluated multiple open lung biopsies 
involving more than one lobe of the lung in 109 patients with UIP.  Forty-seven percent 
of patients (mean age 63.3 years) exhibited the histopathology of UIP in all lobes.  
Twenty-six percent of patients (mean age 56.9 years) demonstrated the histopathology 
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of non-specific interstitial pneumonia (NSIP) in at least one lobe and UIP in at least one 
lobe, indicating the presence of two different idiopathic pulmonary processes in the lung 
at the same time.  NSIP is believed to be an inflammatory condition, which in the 
majority of cases is responsive to corticosteroids (Travis et al., 2008).  In the remaining 
26% of patients (mean age 53.1 years), NSIP was found in all lobes.  Ten percent of 
patients had two or more biopsy specimens obtained from the same lobe; among these 
patients, 73% of the lobes had co-existent NSIP and UIP. 
 
Importantly, it has been demonstrated that corticosteroids actually induce alternative 
activation of macrophages (Gratchev et al., 2001; Gratchev et al., 2005), and several 
recent studies have suggested that alternatively activated macrophages may regulate 
myofibroblasts in vitro (Song et al., 2000; Prasse et al., 2006).  In some studies 
macrophages with pro-fibrotic functions have been implicated as key effector cells in the 
pathogenesis of IPF (Uh et al., 1998; Wynes et al., 2003; Wynes et al., 2004).  Several 
other papers have suggested the potential importance of macrophages (Mora et al., 2006; 
Prasse et al., 2006; Okuma et al., 2004; Baran et al., 2007).   
 
Okuma and colleagues examined the pathogenesis of pulmonary fibrosis using the 
bleomycin model (Okuma et al., 2004).  They established at 21 days post-bleomycin 
administration that CCR2-null mice showed limited areas of fibrosis and retained 
alveolar structures as visualised by histology in contrast to CCR2 wild-type mice which 
exhibited diffuse fibrosis and obliteration of normal alveolar structures.  Reduction in 
fibrosis in CCR2-null mice was corroborated by hydroxyproline assay.  Analysis of 
differential cell counts from BALF demonstrated a peak influx of macrophages between 
days 14 and 21, with a significant reduction in numbers of BALF macrophages in the 
CCR2-null mice.  Interestingly, they showed that BALF activities of MMP2 and MMP9 
were reduced at day 14 in CCR2-null mice, that MMP2 and MMP9 activity in proteins 
extracted from alveolar macrophages were reduced at day 3 in CCR2-null mice, and that 
MMP2 and MMP9 staining as visualised by immunocytochemistry was reduced at day 3 
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in CCR2-null mice.  It should be noted that in their model peak fibrosis occurs around 
21 days, and as such the specifics of the MMP results should be interpreted with caution. 
In a murine model of pulmonary fibrosis induced by the administration of murine γ-
herpes-virus 68 to IFN-γ-receptor-deficient mice, Mora and colleagues (Mora et al., 
2006) demonstrated that there was recruitment of alveolar macrophages to areas of 
epithelial hyperplasia and fibrosis.  Furthermore these macrophages showed expression 
of molecules (such as Ym1 and arginase I) indicative of activation of macrophages by 
the alternative pathway.  As alternatively activated macrophages are associated with 
tissue fibrosis, the authors suggested that alternative activation of macrophages may be 
important in the pathogenesis of pulmonary fibrosis.   
 
Using the bleomycin model of pulmonary fibrosis Baran and colleagues (Baran et al., 
2007) showed that macrophage colony-stimulating factor (M-CSF)- and CCL2- null 
mice had less lung fibrosis, mononuclear phagocyte recruitment, collagen deposition, 
and CTGF expression than wild type.  In addition they found that BALF from patients 
with IPF contained significantly more M-CSF and CCL2 than BALF from normal 
volunteers, suggesting an important role for M-CSF and mononuclear phagocytes in the 
pathogenesis of pulmonary fibrosis.   
 
The importance of a human marker of alternative macrophage activation, CCL18, has 
been suggested in two recent studies.  Prasse and colleagues demonstrated that CCL18 
mRNA and protein expression as visualised by in-situ hybridisation and 
immunohistochemistry, respectively, were increased in patients with IPF compared to 
controls, the increased expression being particularly obvious on epithelial cells (Prasse 
et al., 2006).  Furthermore CCL18 gene expression and protein production were up-
regulated in normal alveolar macrophages after co-culture with human lung fibroblasts, 
and they established that native collagen up-regulated CCL18 expression in normal 
alveolar macrophages that were alternatively activated.  On the basis of these findings, 
the authors proposed that alveolar macrophages and fibroblasts may promote pulmonary 
fibrosis via the effects of CCL18.  Interestingly they demonstrated that levels of CCL18 
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in BALF were higher in patients with IPF than controls, and correlated negatively with 
DLCO.   The same group subsequently showed that CCL18 is abundantly expressed in 
the culture supernatants of BALF cells, BALF and sera from patients with histologically 
proven pulmonary fibrosis (in a group of patients with a variety of interstitial lung 
diseases) and that there was a negative correlation between changes in total lung 
capacity and changes in serum CCL18 concentrations (Prasse et al., 2007).  Specifically 
in relation to IPF they have since demonstrated that CCL18 serum concentrations predict 
outcome in IPF: using receiver operating characteristics analysis they found that there 
was a significantly higher mortality in patients with IPF in whom the serum CCL18 
concentration was greater than 150ng/ml, and this corresponded with a higher incidence 
of disease progression (Prasse et al., 2009).  CCL18, also known as AMAC1 (alternative 
macrophage activation-associated CC-chemokine 1) is a marker of alternative 
macrophage activation (Gordon 2002).  It has been suggested to share some features 
with TGFβ (Prasse et al., 2009) as like TGFβ it stimulates collagen production in lung 
fibroblasts (Atamas et al., 2003). 
 
These studies provide circumstantial evidence for the putative role of macrophages in 
the pathogenesis of pulmonary fibrosis and highlight the need for further studies to 





The kinetics and origin of monocytes were first described by van Furth and Cohn (van 
Furth & Cohn 1968; van Furth et al., 1970).  Using tritiated-thymidine labelling of 
monocytes, they showed that monocytes in the peripheral blood do not multiply, but that 
mononuclear phagocytes of the bone marrow do and are the progenitors of blood 
monocytes.  In addition, following injection of newborn calf serum into the peritoneum 
they established that there was a rapid extravasation of blood monocytes into the 
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peritoneal cavity, and they concluded that monocytes in the peripheral blood are the 
precursors of tissue macrophages (van Furth & Cohn 1968). 
 
Mouse monocytes were originally phenotypically defined as cells expressing high levels 
of CD11b, Ly6C and CD62L (Lagasse & Weissman 1996), and not expressing CD11c 
nor MHC class II molecules (Leon et al., 2004).  Jung and colleagues developed an 
CX3CR1GFP/+ transgenic mouse where one allele for the gene encoding CX3CR1, the 
receptor for fractalkine, has been replaced by the gene encoding GFP.  This results in 




 cells (Jung et al., 2000).  Using this 
system Geissmann and colleagues (Geissmann et al., 2003) defined two murine 
monocyte subsets: CX3CR1
lo
 monocytes which are large granular mononuclear cells, 
and CX3CR1hi monocytes which are small mononuclear cells.  Using Ki67 they 
confirmed the findings of van Furth & Cohn that monocytes are non-cycling in the 

















, respectively.  However, 
the Gr1 label refers to the specificity of the monoclonal antibody RB6-8C5 that 
recognises both the Ly6G and Ly6C antigens (Fleming et al., 1993), and as Ly6G is 
expressed only on granulocytes (Fleming et al., 1993) whereas Ly6C is expressed on 
both monocytes (Sunderkötter et al., 2004) and granulocytes (Fleming et al., 1993), it 
was felt that the Gr1 label was not appropriate for classifying monocytes.  As such, the 









CX3CR1hi, CCR2-, CD62L-, Ly6Clo, respectively (Auffray et al., 2009) (Figure 1.4). 
Geissmann and colleagues (Geissmann et al., 2003) went on to stain human peripheral 
blood cells with a fractalkine-Fc fusion protein specific for CX3CR1 and identified by 









.  These subsets, although differing from murine monocytes in terms of 


















respectively.  They have in common size, granularity, and expression patterns of 
 61 
adhesion molecules and chemokines receptors.  The Ly6C
hi
 subset is often referred to as 














Figure 1.4.  Blood monocyte populations.   
 




Monocytes, fibrocytes and pulmonary fibrosis 
 
The role of monocytes in fibrosis has recently been intensely studied.  As discussed 
earlier, Karlmark and colleagues have recently shown in the context of liver 
inflammation and fibrosis that inflammatory Ly6C
hi
 monocytes are recruited into the 
injured liver via CCR2-dependent bone marrow egress, and promote the progression of 
liver fibrosis (Karlmark et al., 2009).  In addition, Lin and colleagues have recently 
shown that Ly6C
hi
 monocytes are recruited to the kidney following unilateral ureteric 
kidney obstruction, a model for renal fibrosis, and differentiate into monocyte 
populations that participate in the promotion of kidney fibrosis (Lin et al., 2009) 
 
Until very recently there has been very little interest in the role of monocytes in lung 
fibrosis.  Much of the interest in circulating cells that contribute to lung fibrosis has 
centred on the fibrocyte.  As mentioned previously, fibrocytes were first described by 







in addition were also positive for the markers vimentin, fibronectin, collagen III, CD11b 
and CD18.  Fibrocytes were found in regions of scar formation and it was proposed by 
Bucala and colleagues that these cells may play a role in a variety of pathological 
conditions characterised by excessive fibrosis.  They were subsequently found to 
comprise only 0.1-0.5% of nucleated cells in peripheral blood (Quan et al., 2004).  
Phillips and colleagues established that human fibrocytes express CD45, Col I and 
CXCR4 and migrate in response to CXCL12 (Phillips et al., 2004).  They went on to 
establish that fibrocytes accumulate in the lungs of bleomycin-treated mice, and that 
administration of specific neutralising anti-CXCL12 (the ligand for CXCR4) antibodies 
diminished the recruitment of fibrocytes to the lung and ameliorated lung fibrosis as 
measured by Sircol assay.  Moeller and colleagues sampled blood from patients with 
stable IPF and during acute exacerbations of the disease (Moeller et al., 2009).  




.  They established that there 
was an increase in numbers of fibrocytes in patients with stable IPF compared with 
healthy controls, and that the numbers were further increased in patients during acute 
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exacerbations.   Fibrocyte numbers were not correlated with radiological severity scores 
or lung function, but were in fact an independent predictor of mortality; the mean 
survival of patients with a fibrocyte proportion of greater than 5% of total blood 
leukocytes was only 7.5 months, in contrast to 27 months for patients with a fibrocyte 
proportion of less than 5% (Moeller et al., 2009). 
 
The potential link between fibrocytes and monocytes has recently been highlighted in an 
elegant paper by Niedermeier and colleagues (Niedermeier et al., 2009).  Using cell 







 monocytes appear to be the precursor cells of murine fibrocytes, but require 
CD4
+
 T cells or molecules derived from them to make this transition.  Interestingly, 
activation of CD4+ T cells in the presence of cyclosporin A markedly enhanced the 
production of fibrocytes in vitro and increased the level of Collagen I mRNA and tissue 
fibrosis in the unilateral ureteric obstruction model of renal fibrosis.  Treatment with 
rapamycin in contrast did not affect the number of fibrocytes, expression of Collagen I 
or tissue fibrosis.   
 
Two papers just published have provided more direct evidence for a role of monocytes 
in the pathogenesis of pulmonary fibrosis.  Murray and colleagues analysed plasma from 
IPF and control patients and showed that the two monocyte markers IL-1RA and CCL2 
(MCP-1) were increased in patients with IPF (Murray et al., 2010).  In addition they 
demonstrated that patients with “progressive” IPF had a greater percentage of CD14+ 
monocytes expressing the human alternatively activated macrophage marker CD163 
compared with patients with stable IPF and controls.  Analysis of protein lysates of 
whole lung tissue showed that there were elevated levels of the M2 macrophage markers 
IL-13 and IL-1RA in patients with IPF, but not IL-4 or resistin.  The level of the M1 
macrophage marker CX3CL1 was decreased in patients with IPF, but there was no 
reduction in the levels of other M1 markers CXCL10/IP10 and CCL3/MIP-1α.  They 
went on to show that in mice treated with bleomycin to induce pulmonary fibrosis that 
additional administration of serum amyloid P (SAP) on days 11-20 of their 21 day 
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model resulted in a reduction in fibrosis, as visualised on lung sections stained with 
haematoxylin and eosin (H&E), and quantified by hydroxyproline assay.  The authors 
concluded that SAP-mediated inhibition of alternatively activated macrophages may be 
a therapeutic strategy for patients with IPF.  Work from the same group has shown that 





 monocytes as well as IL-4, IL-10, IL-13, CCL2 
and CCL18, suggesting that alternatively activated macrophages may be important in the 
pathogenesis of fibrotic lung disease (Mathai et al., 2010). 
 
 
Aims and hypothesis 
 
As can be seen from the introduction above, it is clear that while great advances have 
been made in understanding the pathogenesis of pulmonary fibrosis, there remains much 
controversy.  In particular, the role of “immune-type” cells is still uncertain.  With this 
mind, and taking into account previous work exploring the role of macrophages in 
pulmonary fibrosis, I hypothesised that monocytes and macrophages would be important 
in regulating pulmonary fibrosis. 
 
As such, the aim of my research is to establish categorically the role of monocytes and 
macrophages in pulmonary fibrosis.  I aim to establish whether circulating monocytes 
and lung macrophages are important during various phases of pulmonary inflammation 
and fibrosis, using the best available models of pulmonary fibrosis, bleomycin and 
AdTGFβ, and several methods of cellular depletion.  The experimental outlines for this 












ii.) Does depletion of lung macrophages during the inflammatory phase of 






iii.) Do lung macrophages regulate the progressive fibrotic phase of pulmonary 
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iv.) Do lung macrophages regulate the progressive fibrotic phase of pulmonary 





v.) Do lung macrophages regulate the resolution phase of pulmonary fibrosis in 
the bleomycin model? 
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vii.) Does depletion of circulating monocytes during the inflammatory phase of 






viii.) Do circulating monocytes regulate the progressive fibrotic phase of 
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ix.) Do circulating monocytes regulate the progressive fibrotic phase of 





I plan to confirm any significant effect of depletion using a complimentary add-back or 
add-in experiment.  By focusing on MMP biology, I aim to establish whether new 
mechanistic insights into pulmonary fibrosis pathogenesis can be gained.  Finally, by 
using human tissue samples, I hope to corroborate any findings identified in the mouse, 
and as such provide translational evidence for the potential importance of any novel 
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Female C57Bl/6 mice were bred in-house or purchased from Harlan and maintained in 
12-hour light/12-hour dark cycles with free access to food and water.  All procedures 
were performed in accordance with Home Office guidelines [Animals (Scientific 
Procedures) Act 1986].   
 
2.2 Bleomycin model of pulmonary fibrosis 
 
Female mice 8-14 weeks old were anaesthetised with isoflurane (L2901, Merial Animal 
Health Ltd, Harlow, UK), and bleomycin sulphate (BI3543, Apollo Scientific, 
Stockport, UK) (0.0167mg or 0.033 mg in 50 µl of 0.9% saline) or 0.9% saline was 
administered intra-tracheally by an aspirational technique.  For comparative studies mice 
were age- and weight-matched.  Mice were culled on day 3, 7, 14, 18, 21, 22, 25, 28, 32, 
56 and 136 by intra-peritoneal injection of pentobarbital sodium (Merial Animal Health 
Ltd, Harlow, UK).  Lungs were removed en bloc; the left lobe was tied off and snap 
frozen in liquid nitrogen for collagen analysis.  In some experiments, in addition, the 
right apical lobe was tied off and snap frozen in liquid nitrogen for RNA/protein 
analysis.  In some experiments the trachea was cannulated and the lungs lavaged with 3 
x 0.8 ml (4 x 0.8ml for flow cytometry experiments) sterile Dulbecco’s phosphate 
buffered saline (PBS) pH7.4 (D8537, Sigma, UK) containing 2mM EDTA (E5134, 
Sigma, UK).  The remaining lung was inflated under gravity with methyl carnoys 
solution (60% methanol (C-M400017-X, Fisher Scientific, UK), 30% chloroform (C-
C496017-X, Fisher Scientific, UK), 10% glacial acetic acid (A6283, Sigma, UK)) or 
10% formalin solution (Sigma, UK) and then incubated in the same solution overnight.  
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Lungs were then transferred into 70% ethanol prior to paraffin embedding and 
sectioning for histology and immunohistochemistry. 
 
2.3 AdTGFβ model of pulmonary fibrosis 
 
AdTGFβ refers to porcine TGF-β1 adenovirus (AdTGFβ1
223/225
), an adenovirus construct 
containing a mutation of cysteine to serine at positions 223 and 225, rendering the 
expressed TGFβ1 biologically active (Sime et al., 1997).  Control virus (AdDL70-3) was 
constructed as previously described (Bett et al., 1994).  Both AdTGFβ and AdDL70-3 
were kindly supplied by Professor Jack Gauldie (Hamilton, Ontario). Female mice 10-14 
weeks old, weight-matched, were anaesthetised with isoflurane, and AdTGFβ or 
AdDL70-3 administered intra-tracheally (50µl).  Mice were culled on days 5 and 14 by 
intra-peritoneal injection of pentobarbital sodium (Merial Animal Health Ltd, Harlow, 
UK).  Retrieval and processing thereafter was performed as described above for the 
bleomycin model. 
 
2.4 Liposomal clodronate and liposomal PBS 
 
Clodronate was a gift of Roche Diagnostics GmbH, Mannheim, Germany.  It was 
encapsulated in liposomes as previously described (van Rooijen & Sanders 1994).  
Liposomal PBS was supplied by Dr Nico van Rooijen (Amsterdam, Netherlands).  
Liposomal clodronate and liposomal PBS were administered intra-tracheally (100µl) or 
intra-peritoneally (400µl).  For intra-tracheal administration mice were anaesthetised 
with isoflurane and the liposomal clodronate given by aspirational technique as for 






2.5 Diphtheria Toxin 
 
Diphtheria toxin (D0564, Sigma, UK) was re-constituted in sterile H2O at a 
concentration of 1mg/ml and stored at -80
o
C.  Upon thawing of aliquots, DT suspension 
was diluted in sterile PBS to make a working stock solution at a concentration of 
100µg/ml.  
 
2.6 Determination of lung fibrosis 
 
Paraffin-embedded sections of mouse tissue were stained with Masson’s trichrome as 
per manufacturer’s instructions.  Fibrosis score was evaluated (x100) as the quantity of 
the section positively stained for collagen and displaying alveolar wall thickening (1 = 
<25%, 2 = 25-50%, 3 = 50-75%, 4 = 75-100%).  This score is as yet unpublished.  It was 
developed by Professor Sarah Howie (MRC/University of Edinburgh Centre for 
Inflammation Research, Edinburgh), as a modified version of the Ashcroft Score 
(Ashcroft et al., 1988), that is felt to be more applicable to the bleomycin model, 
combined with a previously published fibrosis score used in the bleomycin model (Pardo 
et al., 2003).  Professor Howie ensured that I was adequately trained.  Only fields where 
the majority of the field was composed of alveoli were scored.  Blinded analysis of the 
entire lung section was performed.  Mulitple practice runs were performed until scoring 
became consistent.  Thereafter all lung sections were scored with no time gaps to 
minimise variability of scoring.  Repeat scoring ensured that the results were 
reproducible. 
 
2.7 Determination of lung inflammation  
 
Paraffin-embedded sections of mouse tissue were stained with Masson’s trichrome as 
per manufacturer’s instructions.  Peri-vascular and peri-bronchial inflammation scores 
were evaluated based on methods previously published (Fisher et al., 2005), with minor 
modifications to ensure applicability to the bleomycin model.  Peri-vascular 
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inflammation score was evaluated (x100) as the number of cells surrounding vessels (1 = 
<10, 2 = 10-20, 3 = 20-50, 4 = >50) that were <50% of the size of the field in view.  
Peri-bronchial inflammation score was evaluated (x100) as the number of cells 
surrounding bronchi (1 = <10, 2 = 10-20, 3 = 20-50, 4 = >50) that were <50% of the size 
of the field in view.  Only fields where the majority of the field was composed of alveoli 
were scored.  A run-in period and confirmatory scoring were performed as for the lung 
fibrosis score (above).  Blinded analysis of the entire lung section was performed.   
 
2.8 Determination of lung collagen by Sircol assay 
 
Collagen content of the left lung was carried out by Sircol assay as per manufacturer’s 
instructions (Biocolor Ltd, County Antrim, UK); the left lung was minced in 5 ml of 
0.5M acetic acid (A6283, Sigma, UK) with pepsin (P6887, Sigma, UK) added at a ratio 
of 1:10 (w:w, pepsin:lung) and incubated with shaking at 4
o
C for 24 hours.  Cleared lung 
extract (0.2 ml) was incubated with 1ml Sircol dye reagent for 30 minutes on a rotator at 
room temperature then centrifuged at 12,000g for 10 minutes at 4
o
C.  Supernatant was 
decanted.  Pellets were solubilised in 1 ml 0.5M sodium hydroxide (S5881, Sigma, UK) 
and absorbance measured at 540 nm alongside collagen standards (Sircol bovine 




Tissues were fixed with methyl carnoys solution and embedded in paraffin.  5µm 
sections were treated with 12.5% proteinase K [dissolved in pre-heated PBS] (P8044, 
Sigma, UK) for 5 minutes at 37oC (F4/80) or microwaved in 10mM sodium citrate 
(S4641, Sigma, UK) for 15 minutes (α-SMA, Ym1) for antigen retrieval.  Sections were 
blocked with 1% hydrogen peroxide [dissolved in de-ionised H20] (H1009, Sigma, UK) 
for 15 minutes followed by 20% rabbit serum [diluted in PBS] (X0902, Dako UK Ltd, 
Cambridgeshire) (F4/80) or 20% swine serum [diluted in PBS] ((X0901, Dako UK Ltd, 
Cambridgeshire) (α-SMA, Ym1) for 30 minutes.  Sections were then incubated with 
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primary antibody for 1hour to F4/80 (Rat monoclonal [CI:A3-1] anti-F4/80, 1:300, 
AB6640, Abcam, Cambridge, UK), α-SMA (Murine monoclonal anti-α-smooth muscle 
actin, clone 1A4, FITC conjugate, 1:15,000, F377, Sigma, UK) or Ym1 (Rabbit 
polyclonal anti-Ym1, 1:100, 01404, Stem cell technologies, Grenoble, France) followed 
by a biotinylated secondary antibody for 30 minutes (F4/80: biotinylated polyclonal 
rabbit anti-rat, 1:400, E0468, Dako UK Ltd, Cambridgeshire; α-SMA: polyclonal rabbit 
anti-FITC, 1:500, 71-1900, Zymed Laboratories Inc., USA; Ym1: biotinylated 
polyclonal swine anti-rabbit, 1:200, E0431, Dako UK Ltd, Cambridgeshire).  In the case 
of α-SMA this was followed by a biotinylated tertiary antibody for 30 minutes 
(Biotinylated polyclonal swine anti-rabbit, E0353, Dako UK Ltd, Cambridgeshire).  For 
all antibodies this was followed by addition of the ABC reagent (R.T.U. Vectastain Elite 
ABC Reagent, PK-7100, Vector Labs, Burlingame, CA, USA) for 30 minutes followed 
by liquid diaminobenzidine (DAB) (Liquid DAB+Substrate Chromogen System, K3468, 
Dako UK Ltd, Cambridgeshire) in the dark for 5 (α-SMA, Ym1) or 10 (F4/80) minutes.  
Sections were counterstained with haematoxylin, dehydrated in alcohols, and mounted.  
The following isotype controls were used: for F4/80: rat IgG (sc2026, Santa Cruz 
Biotechnology, USA) and for Ym1: rabbit IgG (sc2027, Santa Cruz Biotechnology, 
USA).  Ym1 and F4/80-positive cells taken from >50 randomly selected high-power 
fields (x200 Ym1, x320 F4/80) (if more than 50 fields, 200 cells were used instead) were 
quantified. 
 
It should be noted that αSMA is generally accepted to be a marker of myofibroblasts 
(Zhang et al., 1994).  F4/80 is a murine macrophage restricted marker (Austyn & 





Cell suspensions were created in a solution of 0.1% bovine serum albumin (A7906, 
Sigma, UK).  Numbers of cells were determined using nucleocassettes (941-0002, 
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Chemometec, Denmark) and a nucleocounter (SCC-100, Chemometec, Denmark).  An 
aliquot of the cell suspension (20,000-40,000 cells) was pipetted into a cytofunnel 
(combined with a cytoclip, slide and filter card) (3120110, Thermo Scientific) and spun 
at 300RPM for 3 minutes using a Shandon Cytospin 4 cytocentrifuge (Thermo 





Cytospins were created as above using bronchoalveolar lavage fluid from mice and 
humans.  However, instead of using the Quik Diff kit to fix and stain, slides were fixed 
in 90% anhydrous acetone/10% methanol (murine) or methanol (human)).  Processing 
was as for immunohistochemistry except that no antigen retrieval was used.  Processing 
using the Ym1 antibody used the same antibodies and controls as for IHC.  For CD163 
the following reagents were used: blocked with 20% rabbit serum [diluted in PBS] 
(X0902, Dako UK Ltd, Cambridgeshire); primary antibody: mouse monoclonal antibody 
[RM3/1] to CD163 (ab17051, 1:50, Abcam, Cambridge, UK); secondary antibody: 
biotinylated rabbit anti-mouse (E0354, 1:200, Dako UK Ltd, Cambridgeshire); isotype 
control antibody: mouse IgG (sc2025, Santa Cruz Biotechnology, USA). 
 
2.12 TGFβ1 ELISA 
 
TGFβ1 ELISA kit was purchased from R&D Systems (DuoSet ELISA development kit, 
DY 1679, Abingdon, UK).  Capture antibody (mouse anti- TGFβ1, (from kit), 4µg per 
ml in Dulbecco’s phosphate buffered saline (PBS) pH7.4 (D8537, Sigma, UK)) was 
added to 96-well microplates (Corning Costar cell culture plates (CLS3595, Sigma, UK) 
and incubated overnight at room temperature.  Wells were aspirated and washed three 
times with wash buffer (0.05% Tween 20 (P2287, Sigma, UK) in Dulbecco’s PBS).  
Plates were blocked by adding 300µl of block buffer (5% Tween 20 in Dulbecco’s PBS) 
to each well and incubated at room temperature for 1 hour.  Wells were aspirated and 
 75 
washed three times with wash buffer.  100µl of sample (neat) or standards (Recombinant 
TGFβ1 (from kit), diluted in reagent diluent (1.4% bovine serum albumin (A7906, 
Sigma, UK) and 0.05% Tween 20 in Dulbecco’s PBS, pH 7.2-7.5, 0.2µm filtered), 
working concentration 2000pg/ml, top standard 1000pg/ml) were added to wells and 
incubated for 2 hours at room temperature.  Aspiration and wash were performed as 
above.  100µl of streptavidin-HRP (from kit) was added to each well and incubated for 
20 minutes at room temperature.   Aspiration and wash were performed as above.  100µl 
of substrate solution (3,3,5,5-tetramethylbenzidine liquid substrate (TMB, T4444, 
Sigma, UK)) was added to each well and incubated for 20 minutes at room temperature.  
50µl of stop solution (2N H2SO4, DY994, R&D Systems, Abingdon, UK) was added to 
each well.  The absorbance at 450nm was determined using a microplate reader 
(Synergy HT multi-mode microplate reader / Gen5 data analysis software, BioTek, UK), 
and TGFβ1 concentrations calculated from the standard curve. 
 
2.13 RNA extraction and qPCR 
 
Lung tissue was snap-frozen.  Total RNA was extracted using an RNeasy Mini Kit 
(74104, QIAGEN, UK).  First-strand cDNA synthesis was performed as outlined: (per 
reaction) 1 µg of total RNA (diluted to 9µl with H20) added to 2µl random primers 
(50ng/µl, 48190-011, Invitrogen, UK) and heated at 70oC for 10 minutes.  This was 
followed by addition of 0.5µl SuperScript™ II Reverse Transcriptase (18064-014, 
Invitrogen, UK), 4µl 5X first strand buffer (Invitrogen, UK), 2µl 0.1M DTT, 0.5µl 
RNaseOUT™ Recombinant Ribonuclease Inhibitor (10777019, Invitrogen, UK), 0.5µl 
of 10mM dNTP mix (U1240, Promega UK Ltd) and 1.5µl H2O and heated at 40
o
C for 1 
hour.  cDNA was stored in aliquots diluted 1:100 at -20oC prior to qPCR.  For standards 
an identical volume of each sample was combined and the final mix diluted 1:10 to 
make the S1 standard.  Subsequent standards (S1, S2, S3 etc.) were made by serial 
dilutions 1:1 with H2O.  qPCR was performed using SYBR-Green and TaqMan based 
detection methods (Invitrogen).   For SYBR-Green based analyses the specificity of the 
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PCR products was confirmed by melting curve analysis.  The standard curve method 
was used to quantify the expression of the target genes.  The expression level of each 
gene was normalised to that of 18S rRNA. Ym1 was purchased as a TaqMan gene 
expression assay (MM00657889_MH, Applied Biosystems, UK).  18S was purchased as 
a TaqMan endogenous control (4352930E, Applied Biosystems, UK).  These primer 
products are predesigned and fully validated by Applied Biosystems.  All other primers 






α-SMA:  Forward 5’-TCAGCGCCTCCAGTTCCT-3’  
  Reverse 5’-AAAAAAAACCACGAGTAACAAATCAA-3’ 
  
Col1A1:  Forward 5’-GATGACGTGCAATGCAATGAA-3’  
  Reverse 5’-CCCTCGACTCCTACATCTTCTGA-3’ 
 
Arginase1:  Forward 5’-TTGGGTGGATGCTCACACTG-3’  
  Reverse 5’-TTGCCCATGCAGATTCCC-3’ 
  
iNOS:   Forward 5’- CTATCTCCATTCTACTACTACCAGATCGA-3’ 
  Reverse 5’- CCTGGGCCTCAGCTTCTCAT-3’ 
 
MMP9:  Forward 5’- CGAACTTCGACACTGACAAGAAGT -3’  
  Reverse 5’- GCACGCTGGAATGATCTAAGC -3’ 
TaqMan 
MMP2:  Forward 5’- AACTACGATGATGACCGGAAGTG -3’  
  Reverse 5’- TGGCATGGCCGAACTCA -3’ 
  Probe - TCTGTCCTGACCAAGGATATAGCCTATTCCTCG 
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TIMP1:  Forward 5’- ATGGAAAGCCTCTGTGGATATG -3’  
  Reverse 5’- AAGCTGCAGGCACTGATGTG -3’ 
  Probe - CTCATCACGGGCCGCCTAAGGAAC 
 
MMP13:  Forward 5’- GGGCTCTGAATGGTTATGACATTC -3’  
  Reverse 5’- AGCGCTCAGTCTCTTCACCTCTT -3’ 
  Probe- AAGGTTATCCCAGAAAAATATCTGACCTGGGATTC 
 
They have all been previously fully validated and optimised in the MRC/University of 
Edinburgh Centre for Inflammation Research by Dr Stephen Hartland, Iredale Group. 
 
qPCR reaction mixtures were made as follows (per reaction): for SYBR-Green based 
analyses: cDNA 4µl, Express SYBR Green ER qPCR supermix (with premixed ROX) 
(11794, Invitrogen, UK) 5µl, forward primer 0.1µl, reverse primer 0.1µl, H2O 0.8µl.  
For TaqMan based analyses: cDNA 4µl, Express qPCR supermix (with premixed ROX) 
(11795, Invitrogen, UK) 5µl, forward primer 0.1µl, reverse primer 0.1µl, primer probe 
0.1µl, MgCl2 (Invitrogen, UK) 0.1µl, H2O 0.6µl.  For Ym1: cDNA 4µl, Express qPCR 
supermix (with premixed ROX) (11795, Invitrogen, UK) 5µl, Ym1 TaqMan gene 
expression assay mix 0.5µl, H2O 0.5µl.  For 18S: cDNA 0.8µl, Express qPCR supermix 
(with premixed ROX) (11795, Invitrogen, UK) 5µl, 18S TaqMan endogenous control 
mix 0.5µl, H2O 3.7µl.  These reaction mixtures have been previously validated and 
optimised within the Forbes, Iredale and Sethi groups, MRC/University of Edinburgh 
Centre for Inflammation Research. 
 
Samples were inserted into MicroAmp™ fast optical 96-Well reaction plates (4346906, 
Applied Biosystems, UK), and run using the 7500 Real-Time PCR system (Applied 
Biosystems, UK).  Data was analysed using the 7500 Fast System Sequence Detection 
Software, version 1.4 (Applied Biosystems, UK). 
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2.14 Isolation of alveolar macrophages for qPCR analysis 
 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl) +/- liposomal 
clodronate (100µl) i.t. day 21 and culled on day 22.  Lungs were lavaged with 3 x 0.8 ml 
sterile Dulbecco’s phosphate buffered saline (PBS) pH7.4 (D8537, Sigma, UK) 
containing 2mM EDTA (E5134, Sigma, UK).  Lavage fluid was spun at 2000RPM for 5 
minutes.  Red cell lysis buffer (0.15 M NH4CL (A0171, Sigma, UK)/1mM KHCO3 
(P9144, Sigma, UK)/0.1mM Na2EDTA (E5134, Sigma, UK) was added to the cell 
pellet, incubated on ice for 5 minutes, and spun at 2000RPM for 5 minutes.  Cell pellets 
were re-suspended in 2mls Dulbecco’s modified Eagle’s medium 
(DMEM)/F12+Glutamax (31331, Gibco, UK) and incubated at 37oC for 1 hour.  Media 
was gently removed and cells washed twice with PBS.  RLT buffer (79216, QIAGEN, 
UK) plus β-mercaptoethanol (M7522, Sigma, UK) (100:1, v:v) was added, cells lysed 
and stored at -80oC. 
 
2.15 Preparation of lung homogenates 
 
Lungs were thawed on ice.  One protease inhibitor tablet (11836145001, Roche Applied 
Science, UK) was added to lysis buffer (500mM TRIS HCl (T5941, Sigma, 
UK)/200mM  NaCl (S6150, Sigma, UK)/10mM CaCl2 (C1016, Sigma, UK)) (1 tablet 
per 50mls). 500µl of lysis buffer/protease inhibitor solution was added to lung in a 2ml 
eppendorf and a steel ball bearing (69989, QIAGEN, UK) added.  Lung was 
homogenised at 20Hz for 1 minute using a tissue lyser (85220, QIAGEN, UK).  Triton 
X-100 (T8787, Sigma, UK) was added to make a final concentration of 0.1%.  This was 
left on ice for 15 mins then spun at top speed (4oC) for 5 mins.  Protein extract 








2.16 Arginase assay 
 
Arginase activity in lung homogenates was assessed, as previously described (Corraliza 
et al., 2004), by the production of urea generated by the arginase-dependent hydrolysis 
of L-arginine.  This is now described with modifications: lung homogenates were 
prepared as described earlier.  20µl sample was added to 20µl 100mM MnCl2 (BDH 
Laboratory Supplies, Poole, UK)/50mM TRIS HCl (T5941, Sigma, UK), pH 7.4.  The 
solution was incubated at 55
o
C for 10 minutes in heat block followed by addition of 
40µl 0.5M L-arginine (A5006, Sigma, UK), pH9.7.  This was incubated for 1 hour at 
37
o
C.  To this solution was added 320µl H2SO4 (BDH Laboratory Supplies, Poole, 
UK)/H3PO4 (P6560, Sigma, UK)/H2O (1:3:7, v:v:v) to stop the reaction.  Subsequently, 
20µl α-isonitrosopropiophenone (I3502, Sigma, UK) (9% solution in 100% ethanol) was 
added and the solution heated at 95
o
C for 45-60 minutes.  Aliquots were placed in 96 
well plates and the absorbance read at 560nm.  Arginase activity was normalised to 
quantity of protein as measured by BCA assay. 
 
Standards were prepared as follows.  A solution of 100mM urea in PBS was made.  A 
twelve point standard curve was generated by serial dilutions (1:1) of the 100mM urea 
(U5378, Sigma, UK) solution with PBS.  To each standard was added 320µl 
H2SO4/H3PO4/H2O (1:3:7, v:v:v)  and the assay continued as for the samples, above. 
 
2.17 Protein quantification 
 
Protein quantity was assessed using the Pierce bicinchoninic acid (BCA) protein assay 
kit (23227, Perbio Science UK Ltd.).  For lung tissue protein extracts, samples were 
diluted 1:6 with H2O.  10µl was added to 200µl of the BCA protein assay kit working 
reagent (50 parts reagent A plus 1 part reagent B) in 96 well plates.  Plates were 
incubated for 30 minutes at 37oC and absorbance read at 562nm.  Standards were 
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supplied in the BCA protein assay kit (bovine serum albumin).  Standards ranging from 
0-2mg/ml (diluted in PBS) were used. 
 
2.18 Western Blotting 
 
Upper and lower gels were prepared as follows: upper gel: buffer prepared by adding 
30g TRIS base (T6066, Sigma, UK) and 2g sodium dodecyl sulphate (SDS) (L3771, 
Sigma, UK) to 500mls H2O, pH6.8.  Gel stock was made by combining 50ml buffer with 
32ml acrylamide (30%) (A3699, Sigma, UK) and 118mls H2O.  Gel was made by 
adding 40µl ammonium persulphate (APS) (A3678, Sigma, UK) and 20µl 
tetramethylethylenediamine (TEMED) (T9281, Sigma, UK) to 6mls of gel stock.  Lower 
gel: buffer prepared by adding 90.8g TRIS base and 2g SDS to 500mls H2O, pH8.8.  Gel 
stock was made by combining 40mls buffer with 36mls glycerol (G5516, Sigma, UK), 
20mls H2O and 64mls acrylamide (30%).  Gel was made by adding 60µl APS and 30µl 
TEMED to 11mls of gel stock.  5µl of ladder was added (Precision Plus Protein 
Kaleidoscope Standard, 161-0375, BIO-RAD, USA).  30µl of BALF sample or 25µl of 
normalised lung tissue protein extract was added.  Gel was run at 75V until sample 
within gel and then run at 120V in both upper and lower gels.  Running buffer (X10) 
was 10g SDS, 144g Glycine (G8898, Sigma, UK) and 30.3g TRIS base in 1l H2O.  
Blotting was performed for 1 hour (300mA).  Transfer buffer was 100mls 10X transfer 
buffer (144g glycine and 30.3g TRIS base in 1l H2O) added to 200mls methanol and 
700mls H2O.  Blots were blocked for 1hr in 5% dry milk (Marvel) in TBS-Tween 
(TBST) (100mls 10X TBS(12.11g TRIS base and 90g NaCl (S3014, Sigma, UK) in 1l 
H2O, pH7.6), 900mls H2O, 0.5mls Tween-20 (P1379, Sigma, UK)).  Blots were then 
washed twice in TBST (1 minute each in 50ml Falcon).  6mls of primary antibody was 
added (polyclonal goat anti-mouse TIMP1 antibody, 1:500 in 5% milk-TBST, AF980, 
R&D Systems, UK), incubated at 4
o
C overnight, and washed x5 with TBST.  Secondary 
antibody was added (rabbit anti-goat HRP, 1:2000 in 5% TBST, P0447, Dako UK Ltd, 
Cambridgeshire) for 1 hour.  Working horseradish peroxidase (HRP) substrate was made 
by mixing equal volumes of luminol reagent and peroxide solution (chemiluminescent 
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HRP substrate, P90720, Millipore Corporation, USA), leaving for 10 minutes at room 
temperature, adding to blot, leaving for 5 minutes.  Antibody was detected by exposing 
the blot to x-ray film (Amersham HyperfilmTM ECL, 28-9068-35, GE Healthcare Ltd., 
Buckinghamshire, UK) in a Hypercassette (Amersham Biosciences UK Ltd.) for 
variable exposure times.  To strip blots they were incubated in stripping buffer (10mls 
10X stripping buffer (7.5g TRIS base and 10g SDS in 100mls H2O, pH6.7), 2mls β-
mercaptoethanol (M7522, Sigma, UK) and 100mls H2O, pH6.7) for 10 minutes at 65
o
C, 
blots drained briefly, washed x4 (each of 5 minutes) in TBST in glass dish, washed x2 
(each of 3 minutes) in TBST in 50ml falcons and blocked with 5% milk-TBST for 30 
minutes.  Where a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) probe was 
used, primary antibody was added (monoclonal mouse anti-GAPDH antibody, 1:20,000 
in 5% milk-TBST, CB1001, Calbiochem) to blot, incubated overnight at 4
o
C, and 
washed x5 with TBST.  Secondary antibody was added (horse anti-mouse IgG, HRP-
linked antibody, 1:2000 in 5% milk-TBST, #7076, Cell Signaling Technology, USA) for 
1 hour and detected as above. 
 
2.19 Gelatin Zymography 
 
Samples were subjected to electrophoresis on a 10% SDS-PAGE gel co-polymerised 
with 1% gelatin substrate (24350.262, BDH, UK).  Following electrophoresis, gels were 
renatured in 2.5% Triton X-100 (T8787, Sigma, UK) for 30minutes before incubation in 
activity buffer (50mM TRIS base (T6066, Sigma, UK), 200mM NaCl (S3014, Sigma, 
UK), 5mM CaCl2 (anhydrous) (C1016, Sigma, UK), 0.02% Brij-35 (B4184, Sigma, 
UK), pH 7.5) at 37
o
C for 16-24hrs. Gels were then stained with Coomassie Brilliant 
Blue R250 (27816, Sigma, UK) before destaining in 40% methanol (C-M400017-X, 
Fisher Scientific, UK), 10% acetic acid (A6283, Sigma, UK).  Gelatinolytic activity was 
detected as destained bands against a background of Coomassie brilliant blue stained 
gelatin and the molecular weight correlated against the included protein ladder 
(Benchmark prestained protein ladder, 10748-010, Invitrogen, UK). 
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2.20 Preparation and stimulation of bone marrow derived macrophages 
 
In preparing cells for intra-tracheal “add-back” experiments, primary murine bone 
marrow-derived macrophages (BMDMs) were prepared from C57Bl/6 mice as follows:  
bones were removed from mice and placed in GIBCO
TM
 Hank’s balanced salt solution 
(14170120, Invitrogen, UK).  Bones were stripped of flesh and ends removed.  Bone 
marrow was obtained using standard sterile techniques from femurs and tibias by 
flushing through with 10mls of media (Dulbecco’s modified Eagle’s medium 
(DMEM)/F-12 (with glutamax) (31331, Invitrogen, UK) with 10% heat inactivated fetal 
bovine serum (FBS) (S1900-500, Biosera, Ringmer, UK) 20% L929 cell conditioned 
medium and 1% penicillin-streptomycin (P11-010, PAA Laboratories Ltd., UK)  per 
bone.  Cells were matured for 7 days in sterile Teflon pots (Roland Vetter Laborbedarf 
OHG, Germany).  25% of the media was replaced on alternate days.  If stimulation was 
required, on the 6th night cells were pelleted by centrifugation at 300g for 5 minutes, 
washed twice with PBS, and serum starved overnight (in DMEM/F-12 with 1% 
penicillin-streptomycin).  Cells were then spun down again at 300g for 5 minutes and re-
suspended in stimulating media; for alternative activation they were re-suspended in 
DMEM/F-12 with 1% penicillin-streptomycin and stimulated with recombinant mouse 
interleukin-4 (IL-4) (404-ML/CF, R&D Systems, UK) at a concentration of 10ng/ml for 
24 hours.  For classical activation they were re-suspended in DMEM/F-12 with 1% 
penicillin-streptomycin and stimulated with recombinant interferon-γ (IFN-γ) (485-MI, 
R&D Systems, UK) at a concentration of 20ng/ml and lipopolysaccharide (LPS) (L4516, 
Sigma, UK) at a concentration of 50ng/ml for 24 hours.  Cells were pelleted by 
centrifugation at 300g for 5 minutes, washed twice with PBS, re-suspended in PBS at a 
concentration of 1x10
6







2.21 Flow cytometry 
 
BAL 
Mice were culled as described previously.  Lungs were lavaged with 4x0.8mls of ice 
cold, sterile PBS supplemented with 2mM EDTA.  Cells were pelleted by spinning at 
2000RPM for 5 minutes then re-suspended in 0.5mls red cell lysis buffer (0.15 M 
NH4CL (A0171, Sigma, UK)/1mM KHCO3 (P9144, Sigma, UK)/0.1mM Na2EDTA 
(E5134, Sigma, UK).  Samples were lysed on ice for 5 minutes, spun at 2000RPM for 5 
minutes, then re-suspended in FACS buffer (PBS/0.5% bovine serum albumin (A7906, 
Sigma, UK)).  Cytospins were created as previously described.  Fc block
TM
 (rat anti-
mouse CD16/CD32, 1:500, 553142, BD Europe) was added to samples and incubated at 
4oC for 15 minutes.  1ml of FACS buffer was added, samples spun at 2000RPM for 5 
minutes and re-suspended in FACS buffer.  Antibodies were added (PE anti-mouse I-Ab 
(MHC II), 1:200, 553104, BD Europe; PERCP-Cy5.5 anti-mouse CD11b, 1:200, 45-
0112-80, eBioscience Ltd., UK; APC anti-mouse CD11c, 1:200, 550261, BD Europe; 
FITC rat IgG2aκ isotype, 553457, BD Europe; PERCP-Cy5.5 rat IgG2bκ isotype, 
550764, BD Europe; APC hamster IgG isotype, #0300A/HM05, Caltag Laboratories, 
UK) and stained on ice for 30 minutes.  1ml FACS buffer was added, samples spun at 
300g for 5 minutes, re-suspended in 200µl FACS buffer and analysed using a BD FACS 
Calibur Flow Cytometer: 4-Color.  Data was analysed using FlowJo software, version 
7.2.4 (Tree Star Inc., USA). 
 
Lung 
Mice were culled as described previously.  Lungs were removed and placed in 
GIBCO
TM
 Hank’s balanced salt solution (14170120, Invitrogen, UK).  Lungs were 
placed in 2ml digestion mixture (collagenase D (#11088866001, Roche Applied 
Sciences, UK) in FACS buffer, 4mg/ml), minced into a “slurry” using scissors, and 
digested at 37
o
C for 1 hour.  Cells were released from tissue by vigorous pippetting, 
spun at 300g for 15 minutes and washed with FACS buffer.  After a further spin at 300g 
for 5 minutes, 2mls red cell lysis buffer (0.15 M NH4CL (A0171, Sigma, UK)/1mM 
 84 
KHCO3 (P9144, Sigma, UK)/0.1mM Na2EDTA (E5134, Sigma, UK) was added and 
lung mix lysed for 5 minutes on ice.  Samples were topped up with FACS buffer, spun at 
300g for 5 minutes and re-suspended in FACS buffer before pouring through a 40µm 
cell strainer (352340, BD Biosciences, UK).  This single cell suspension was spun at 
300g for 5 minutes, and re-suspended in FACS buffer.  An aliquot was used for cell 
counting, using nucleocassettes (941-0002, Chemometec, Denmark) and a nucleocounter 
(SCC-100, Chemometec, Denmark).  Fc block
TM
 (rat anti-mouse CD16/CD32, 1:500, 
553142, BD Europe) was added to the lung suspension for 15 minutes at 4
o
C.  Samples 
were topped up with FACS buffer and spun at 300g for 5 minutes.  FACS buffer was 
added to produce a final concentration of 1x107 cells per ml.  Antibodies were added  
(FITC anti-mouse Ly6G, 1:100, 127605, Biolegend, USA; PERCP-Cy5.5 anti-mouse 
CD11b, 1:200, 45-0112-80, eBioscience Ltd., UK; APC anti-mouse CD11c, 1:200, 
550261, BD Europe; FITC rat IgG2a isotype, 11-4321-81, BD Europe; PERCP-Cy5.5 
rat IgG2bκ isotype, 550764, BD Europe; APC hamster IgG isotype, #0300A/HM05, 
Caltag Laboratories, UK) to 200µl aliquots and stained on ice for 30 minutes.  1ml 
FACS buffer was added, samples spun at 300g for 5 minutes, re-suspended in 200µl 
FACS buffer and analysed as above. 
 
Blood 
Mice were anaesthetised with a lethal dose of pentobarbital sodium as previously 
described.  Blood was removed from the inferior vena cava and immediately added to 
3.9% citrate (1:1).  Aliquots of 60µl were used for subsequent analysis.  Antibodies were 
added (FITC anti-mouse Ly6G, 1:120, 127605, Biolegend, USA; PE anti-mouse CD115, 
1:120,  12-1152-82, eBioscience Ltd., UK; PERCP-Cy5.5 anti-mouse CD11b, 1:240, 45-
0112-80, eBioscience Ltd., UK; Alexa Fluor 647 anti-mouse 7/4, 1:240, MCA771A647, 
AbD Serotec, UK; FITC rat IgG2a isotype, 11-4321-81, BD Europe; PE rat IgG2b 
isotype, 12-4321-81, eBioscience Ltd., UK; PERCP-Cy5.5 rat IgG2bκ isotype, 550764, 
BD Europe; Alexa Fluor 647 rat IgG2a isotype, MCA1124A647, AbD Serotec, UK) and 
stained on ice for 30 minutes.  Red blood cells were lysed by adding 0.5mls of 1x FACS 
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lysing solution (349202, BD Europe), vortexing the solution and incubating for 10 
minutes at room temperature in the dark.  FACS buffer was added, samples spun at 300g 
for 5 minutes, washed with FACS buffer and re-suspended in 200µl FACS buffer and 
analysed as above. 
 
2.22 Flow sorting 
 
In order to produce a single cell suspension for the “add-in” experiments, bone marrow 
was retrieved as described previously.  Cells were then counted using a Nucleocounter 
as described previously.  Fc blockTM (rat anti-mouse CD16/CD32, 1:500, 553142, BD 
Europe) was added and incubated for 15 minutes at 4
o
C.  Cells were spun at 300g for 5 
minutes and re-suspended in GIBCO
TM
 Hank’s balanced salt solution (14170120, 
Invitrogen, UK) at a concentration of 1x107 cells per ml.  Antibodies were added (FITC 
anti-mouse Ly6G, 1:100, 127605, Biolegend, USA; PE anti-mouse CD115, 1:100,  12-
1152-82, eBioscience Ltd., UK; PERCP-Cy5.5 anti-mouse Ly6C, 1:100, 45-5932-82, 
eBioscience Ltd., UK; APC anti-mouse CD11b, 1:100, 553312, BD Europe) and stained 
for 30 minutes on ice.  Cells were spun at 300g for 5 minutes and re-suspended in 
GIBCO
TM
 Hank’s balanced salt solution/1% FBS (S1900-500, Biosera, Ringmer, UK) at 
a concentration of 4x10
7
 cells/ml.  Cells were sorted as described in results into a 
solution of RPMI 1640 (G0029, 3010, PAA Laboratories Ltd., UK) / 10% FBS.  Cells 
were counted, re-suspended in RPMI 1640 at a concentration of 5x10
6
 cells/ml, and 
200µl (1x106cells) injected into the tail vein of mice.  All methods performed were in 
sterile conditions.  Furthermore, the BD FACS Aria II (Special order system) was 
specifically designed with sterility in mind, and has several features that minimise the 
occurrence of contamination and facilitate the cleaning and decontamination of the 






2.23 Statistical analysis 
 
Paired data columns were evaluated using a two-tailed Student’s t test with GraphPad 
Prism version 5.00 for Windows (GraphPad Software, San Diego, USA).  As bleomycin 
is the positive control throughout, and all comparisons are made directly with that, then 
the Student’s t-test is believed to be the preferred choice of statistical analysis.  Where 
multiple groups are involved, the relation of each to another is not believed to be 
stastically relevant; only the relationship to the positive control, and for this reason the 
Student’s t-test was used here also.  Data were tested for normality and variance. 
Fibrosis score is presented as box and whiskers, inter-quartile range, minimum to 
maximum.  Significance of the difference between medians was assessed using a Mann 
Whitney test with GraphPad Prism.  A P value less than 0.05 was considered significant.  
 
2.24 Human tissue samples.   
 
Written informed consent was obtained from all subjects.  The study was approved by 
the Lothian Research Ethics Committee.  Bronchoalveolar lavage was performed as part 
of ongoing clinical research studies.  All cases were discussed at the Lothian 
clinicopathoradiological meeting.  Patients were defined as having IPF by ATS/ERS 
















Many attempts have been made over the years to produce the optimal model of 
pulmonary fibrosis.  The widely accepted gold standard is the bleomycin model of 
pulmonary fibrosis.  Bleomycin is classically given by intra-tracheal route, although may 
be given intra-peritoneally or intra-venously.  A criticism of the intra-tracheal route is 
that it produces a bronchiolocentric pattern of lung fibrosis, following a significant 
period of lung inflammation, in contrast with the peripheral pattern of injury and “pure” 
fibrosis deemed to be present in the archetypal human form of pulmonary fibrosis, IPF.  
A second model that has been established is the adenoviral transforming growth factor-β 
(AdTGFβ) model.  When AdTGFβ is given by intra-tracheal route it is believed to 
produce a more peripheral fibrosis, with minimal inflammation, and as such many 
researchers believe is more representative of the human form of pulmonary fibrosis.  In 
investigating the role of monocytes and macrophages in pulmonary fibrosis, I sought to 
use these two models to ensure that any results were not biased to a particular model, but 














Bleomycin is the best characterised model of pulmonary fibrosis.  As mentioned 
previously, it was first given to animals in experimental form by Robert Fleischman and 
colleagues (Fleischman et al., 1971) and was subsequently given to mice intra-
peritoneally by Adamson and Bowden (Adamson & Bowden 1974) and intra-tracheally 
by Raisfeld and colleagues (Raisfeld et al., 1982).  In the early 1980s most of the 
bleomycin studies were performed in rabbits, hamsters and rats.  It is well known that 
the response to bleomycin is variable dependent on factors such as age, sex, and strain of 
mice, C57Bl/6 mice being more susceptible to bleomycin-induced fibrosis than Balb/c 
mice (Schrier et al., 1983).  Furthermore, it is known that bleomycin has a variable 
activity range (Stefanou & Siderov 2001), and as such the source from which the 
bleomycin is obtained will be a factor in the model of bleomycin-induced pulmonary 
fibrosis that is produced.  It is therefore imperative that any research performed using the 
bleomycin model is preceded by an optimisation of the model in that specific research 
facility.  As such I optimised the bleomycin model as will subsequently be described. 
 
In order to ensure that any findings demonstrated in the bleomycin model were 
attributable to a monocyte/macrophage effect on pulmonary fibrosis, rather than a 
monocyte/macrophage effect on bleomycin lung injury, I used a second model of 
pulmonary fibrosis, that of the AdTGFβ model.  This model was developed by Patricia 
Sime in Jack Gauldie’s laboratory and as described earlier uses a replication deficient 
adenoviral vector that expresses biologically active TGFβ1 (Sime et al., 1997).  Given 
intra-tracheally it causes lung fibrosis with minimal inflammation in both rats (Sime et 
al., 1997) and mice (Warshamana et al., 2002) and in a pattern more resemblant of IPF.  
As a result it can be used as an adjunct to study the effects of monocytes and 







Bleomycin-induced pulmonary fibrosis is affected by dose given 
To determine an optimal dose of bleomycin to be used in subsequent experiments, two 
doses of bleomycin were chosen – 0.0167mg and 0.033mg (by weight) (Figure 3.1A).  
These are approximately equivalent to 0.025mg and 0.05mg (by potency), and thus are 
approximately equivalent to 0.025U and 0.05U, respectively.  (IU is equivalent to 1mg 
by potency).  As described in numerous publications a dose of approximately 0.025U is 
a “standard” dose and 0.05U a “high” dose.  Bleomycin was given intra-tracheally (i.t.).  
0.9% saline was given i.t. as a control.  Mice were culled on day 18.  As shown in Figure 
3.1A, there is an increase in pulmonary fibrosis as measured by Sircol assay and 
confirmed by Masson’s trichrome staining of lung sections (Figure 3.1, B-D).when the 
larger dose of 0.033mg is given.  However this effect was not statistically significant and 
























































Bleomycin-induced pulmonary fibrosis is affected by dose given 
Female C57Bl/6 mice were given 0.9% saline, 0.0167mg or 0.033mg of bleomycin 
intra-tracheally (i.t.) (50µl) and culled on day 18.  Fibrosis was quantified by Sircol 
assay (A) or visualised by Masson’s trichrome staining (B)-(D).  (A) Bleomycin induces 
pulmonary fibrosis which is affected by dose given: 0.9% saline vs. bleomycin 
0.0167mg, ***p=0.0009; 0.9% saline vs. bleomycin 0.033mg, **p=0.0011.  (B)-(D) 
Representative images of lung sections stained by Masson’s trichrome where the 
substances given i.t. were: (B) 0.9% saline, (C) bleomycin 0.0167mg, and (D) 






















Bleomycin-induced pulmonary fibrosis is reversible 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. and culled on days 3, 7, 14, 
21, 28, 56 and 136.  0.9% saline was given i.t. as a control and mice culled on day 3.  As 
demonstrated in Figure 3.2A, pulmonary fibrosis as measured by Sircol assay peaks 
around 28 days.  By 56 days fibrosis has significantly reduced, with a further reduction 
by day 136.  This increase in fibrosis to day 28 is confirmed by Masson’s trichrome 
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Bleomycin-induced pulmonary fibrosis is reversible 
Female C57Bl/6 mice were given 0.033mg of bleomycin i.t. (50µl) and culled on day 3, 
7, 14, 21, 28, 56, 136.  0.9% saline was given i.t. as a control and mice culled on day 3.  
Fibrosis was measured by Sircol assay (A) or demonstrated by Masson’s trichrome 
staining (B)-(I).  (A) Bleomycin induces pulmonary fibrosis which peaks around 28 days 
and exhibits reversibility thereafter.  (B)-(I) Representative images of lung sections 
stained by Masson’s trichrome: (B) 0.9% saline, (C) bleomycin, day 3, (D) bleomycin, 
day 7, (E) bleomycin, day 14, (F) bleomycin, day 21, (G) bleomycin, day 28, *(H) 
bleomycin, day 56, (I) bleomycin, day 136.  n=3-4 per group, except *n=2. Data are 





















Macrophages increase in number during bleomycin-induced pulmonary fibrosis 
Female C57Bl/6 mice were given 0.033mg of bleomycin i.t. (50µl) and culled on day 3, 
7, 14, 21, 25 and 28.  0.9% saline was given i.t. as a control and mice culled on day 14.  
Sections were stained for the presence of the F4/80 antigen.  The F4/80 antigen is a 
macrophage restricted marker (McKnight & Gordon 1998) and therefore is an ideal 
target for immunohistochemical localisation of tissue macrophages.  Using 
immunohistochemistry I demonstrate that macrophage numbers appear to increase 
during bleomycin-induced pulmonary fibrosis, as shown in Figure 3.3, A-F, with a 
possible peak between 21 and 28 days.  This was not formally quantified, but the 
appearances were consistent on multiple sections analysed.  Macrophages are present in 
control mice (Figure 3.3G), but their numbers are markedly reduced compared to 
bleomycin-treated animals.  There is no staining when an isotype control was used 
instead of primary antibody (Figure 3H) or when a no primary control was performed 
(Figure 3.3I).  With all antibodies, the question has to be asked whether there is the 
possibility that macrophage subtypes change (during disease progression), and that the 
F4/80 staining may simply reflect F4/80-positive macrophage subtypes at particular 
phases of pulmonary fibrosis.  However, there is no evidence to date that F4/80-positive 
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Macrophages increase in number during bleomycin-induced pulmonary fibrosis 
Female C57Bl/6 mice were given 0.033mg of bleomycin i.t. (50µl) and culled on day 3, 
7, 14, 21, 25 and 28.  0.9% saline was given i.t. as a control and mice culled on day 14.  
Immunohistochemistry was performed for the F4/80 antigen (A)-(F).  An isotype control 
was given instead of primary antibody (G), and a no primary control was also performed 
(H).  (A) Mice given bleomycin and culled on day 3 show minimal staining for the 
F4/80 antigen.  (B) Mice given bleomycin and culled on day 7 show minimal staining 
for F4/80.  (C) Mice given bleomycin and culled on day 14 show an increase in staining 
for F4/80.  (D) Mice given bleomycin and culled on day 21 show a marked increase in 
F4/80 staining.  (E) Mice given bleomycin and culled on day 25 show a persistence of a 
marked increase in F4/80 staining.  (F) Mice given bleomycin and culled on day 28 
show a persistence of a marked increase in F4/80 staining.  (G) Mice given 0.9% saline 
and culled on day 14 show some minimal staining for F4/80.  (H) Mice given bleomycin 
and culled on day 25 show no staining when an isotype control antibody was used 
instead of the F4/80 primary antibody.  (I) Mice given bleomycin and culled on day 21 
show no staining when secondary, but no primary, antibody was given.  Arrow: F4/80 














Myofibroblasts increase in number during bleomycin-induced pulmonary fibrosis 
Female C57Bl/6 mice were given 0.033mg of bleomycin i.t. (50µl) and culled on day 3, 
7, 14, 21, and 28.  0.9% saline was given i.t. as a control and mice culled on day 14.  
Sections were stained for the presence of the α-smooth muscle actin (α-SMA) antigen.  
The α-SMA antigen is a marker of myofibroblasts, a term originally coined by Gabbiani 
and colleagues (Gabbiani et al., 1971).  Myofibroblasts are believed to contribute 
significantly to collagen deposition (Zhang et al., 1994) and play a major role in the 
pathogenesis of pulmonary fibrosis (Zhang et al., 1994; Gharaee-Kermani et al., 2009).  
Using immunohistochemistry I have established that myofibroblast numbers increase in 
my model of bleomycin-induced pulmonary fibrosis, as shown in Figure 3.4, A-E, with 
an apparent peak between 14 and 28 days.  The apparent peak is not an absolute 
description.  The difficulty with a non solid organ such as the lung is that in any one 
lung histological section, staining for myofibroblasts can be seen to be positive, but as 
the shape of myofibroblasts is such that they have long projections, any positive staining 
is not quantifiable in terms of cell numbers.  An alternative approach is to quantify the 
percentage of positive staining, which is possible in the liver and kidney.  However, as 
the lung consists of so much air, then this method of quantification is also not possible.  
Therefore, while the apparent peak of myofibroblast staining is between 14 and 28 days, 
it is not possible to be absolute sure that this is true.  However, in all lung sections 
analysed it is clear that this increase in staining between 14 to 28 days is consistent, and 
is probably therefore a true effect.  In control mice myofibroblasts are only present in 
vessels (Figure 3.4F).  There is no staining within the lung interstitium or in vessels 
when a no primary control was performed (Figure 3.4G). 
 
One question that can be asked is whether α-SMA defines all myofibroblasts, and 
therefore whether α-SMA staining is sensitive in the detection of myofibroblasts.  While 
it is likely that there is considerable fibroblast heterogeneity (Phan 2008), it is well 
established that α-SMA-positive fibroblasts are myofibroblasts, and these are the 
predominant source of type I collagen and fibrogenic cytokines in the lung, as well as 
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exerting mechanical effects on fibrotic tissue (Zhang et al., 1994, Phan 2002).  Whether 
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Myofibroblasts increase in number during bleomycin-induced pulmonary fibrosis 
Female C57Bl/6 mice were given 0.033mg of bleomycin i.t. (50µl) and culled on day 3, 
7, 14, 21 and 28.  0.9% saline was given i.t. as a control and mice culled on day 14.  
Immunohistochemistry was performed for the α-SMA antigen (A)-(F).  A no primary 
control was also performed (G).  (A) Mice given bleomycin and culled on day 3 show no 
staining within the lung interstitium, but appropriate staining within vessels.  (B) Mice 
given bleomycin and culled on day 7 show some staining within the lung interstitium.  
(C) Mice given bleomycin and culled on day 14 show an increase in staining within the 
lung interstitium.  (D) Mice given bleomycin and culled on day 21 show an increase in 
staining within the lung interstitium.  (E) Mice given bleomycin and culled on day 28 
show an increase in staining within the lung interstitium.  (F) Mice given 0.9% saline 
and culled on day 14 no staining within the lung interstitium but appropriate staining 
within vessels.  (G) Mice given bleomycin and culled on day 28 show no staining when 

















Stages of bleomycin-induced pulmonary fibrosis 
Following on from the previous results I sought to consolidate my earlier findings of the 
stages of pulmonary fibrosis using higher ‘n’ numbers, and further defining the model in 
some more detail.  Female C57Bl/6 mice, 10-14 weeks old and weight matched, were 
given 0.033mg bleomycin i.t. (50µl) and culled on days 18, 32 and 56.  Fibrosis was 
quantified by Sircol assay on days 18, 32 and 56 and corroborated with histopathological 
fibrosis score on days 18 and 32.  Peri-bronchial and peri-vascular inflammation scores 
were performed on days 18 and 32.  As can be seen in my model, administration of  
0.033mg bleomycin i.t. to female C57Bl/6 mice reliably causes acute inflammation, 
followed by early fibrosis at 18 days (Figure 3.5, A, B and F) and peak fibrosis at 32 
days (Figure 3.5, A, B and G).  Peri-vascular and peri-bronchial inflammation increase 
until day 18 and decrease thereafter (Figure 3.5, C and D).  Furthermore I demonstrate 
that fibrosis is reversible after 32 days, with a significant reduction in lung fibrosis 
occurring by day 56 as measured by Sircol assay (Figure 3.5A) and confirmed by 
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Figure 3.5.2 
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Figure 3.5  
Stages of bleomycin-induced pulmonary fibrosis 
Female C57Bl/6 mice were given 0.033mg bleomycin intra-tracheally (i.t., 50µl) and 
culled on days 18, 32 and 56.  0.9% saline was given as a control.  Fibrosis was 
measured by Sircol assay (A) or semi-quantitative fibrosis score (B).  Inflammation was 
assessed by semi-quantitative peri-bronchial (C) and peri-vascular (D) scores.  (A) Mice 
were given 0.9% saline or bleomycin by i.t. instillation, culled during early lung fibrosis 
(day 18), progressive fibrosis (day 32), fibrosis resolution (day 56), and lung collagen 
assessed.  Significant differences in lung collagen were found between 0.9% saline-
treated and bleomycin-treated groups at both 18 days (**, p=0.0051) and 32 days (***, 
p=0.0008).  By 56 days collagen levels had returned to near 0.9% saline levels.  (B) 
Mice given bleomycin were culled at 18 or 32 days and fibrosis score assessed.  Mice 
given 0.9% saline were culled at 18 or 32 days and fibrosis score assessed.  Significant 
differences in fibrosis score were found between mice culled at 32 days (0.9% saline vs. 
bleomycin, ***, p=0.0002) and between mice given bleomycin and culled at day 18 or 
day 32 (**, p=0.0011). (C) Mice were given 0.9% saline and culled at 18 days, or 
bleomycin and culled at 18 and 32 days.  Peri-bronchial inflammation score was 
assessed.  Significant differences in score were found between mice culled at 18 days 
(0.9% saline vs. bleomycin, **, p=0.0024) and between mice given bleomycin and 
culled at day 18 or day 32 day (**, p=0.0073).  (D) Mice were given 0.9% saline and 
culled at 18 days, or bleomycin and culled at 18 and 32 days.  Peri-vascular 
inflammation score was assessed.  Significant differences in score were found between 
mice culled at 18 days (0.9% saline vs. bleomycin, **, p=0.0047).  There was a trend to 
reduction in score between mice given bleomycin and culled at day 18 or day 32 day.   
(E) Masson’s trichrome stain, 0.9% saline day 32.  (F) Masson’s trichrome stain, 
bleomycin day 18. (G) Masson’s trichrome stain, bleomycin day 32.  (H) Masson’s 
trichrome stain, bleomycin day 56.  n=4-8 for each group.  Data are presented as (A) 
mean +/- SEM, and (B)-(D) Box and whiskers (Median, Inter-quartile range, minimum 
to maximum).  Bar 200µm (E)-(G), 100µm (H). 
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Adenoviral transforming growth factor-β (AdTGFβ) induces pulmonary fibrosis 
Administration of AdTGFβ by i.t. route has been shown to induce prominent lung 
fibrosis (Sime et al., 1997; Warshamana et al., 2002).  Female C57Bl/6 mice, 10-14 
weeks old and weight matched, were given a range of doses of AdTGFβ i.t. and culled 
on day 5 to assess TGFβ levels in the bronchoalveolar lavage fluid (BALF), and on day 
14 to assess pulmonary fibrosis.  In my hands I have established that at least 1x10
8
 
pfu/50µl of AdTGFβ administered by i.t. route were required to ensure that TGFβ was 
detectable in bronchoalveolar lavage fluid (BALF) after 5 days as measured by ELISA 
(Figure 3.6A).  Fibrosis measured at 14 days by Sircol assay was dose dependent (Figure 
3.6B).  At quantities of AdTGFβ of 5x108 pfu/50µl mice became unwell and had to be 
culled early.  Administration of empty viral vector (AdDL70-3) did not induce lung 
fibrosis as seen on lung sections stained by Masson’s trichrome (Figure 3.6C) or as 
measured by Sircol assay (Figure 3.6A).  Administration of AdTGFβ causes significant 






















































Adenoviral transforming growth factor-β  (AdTGFβ) induces pulmonary fibrosis 
Female C57Bl/6 mice were given adenoviral-TGFβ (AdTGFβ) intra-tracheally (i.t., 
50µl).  AdDL70-3, empty viral vector, was given as a control.  (A) Administration of 
AdTGFβ results in production of TGFβ, as measured in bronchoalveolar lavage fluid 
(BALF), and is dose-dependent. (B) AdTGFβ induces pulmonary fibrosis as measured 
by Sircol assay and is dose-dependent. (C) Masson’s trichrome staining 14 days 
following administration of AdDL70-3 (1x10
8
 pfu/50µl).  (D) Masson’s trichrome 
staining 14 days following administration of AdTGFβ (1x108 pfu/50µl).  (A)-(B) n=3 























I have shown that I have developed a model of pulmonary fibrosis induced by 
administration of bleomycin intra-tracheally.  I have shown that 0.033mg (~0.05U) of 
bleomycin may be administered safely to induce lung injury characterised by very early 
inflammation, early fibrosis at 18 days, and peak fibrosis around 28-32 days.  
Furthermore I have shown that during injury there is an increase in macrophage numbers 
with a peak around 21-28 days, and a concurrent increase in myofibroblast numbers with 
a peak between 14 and 28 days.  By 56 days, pulmonary fibrosis has significantly 
resolved, and is absent by 136 days.   
 
As has been mentioned previously, although bleomycin-induced lung fibrosis is the best 
characterised animal model of pulmonary fibrosis, there remains debate in the literature 
as to its usefulness as a model of IPF (Borzone et al., 2001; Chua et al., 2005).  This 
debate has arisen as a result of a number of factors.  Firstly, intra-tracheal administration 
of bleomycin produces a bronchiolocentric pattern of lung fibrosis.  This is in contrast to 
IPF where a peripheral and sub-pleural pattern of fibrosis is seen (Scadding & Hinson 
1967).  However, intravenous or intra-peritoneal administration of bleomycin will 
induce pulmonary fibrosis in a peripheral and sub-pleural distribution (Adamson 1976; 
Baran et al., 2007), akin to IPF.  The question therefore (to my mind) is not whether the 
pattern of fibrosis that bleomycin induces is absolutely comparable with IPF, but 
whether the fibrosis that bleomycin induces may be used as a tool to study the fibrosis of 
IPF.  It is clear from over the years that the bleomycin model has informed considerable 
understanding of pulmonary fibrosis, of direct applicability to IPF, and it is for these 
reasons that bleomycin continues to be used.   
 
A second aspect of the bleomycin model which often raises concern is that it induces 
significant inflammation that precedes fibrosis.  This is in contrast to modern theories of 
IPF which propose that IPF develops in the absence of preceding inflammation (Selman 
et al., 2001; Gauldie 2002).  However, a well recognised advantage of the bleomycin 
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model is its reproducibility (Chua et al., 2005).  As such, once the model has been 
optimised in a research facility, the stage of progressive fibrosis can be defined and 
interrogated.  This approach has become increasingly adopted, with investigators 
targeting this post-inflammatory fibrotic phase of the bleomycin model to gather 
information that has clear translational potential (Fichtner-Feigl et al., 2006; Chaudhary 
et al., 2007; Choi et al., 2009) with regard to fibrotic lung disease.  It was using this 
premise that my depletional studies were designed.  Whether inflammation precedes 
fibrosis in IPF is in itself a matter for much debate (Gauldie 2002; Strieter 2002; Stramer 
et al., 2007).  The dominant theory in the lung community at present is that the fibrosis 
of IPF occurs in the absence of inflammation (or in the presence of minimal 
inflammation) (Selman et al., 2001), although some prominent respiratory researchers 
do still favour an inflammation-fibrosis link in IPF (Strieter 2002; Keane 2008). 
 
A third aspect of the bleomycin model that raises concern is its durability (Borzone et 
al., 2001; Chua et al., 2005).  Borzone and colleagues have questioned the usefulness of 
the bleomycin model as a model of lung fibrosis.  In their paper they state that the 
fibrosis seen in the bleomycin model is bronchiolocentric rather than peripheral, as in 
IPF, a contention that has been discussed above.  Furthermore, they state that the later 
stage of their bleomycin model (>30 days in rats) is characterised by emphysema.  This 
is because the greatest difference in emphysema score between control mice and 
bleomycin-treated mice was present at 130 days.  However, analysis of the data shows 
that in bleomycin-treated animals emphysema is present at 15 days and is similar to that 
seen at 130 days.  The difference that they cite thus reflects a reduction in emphysema 
score in control animals rather than an increase in bleomycin-treated animals per se.  
Furthermore, they have used a parametric test to analyse data that should have been 
analysed by a non-parametric test, questioning the validity of the data.  Furthermore, this 
researcher believes that any emphysema score has inherent problems; the mere act of 
fixing lungs can induce “emphysema” as a result of the inflation technique used.  My 
own histology demonstrates that lungs can be over-inflated and thus induce artifactual 
emphysema-like changes.  In addition, my own late stage bleomycin groups (day 136) 
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do not have gross emphysema-like changes compared to the earlier time points.  As a 
result therefore, I have some concerns over how much genuine importance can be 
attributed to this much cited paper. 
 
In summary therefore, I have established a model of pulmonary fibrosis that is 
reproducible, reversible, has clearly defined stages of pulmonary fibrosis, and which 
demonstrates the time-points at which the appearance of macrophages and 
myofibroblasts is most prominent.  
 
Finally, I went on to use the AdTGFβ model of pulmonary fibrosis.  I established that 
1x10
8
 pfu of AdTGFβ was the optimal dose that would allow detection of AdTGFβ in 
BALF,  induce significant fibrosis at 14 days, and not be harmful to mice.  The AdTGFβ  
model has been used in several studies examining the pathogenesis of pulmonary 
fibrosis (Sime et al., 1997; Liu et al., 2001; Warshamana et al., 2002a; Washmen et al., 
2002b; Ask et al., 2008).  As mentioned previously, some researchers believe it is more 
resemblant of IPF as it induces lung fibrosis with minimal inflammation.  However, as 
the virus has tropism for the bronchial and alveolar epithelium, then any pulmonary 
fibrosis that ensues is epithelial-dependent.  This would favour the hypothesis that IPF is 
initiated through epithelial injury (Selman et al., 2001), but raises come concern over 
whether this model has general applicability to a more global lung injury, if that is what 
causes IPF.  Regardless, using two well characterised models of pulmonary fibrosis 
should ensure that any findings are likely to reflect the true pathogenesis of pulmonary 















Although alternatively activated macrophages have substantive pro-fibrotic functions, 
the role of macrophages in pulmonary fibrosis remains undefined and controversial.  
Using in vivo depletional strategies I demonstrate that lung macrophages are key 
regulators of pulmonary fibrosis and exhibit differential effects during lung fibrogenesis 
as compared with lung fibrosis resolution.  Specifically, depletion of lung macrophages 
during lung fibrogenesis leads to amelioration of lung fibrosis.  In contrast, depletion of 
lung macrophages during fibrosis resolution leads to a persistence of lung fibrosis.  
Furthermore, I identify the alternatively activated macrophage phenotype as a key 
cellular regulator during lung fibrogenesis in a murine model of lung fibrosis, and show 
the presence of this macrophage phenotype in the archetypal human fibrotic lung 

















Pulmonary fibrosis is the common end-point of many disorders of the lung such as the 
adult respiratory distress syndrome (ARDS), granulomatous disorders of the lung 
including sarcoidosis, occupational lung diseases such as asbestosis, and collagen 
vascular diseases with lung involvement such as rheumatoid arthritis, systemic sclerosis 
and systemic lupus erythematosis (SLE) (American Thoracic Society/European 
Respiratory Society International Multidisciplinary Consensus Classification of the 
Idiopathic Interstitial Pneumonias).  The archetypal fibrotic lung disease, idiopathic 
pulmonary fibrosis, is a devastating disorder with an unknown natural history (Gross et 
al., 2001); there are no effective therapies (Walter et al., 2006), its incidence is rising 
(Raghu et al., 2006) and it has a median survival of between 2.5-3.5 years (Nagai et al., 
1999; King et al., 2000; Selman et al., 2001). 
 
There has been much controversy regarding the role of macrophages in the pathogenesis 
of pulmonary fibrosis.  Several papers have recently suggested their importance (Okuma 
et al., 2004; Mora et al., 2006; Prasse et al., 2006; Baran et al., 2007; Murray et al., 
2010).  Importantly, it has been demonstrated in rodents using the bleomycin model that 
lung macrophages are likely to be the predominant source of transforming growth 
factor-β (TGFβ) (Khalil et al., 1989), a most prominent fibrosis-inducing molecule.  
Furthermore it has been shown in a model of lung fibrosis that corticosteroid treatment 
has no effect on alveolar macrophage secretion of TGFβ, and that when alveolar 
macrophages from bleomycin treated animals are cultured in the presence of 
corticosteroids there is in fact increased secretion of TGFβ (Khalil et al., 1993).  
Moreover, a recent study in patients who develop an accelerated form of fibrotic lung 
disease demonstrated that they have dysregulated alveolar macrophages (Rouhani et al., 
2009). 
 
Functional activation states of macrophages are associated with fibrogenic phenotypes in 
mice and humans (Mantovani et al., 2002; Gordon 2003; Varin & Gordon 2009).  In 
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solid organs such as the liver and kidney, the critical role of the macrophage in 
regulating fibrosis is well established (Duffield et al., 2005; Henderson et al., 2008).   
 
I sought to determine whether lung macrophages are involved in the pathogenesis of 
lung fibrosis.  Using the bleomycin and adenoviral-TGFβ models of lung injury and 
fibrosis in mice, I assessed the effects of depletion of lung macrophages during both the 
early and progressive phases of lung fibrogenesis and during the resolution phase of lung 
fibrosis.  My work demonstrates that lung macrophages are required for both lung 
fibrogenesis and fibrosis resolution.  Furthermore, I demonstrate the importance of the 
alternatively activated lung macrophage phenotype during lung fibrogenesis in mice, and 























Liposomal clodronate depletes lung macrophages  
Administration of liposomal clodronate (dichloromethylene bisphosphonate or Cl2MBP) 
is a well established method of selectively and effectively depleting macrophages (Getts 
et al., 2008; Jaiswal et al., 2009; Zhang et al., 2009).  It is selectively taken up by 
phagocytes which subsequently die of apoptosis, the so called liposome-mediated 
macrophage ‘suicide’ approach (van Rooijen et al., 1994; van Rooijen et al., 1996).  
Liposomal clodronate has been shown to effectively deplete lung macrophages (Thepen 
et al., 1989; Holt et al., 1993; Manicone et al., 2009).  Peak depletion occurs after 24 
hours, but persists for up to 5 days (Thepen et al., 1989).   
 
I administered liposomal clodronate (100µl) by i.t. route to 0.9% saline-treated female 
C57Bl/6 mice and show by immunohistochemistry that lung macrophages are 
effectively depleted (Figure 4.1, A and B).  Lung macrophages were stained using the 
macrophage-restricted marker, F4/80.  To establish whether administration of liposomal 
clodronate i.t. depletes lung macrophages in the context of bleomycin injury, female 
C57Bl/6 mice were given 0.033mg bleomycin i.t. on day 0, liposomal clodronate 
(100µl) i.t. on day 21 and culled on day 22.  I show that lung macrophages are 
effectively depleted (Figure 4.1, C, D and E) and using a semi-quantitative score I 
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Liposomal clodronate depletes lung macrophages  
Female C57Bl/6 mice were given i.) 0.9% saline i.t. (50µl)  +/- liposomal clodronate 
(LC) i.t. (100µl) and culled 24 hours later, or, ii) bleomycin i.t. (50µl) +/- liposomal 
clodronate i.t. (100µl) on day 21 and culled 24 hours later.  Immunohistochemistry 
(IHC) with F4/80 antibody staining was performed on lung sections (A)-(D), and 
quantified (E).  (A) 0.9% saline i.t. alone showing lung macrophages stain with F4/80 
antibody.  (B) 0.9% saline plus LC i.t. demonstrates that lung macrophages are 
effectively depleted.  (C) Bleomycin i.t. alone showing lung macrophages stain with 
F4/80 antibody.  (D) Bleomycin plus LC i.t. demonstrates that lung macrophages are 
effectively depleted.  (E) Mice were given 0.9% saline or bleomycin (B) alone and 
culled on day 22, or B plus LC (day 21) and culled on day 22.  Quantification of F4/80 
positive cells per field was performed.  There was a 70% reduction in the number of 


















Lung macrophages are not necessary for the inflammation initiation of fibrosis 
To assess the role of lung macrophages during the inflammatory phase of bleomycin-
induced lung fibrosis, I administered a single i.t. instillation of 0.033mg bleomycin and 
culled mice after 18 days.  Liposomal clodronate (100µl) was given i.t. on either day 3, 7 
or 14.  Additional controls of 0.9% saline (50µl) and liposomal PBS (100µl) were given 
i.t. on day 0 and mice culled on day 18.  As shown in Figure 4.2A, depletion of lung 
macrophages at any of the time-points has no effect on the inflammatory phase and early 
induction of lung fibrosis as measured by Sircol assay.  This lack of effect was 
confirmed by Masson’s trichrome staining on lung sections as can be seen in 
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Figure 4.2 
Lung macrophages are not necessary for the inflammation initiation of fibrosis 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl) and culled on day 18.  
In addition to bleomycin, groups of mice were also given liposomal clodronate (LC) i.t. 
(100µl) at various time-points.  All mice were culled on day 18.  Fibrosis was measured 
by Sircol assay.  0.9% saline (50µl) and liposomal control (liposomal phosphate 
buffered saline, LPBS (100µl)) were given i.t. as controls and mice culled on day 18.  
Significant differences in fibrosis were found between bleomycin and controls (vs. 
saline, **p=0.0012; vs. LPBS *p=0.0160), but there were no differences when LC was 
given in combination with bleomycin.  (B)-(G) Masson’s trichrome staining on 
representative lung sections of mice treated with: (B) 0.9% saline alone, (C) LPBS 
alone, (D) Bleomycin alone, (E) Bleomycin plus LC i.t. on day 3, (F)  Bleomycin plus 
LC i.t. on day 7, (G) Bleomycin plus LC i.t. on day 14.  n=6-8 per group.  Data are 


















Depletion of lung macrophages during the inflammatory phase of bleomycin-
induced pulmonary fibrosis has no effect on subsequent pulmonary fibrosis  
To assess whether macrophages present during the inflammatory phase of bleomycin-
induced lung fibrosis play a role in the subsequent development of pulmonary fibrosis, I 
administered a single i.t. instillation of 0.033mg bleomycin and culled mice after 32 
days.  Liposomal clodronate (100µl) was given i.t. on three consecutive days: 13, 14 and 
15.  As shown in Figure 4.3A, depletion of lung macrophages during the inflammatory 
phase of bleomycin-induced pulmonary fibrosis has no effect on the subsequent 
development of pulmonary fibrosis, as measured by Sircol assay.  This lack of effect 
was confirmed by Masson’s trichrome staining on lung sections as can be seen in 

























































Depletion of lung macrophages during the inflammatory phase of bleomycin-
induced pulmonary fibrosis has no effect on subsequent pulmonary fibrosis  
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl).  In addition to 
bleomycin, a group of mice were also given liposomal clodronate (LC) i.t. (100µl) on 
three consecutive days: 13, 14 and 15.  All mice were culled on day 32.  Fibrosis was 
measured by Sircol assay.  (A) No difference in fibrosis was found following lung 
macrophage depletion (bleomycin vs. bleomycin, B, plus LC on days 13, 14, 15, p=ns).  
(B) and (C) Masson’s trichrome staining on representative lung sections of mice treated 
with: (B) bleomycin alone or (C) bleomycin plus LC i.t. on days 13, 14, 15.  n=6 per 





















Lung macrophages regulate the progressive fibrotic phase of pulmonary fibrosis in 
the bleomycin model    
Having established that macrophages appear to have no role in the inflammation 
initiation of fibrosis, and that depletion of macrophages during the inflammatory phase 
has no effect on subsequent on pulmonary fibrosis in the bleomycin model, I next  
wished to evaluate the role of lung macrophages during the progressive fibrotic phase of 
pulmonary fibrosis (day 18 onwards).  In my bleomycin model, fibrosis peaks at 32 days 
(Chapter 3, Figure 3.5, A, B and G).  Consequently, female C57Bl/6 mice were given 
0.033mg bleomycin i.t. on day 0 and culled on day 32.  Lung macrophages were 
depleted by giving liposomal clodronate (100µl) as a single instillation i.t. on either day 
21 or day 28.  As shown in Figure 4.4A, depletion of lung macrophages at both time 
points significantly reduces the degree of pulmonary fibrosis that develops as measured 
by Sircol assay.  It has previously been shown that this effect is not due to apoptosis per 
se because rats given apoptotic macrophages (Wang et al., 2003) or apoptotic cells 
(Wang et al., 2006) actually develop lung fibrosis.  However, to ensure that this result 
was mediated by lung macrophage depletion per se rather than being a liposomal effect, 
I set up an independent experiment where female C57Bl/6 mice were given 0.033mg 
bleomycin i.t. alone or 0.033mg bleomycin i.t. on day 0 plus liposomal phosphate-
buffered saline (LPBS) i.t. (100µl) on day 21, and culled on day 32.  As shown in Figure 
4.4, K, L, and M there was no reduction in fibrosis after administration of LPBS.   
 
Reduction in pulmonary fibrosis following lung macrophage depletion was confirmed 
by semi-quantitative fibrosis scoring of lung sections stained by Masson’s trichrome 
(Figure 4.4, B, C, D and E).  Furthermore, quantitative PCR (qPCR) performed on lung 
homogenates 25 days after bleomycin instillation demonstrated a reduction in expression 
of the surrogate markers of fibrosis α−smooth muscle actin (α-SMA) and Col1A1 after 
depletion of lung macrophages (on day 21) (Figure 4.4, F and G, respectively).  Standard 
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Lung macrophages regulate the progressive fibrotic phase of pulmonary fibrosis in 
the bleomycin model    
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl) and fibrosis quantified 
(A), (B).  0.9% saline was given i.t. (50µl) as a control.  Bleomycin 0.033mg (50µl) +/- 
liposomal control (LPBS) i.t. (100µl) were administered to female C57Bl/6 mice in an 
independent experiment (H)-(J).  (A), (B) Mice were given 0.9% saline, bleomycin 
alone, or bleomycin, B, plus liposomal clodronate (LC) i.t. (100µl) during progressive 
fibrosis and culled at peak lung fibrosis (day 32).  Depletion of lung macrophages 
reduces lung fibrosis as measured by Sircol assay (B alone vs. B plus LC (day 21), 
*p=0.0247; B vs. B plus LC (day 28), **p=0.0087).  (B) Depletion of lung macrophages 
reduces lung fibrosis as quantified by fibrosis score (B vs. B plus LC (day 21), 
**p=0.0051; B vs. B plus LC (day 28), trend to reduction).  (C)-(E) Masson’s trichrome 
staining on representative lung sections of mice treated with bleomycin (C),    B plus LC 
(day 21) (D) or B plus LC (day 28) (E).  (F) and (G) Female C57Bl/6 mice were given 
bleomycin 0.033mg (50µl) +/- LC i.t. (100µl) on day 21 and culled on day 25.  qPCR 
was performed on lung homogenates.  (F) Depletion of lung macrophages leads to a 
reduction in α-SMA gene expression, *p=0.0349.  (G) Depletion of lung macrophages 
leads to a reduction in Col1A1 gene expression, **p=0.0083. (H)-(J) Representative 
standard curves used in qPCR analysis are shown for (H) αSMA, bleomycin treated 
lung, (I) Col1A1, bleomycin treated lung, (J) 18S, bleomycin treated lung.  (K)-(M) 
Female C57Bl/6 mice were given bleomycin alone, or bleomycin, B, plus LPBS i.t. 
(100µl) on day 21 and culled on day 32.  (K) Administration of bleomycin plus 
liposomal control does not reduce fibrosis as measured by Sircol assay.  (L)-(M) 
Masson’s trichrome staining on representative lung sections of mice treated with 
bleomycin (L) or bleomycin, B, plus LPBS (day 21) (M).  (A)-(E) n=6-15.  (F)-(G) n=3-
5.  (K)-(M) n=5  Data are presented as (A), (F), (G), (K) mean +/- SEM, and, (B) Box 
and whiskers (Median, Inter-quartile range, minimum to maximum).  Bar 100µm. 
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Lung macrophages regulate the progressive fibrotic phase of pulmonary fibrosis in 
the AdTGFβ model    
Having established that lung macrophages regulate the progressive fibrotic phase of 
bleomycin-induced pulmonary fibrosis, I wished to back up my findings using a second 
model.  As a result I next sought to determine the effect of depletion of lung 
macrophages during the progressive fibrotic phase of fibrosis in the AdTGFβ model.  
Previous work using this model in mice has established that peak fibrosis occurs at 
around 14 days (Warshamana et al., 2002).  My dose finding study (Chapter 3, Figure 
3.6B) identified 1x108 pfu/50µl as the optimal dose of AdTGFβ that could be given to 
induce significant lung fibrosis without causing harm.  As a result female C57Bl/6 mice 
were given 1x10
8
 pfu (50µl) of AdTGFβ i.t. on day 0 and culled on day 14.  In addition 
mice were given liposomal clodronate (100µl) i.t. on day 10.  Empty adenoviral vector 
(AdDL70-3, 1x10
8
 pfu (50µl)) was given i.t. as a control and did not induce fibrosis 
(Figure 4.5, A and B).  Depletion of lung macrophages leads to a reduction in pulmonary 
fibrosis as measured by Sircol assay (Figure 4.5A).  This was confirmed by Masson’s 
trichrome staining of lung sections as can be seen in representative images shown in 
Figure 4.5, C and D.  These results back up my findings in the bleomycin model and 
further suggest that lung macrophages are important in promoting the progressive phase 
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Figure 4.5 
Lung macrophages regulate the progressive fibrotic phase of pulmonary fibrosis in 
the AdTGFβ model    
Female C57Bl/6 mice were given 1x10
8
 pfu of AdTGFβ i.t. (50µl) and fibrosis 
quantified by Sircol assay (A).  AdDL70-3 (1x10
8
 pfu/50µl) was given as a control.  
Masson’s trichrome staining was performed on lung sections (B)-(D).  (A) Mice were 
given AdDL70-3, AdTGFβ alone or AdTGFβ (AdT) plus liposomal clodronate (LC) i.t. 
(100µl) on day 10 and culled at peak lung fibrosis (day 14).  Depletion of lung 
macrophages reduces lung fibrosis as measured by Sircol assay (AdTGFβ alone vs. AdT 
plus LC (day 10), **p=0.0079).  (B) AdDL70-3 does not induce significant fibrosis at 
14 days.  (C) AdTGFβ induces significant fibrosis by 14 days.  (D) Depletion of lung 
macrophages ameliorates lung fibrosis.  (A)-(D) n=4-5.  Data are presented as mean +/- 



















 cells regulate the progressive fibrotic phase of pulmonary fibrosis in the 
bleomycin model    
As the role of macrophages in pulmonary fibrosis has been controversial for such a long 
time, I wanted to be absolutely sure that my previous findings truly indicated the 
importance of macrophages in the pathogenesis of pulmonary fibrosis.  Consequently, I 
sought to establish the role of macrophages in pulmonary fibrosis using a different and 
independent lung macrophage depletional strategy.  As a result I used CD11c-DTR 
transgenic mice.  Their generation has previously been described (Hochweller et al., 
2008).  They were kindly supplied by Dr Andrew MacDonald (Institute of Immunology 
and Infection Research, University of Edinburgh) and Professor Gunter Hammerling 
(Deutsches Krebsforschungszentrum (DKFZ, German Cancer Research Centre), 
Heidelberg).  Administration of diphtheria toxin (DT) i.t. to this transgenic mouse is 
known to deplete CD11c
+
 cells (Landsman et al., 2007; van Rijt et al., 2005).  In the 
lung interstitium, the major CD11c
+
 cell type is the interstitial macrophage, dendritic 
cells being the minor component (Landsman et al., 2007).  Within the alveolar space 
alveolar macrophages represent 80-90% of the CD11c
+
 cell population (Landsman et al., 
2007), the remainder being dendritic cells (Landsman et al., 2007; van Rijt et al., 2005).  
The major effect of the CD11c-DTR transgenic system therefore is the depletion of lung 
macrophages, both interstitial and alveolar.  It also depletes dendritic cells, however they 
represent in absolute numbers the minor component of the lung CD11c
+
 cell population.  
Furthermore, it has been argued that dendritic cells are “immature macrophages” and 
simply represent “a heterogeneous subset of mononuclear phagocytes [macrophages]” 
(Hume 2008), and as such it could be argued (especially in the lung) that all CD11c
+
 
cells are a subset of macrophages.  Administration of DT depletes interstitial 
macrophages for up to 9 days and alveolar macrophages for 2-4 days (Landsman et al., 
2007).  For this reason I used the CD11c-DTR transgenic system as another means of 
evaluating the effect of depletion of lung macrophages on lung fibrogenesis.   
 
I assessed the effect of depletion of lung macrophages on the degree of lung fibrosis 
using the bleomycin model.  Initially I assessed the efficiency of CD11c
+
 cell depletion, 
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using DT, by performing flow cytometric analysis on cells from bronchoalveolar lavage 
(BAL) fluid: female CD11c-DTR mice were given 0.033mg bleomycin i.t. followed by 
DT i.t. (8ng/g, 50µl) on day 21.  Mice were culled on day 22.  As shown in Figure 4.6, 
D-H administration of DT results in a greater than 90% reduction in the number of 
CD11c+ cells in BALF.  Next female CD11c-DTR mice were given 0.033mg bleomycin 
i.t. on day 0 +/- DT (8ng/g, 50µl) i.t. on day 21, and culled on day 32 to assess the effect 
on lung fibrosis.  As demonstrated in Figure 4.6A depletion of lung macrophages results 
in a significant reduction in lung fibrosis as measured by Sircol assay.  Masson’s 
trichrome staining on lung sections confirmed this finding as can be seen in 
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 cells regulate the progressive fibrotic phase of pulmonary fibrosis in the 
bleomycin model    
Female CD11c-DTR mice were given 0.033mg bleomycin i.t. (50µl) +/- diphtheria toxin 
(DT) 8ng/g i.t. (50µl) on day 21 and culled on day 32 (A)-(C) or day 22 (D)-(H).  (A) 
Depletion of lung macrophages ameliorates lung fibrosis as measured by Sircol assay 
(Bleomycin (B) alone vs. B plus DT, **p=0.0044).  (B) and (C) Masson’s trichrome 
staining on representative lung sections of mice treated with B alone (B), or B plus DT 
(C).  Bronchoalveolar lavage (BAL) cells were taken and analysed by flow cytometry 
(D)-(F) or cytospins created (G)-(H).  BAL cells were stained with anti-CD11b:FITC, 
IAb:PE and CD11c:APC.  DT administration depletes BAL macrophages by >90% (E)-
(F).  BAL macrophages (G) are replaced by mononuclear cells and granulocytes 
following DT administration (H).  (A)-(C) n=6-7, (D)-(H) n=2 per group.  Data are 


















Lung macrophages regulate the resolution phase of pulmonary fibrosis   
Previous work from our own group in an experimental model of liver fibrosis has 
demonstrated the distinct functions that macrophages exhibit during liver fibrosis 
progression and resolution (Duffield et al., 2005).  It has been known for some time that 
the bleomycin model exhibits reversibility in its later stages (Izbicki et al., 2002; Moore 
et al., 2008) but this has not been intensely studied.  I have shown already in my model 
that pulmonary fibrosis peaks around 32 days (Chapter 3, Figure 3.5, A, B and G).  
When I extended the time course I established that fibrosis had significantly resolved by 
56 days (Chapter 3, Figure 3.2, A and H; Chapter 3, Figure 3.5, A and H).  I therefore 
aimed to elucidate the role of lung macrophages during the resolution phase of 
bleomycin-induced pulmonary fibrosis. 
 
Female C57Bl/6 mice were given bleomycin 0.033mg i.t. on day 0, with or without 
liposomal clodronate (100µl) i.t. daily on days 42-46.  Mice were culled on day 56.  As 
shown in Figure 4.7B, depletion of lung macrophages leads to a slowing of the 
resolution of fibrosis.  Masson’s trichrome staining of lung sections confirms this effect 
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Figure 4.7 
Lung macrophages regulate the resolution phase of pulmonary fibrosis   
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl) and culled on day 32 or 
56 (A).  In addition a group of mice were given bleomycin plus liposomal clodronate 
(LC) i.t. (100µl) daily on days 42-46 and culled on day 56 (B).  Fibrosis was measured 
by Sircol assay.  Masson’s trichrome staining was performed on lung sections (C)-(D).  
(A) There is significant reversibility of lung fibrosis between day 32 and day 56 
(bleomycin day 32 vs. bleomycin day 56, ***p<0.001).  (B) Depletion of lung 
macrophages during the recovery phase slows the resolution of lung fibrosis (bleomycin 
alone vs. bleomycin, B, plus LC on days 42-46, *p<0.05).  (C) & (D) Masson’s 
trichrome staining of representative lung sections demonstrates resolution of lung 
fibrosis (C), which is attenuated following lung macrophage depletion (D). (A) n=7-15, 


















Alternatively activated macrophages characterise the progressive fibrotic phase of 
pulmonary fibrosis in mice   
Several macrophage phenotypes have now been broadly described (Gordon & Taylor 
2005).  I have demonstrated that lung macrophages regulate the progressive phase of 
pulmonary fibrosis.  As alternatively activated macrophages are believed to have pro-
fibrotic potential I wished to establish whether it is the alternatively activated 
macrophage phenotype that characterises this lung macrophage fibrosis-promoting 
effect. 
 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. on day 0 with or without 
liposomal clodronate (100µl) i.t. on day 21, and culled on day 25.  qPCR was performed 
on lung homogenates for markers of alternative macrophage activation.  As shown in 
Figure 4.8, A and B, depletion of lung macrophages leads to a reduction in gene 
expression of characteristic markers of alternative macrophage activation, Ym1 and 
Arginase1, respectively.  Interestingly, the gene expression of iNOS, the prototypical 
marker of classical macrophage activation, is not affected by bleomycin administration 
and is not significantly reduced by lung macrophage depletion (Figure 4.8C).  This data 
suggests that it may be the alternatively activated lung macrophage that regulates the 
progressive phase of lung fibrosis.  However it is clear that more work is required to 
provide more concrete evidence of this. 
 
Having established a possible effect at the RNA level, I wished to establish whether this 
effect was also seen at the protein level.  Female C57Bl/6 mice were given 0.033mg 
bleomycin i.t. on day 0, with or without liposomal clodronate (100µl) i.t. on either day 
21 or day 28, and culled on day 32.  Immunocytochemistry on BAL fluid cells 
demonstrates that following bleomycin administration, lung macrophages exhibit 
variable levels of protein expression of Ym1 (Figure 4.8D).  Quantitative 
immunohistochemical analysis on lung sections demonstrated a reduction in Ym1 
protein expression following lung macrophage depletion (Figure 4.8, E, F, G and H).  
Moreover, in an independent experiment female C57Bl/6 mice were given 0.033mg 
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bleomycin i.t. on day 0, with or without liposomal clodronate (100µl) i.t. on day 21 and 
culled on day 22.  An arginase activity assay was performed on lung homogenates.  
Following lung macrophage depletion there was a reduction in arginase activity as 
shown in Figure 4.8I in keeping with the qPCR results.  Standard curves for the qPCR 
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Figure 4.8 
Alternatively activated macrophages characterise the progressive fibrotic phase of 
pulmonary fibrosis in mice 
Female C57Bl/6 mice were given bleomycin i.t. (50µl).  Liposomal clodronate (LC) was 
given i.t. (100µl) on either day 21 or day 28.  0.9% saline and liposomal PBS (LPBS) 
were given i.t. as controls.  qPCR was performed on lung homogenates (A)-(C).  
Immunocytochemistry (ICC) was performed on cytospins from bronchoalveolar lavage 
fluid (BALF) (D).  Immunohistochemistry (IHC) was performed on lung sections (E)-
(H).  Arginase activity was performed on lung homogenates (I).  (A)Ym1 gene 
expression is reduced following lung macrophage depletion (bleomycin alone vs. 
bleomycin, B, plus LC on day 21, *p=0.0246).  (B) Arginase1 (Arg1) gene expression is 
reduced following lung macrophage depletion (bleomycin alone vs. B plus LC on day 
21, p=ns, trend to reduction).  (C) iNOS gene expression is not affected following lung 
macrophage depletion.  (D), (F) Lung macrophages from bleomycin treated mice stain 
for Ym1.  (E) Ym1 expressing lung macrophages are reduced following lung 
macrophage depletion (bleomycin alone vs. B plus LC on day 21, p=0.071, trend to 
reduction; or day 28, *p=0.0233).  (G)-(H) Ym1-positive lung macrophages in 
bleomycin treated mice are absent following lung macrophage depletion.  Female 
C57Bl/6 mice were given 0.033mg bleomycin i.t. plus LC (100µl) i.t. on day 21 (G) or 
day 28 (H) and culled on day32.  (I) Arginase activity is reduced following lung 
macrophage depletion (bleomycin alone vs. B plus LC on day 21, *p=0.0367).  (J)-(L) 
Representative standard curves used in qPCR analysis are shown for (J) Ym1, 
bleomycin treated lung, (K) Arg1, bleomycin treated lung, (L) iNOS, bleomycin treated 
lung.  (A)-(C) n=4-5, (D)-(H) n=6-15, (I) n=4-5. Data are presented as mean +/- SEM.  







Alternatively activated lung macrophages are present in patients with IPF.   
Having suggested that alternatively activated lung macrophages are important during the 
progressive phase of fibrosis in a murine model of pulmonary fibrosis I wished to 
establish whether alternatively activated macrophages are present in human disease. 
 
Cytospins were created from BALF from healthy volunteers and patients with IPF.  The 
slides were stained by immunocytochemistry for the human marker of alternative 
macrophage activation, CD163 (Mantovani et al., 2002; Moestrup et al., 2004; 
Tiemessen et al., 2007).  As shown in Figure 4.9, A and B, CD163 is not expressed on 
lung macrophages from elderly healthy volunteers but is up-regulated on lung 
macrophages from patients with IPF, Figure 4.9, E-H.  This further suggests that the 
alternatively activated macrophage may be important during lung fibrogenesis.  Clinical 
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Figure 4.9 
Alternatively activated lung macrophages are present in patients with IPF.   
Cytospins were created from bronchoalveolar lavage fluid from elderly healthy 
volunteers (A)-(B) and patients with idiopathic pulmonary fibrosis (IPF) (C)-(H).  (A)-
(B) CD163 is not expressed on lung macrophages from elderly healthy volunteers.  (C)-
(E) Cytospins from an individual patient with IPF stained with (C) secondary antibody 
only, (D) isotype control and (E) CD163.  (E)-(H) CD163 is expressed on lung 



















Table 2.  Clinical details of patients with IPF. 
¶Brackets for baseline pulmonary functions tests (PFTs) are predicted values.  *Brackets for 
subsequent PFTs are % change from baseline values. 
 
                                                   Patient  
         1           2             3            4 
               Age           65             50               79             77 
      Date of 1
st
 HRCT    22/06/07      09/08/07       07/11/07       11/10/07 
       Baseline FEV1    1.7 (1.73)¶ 2.79 (3.76)      1.94 (2.13)      2.89 (2.62) 
       Baseline VC     2.3 (2.09)        3.3 (4.67)       2.38 (2.85)      3.18 (3.48) 
   Baseline FEV1/VC        73.9%           84.5%           81.5%          90.0% 
        Baseline TLco    1.92 (6.39)        5 (10.56)        4.65 (6.6)       4.06 (7.84)¶ 
       VC at 6 months 2.25 (-2.2%)*    2.72 (-17.6%)      2.35 (-1.3%)     3.3 (+3.8%) 
   TLco at 6 months   1.86 (-3.1%)    4.58 (-8.4%)      4.45 (-4.3%)      4.3 (+5.9%) 
      VC at 12 months   2.28 (-0.9%)    2.66 (-19.4%)       2.2 (-7.6%)      2.9 (-8.8%) 
    TLco at 12 months  2.11 (+9.9%)     4.36 (-12.8%)      4.21 (-9.5%)   3.35 (-17.5%)* 
           BALF date      08/10/09      10/09/09         01/10/09        03/09/09 
      BALF volumes      3x18ml       3x20ml          3x18ml               - 
BALF total cell counts      13x10
6
        32x10
6
          17x10
6
           38x10
6
 
  Cell differentials (%)  
                   Macrophages           61.5            75.5                62             88.5 
                   Neutrophils 31.5             9.5                24               10 
                   Eosinophils            4.5             3.5                 9               0.5 
                   Lymphocytes 2.5            11.5                 5                 1 
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Intra-tracheal administration of bone-marrow derived macrophages subsequent to 
lung macrophage depletion does not affect fibrosis progression 
I have demonstrated that lung macrophages are required for development of fibrosis 
during the progressive fibrotic phase of bleomycin- and AdTGFβ- induced pulmonary 
fibrosis.  My data also suggests that it is the alternatively activated pro-fibrotic 
macrophage that is responsible for this fibrosis-promoting effect.  As a consequence, I 
aimed to establish whether intra-tracheal administration of alternatively-activated bone-
marrow derived macrophages could “recover” pulmonary fibrosis subsequent to lung 
macrophage depletion.  In addition I aimed to see what effect, if any, would be obtained 
if classically-activated bone-marrow derived macrophages were used instead of 
alternatively activated ones. 
 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl) on day 0 and liposomal 
clodronate (100µl) i.t. on day 21.  Groups of mice were then given on day 22, either 
0.9% saline (50µl) i.t., alternatively activated bone-marrow derived macrophages (1x106 
in 50µl) i.t., classically activated bone-marrow derived macrophages (1x106 in 50µl) i.t., 
and culled on day 32.  As shown in Figure 4.10A, there was no difference in fibrosis 
between the groups as quantified by Sircol assay.  This lack of effect was corroborated 
by Masson’s trichrome staining on lung sections for all groups as shown in Figure 4.10, 
B-E.  The life-cycle of the macrophage is unclear.  As has already been discussed, 
alveolar macrophages may proliferate (Tarling et al., 1987), or they may be derived 
from circulating monocytes through a lung macrophage intermediate (Landsman & Jung 
2007).  With this in mind it may not be surprising that a bone-marrow derived 
macrophage is unable to behave in the same way as a bona fide lung macrophage, and 
this would explain why this “add-back” experiment did not “recover” fibrosis.  In 
addition, it is possible that having broken the cycle of macrophage-promoting fibrosis, 
addition of alternatively activated or classically activated macrophages to what is 
probably now a completely different molecular and cellular milieu is unable to alter the 
course of the disease process.  Furthermore, it is unclear whether cells given intra-
tracheally actually get to and engraft within the alveolar space.  It is possible that the 
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cells do not survive.  A further question is whether the number of cells are sufficient.  
However, I believe that 1x106 cells are probably within the range of cells required; this 
number having been chosen as a result of a previous study that showed an effect of cells 
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Intra-tracheal administration of bone-marrow derived macrophages subsequent to 
lung macrophage depletion does not affect fibrosis progression 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl) on day 0 and liposomal 
clodronate (100µl) i.t. on day 21.  In addition after a further 24 hours mice were given 
either 0.9% saline (50µl) i.t., alternatively activated bone-marrow derived macrophages 
(1x106 in 50µl i.t.) or classically activated bone-marrow derived macrophages (1x106 in 
50µl i.t.).  As a control, a group of mice was not given anything subsequent to i.t. 
liposomal clodronate.  All mice were culled on day 32.  Fibrosis was quantified by 
Sircol assay (A) and visualised by Masson’s trichrome staining on lung sections (B)-(E).  
(A) No differences in fibrosis were detected for any of the groups when compared to the 
bleomycin plus liposomal clodronate group.  This lack of effect was confirmed by 
Masson’s trichrome staining of lung section (B)-(E), where bleomycin, B, administration 
was followed by i.t. administration of (B) liposomal clodronate (LC) only, (C) liposomal 
clodronate (LC) plus alternatively activated bone-marrow derived macrophages (AM) 
(1x106 in 50µl i.t.), (D) liposomal clodronate (LC) plus classically activated bone  
marrow-derived macrophages (CM) (1x106 in 50µl i.t.) and (E) liposomal clodronate 













Lung macrophages create a matrix-promoting microenvironment within lung 
tissue 
The MMP/TIMP ratio is known to be critical for ensuring an appropriate wound healing 
response and for controlling lung morphostasis (Perez-Tamayo 1974).  Many MMPs 
have been investigated in the context of both bleomycin injury and in IPF.  Of particular 
interest are the gelatinases MMP2 and MMP9, collagenase 3 (MMP13), and their 
collective inhibitor TIMP1 (Swiderski et al., 1998; Perez-Ramos et al., 1999; Selman et 
al., 2000; Zuo et al, 2002; Atkinson & Senior 2003; Pardo & Selman 2006).  Within 
fibrotic lung tissue the predominant matrix components are the fibrillar collagens I and 
III (Kirk et al., 1984; Raghu et al., 1985; Quinones & Crouch 1986). 
 
I sought to determine the effects of alveolar macrophage depletion on TIMP and MMP 
gene expression and TIMP protein quantity, and specifically to establish whether any 
location specific differences exist.  To this end I firstly examined expression and protein 
quantity within lung tissue.  
 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. on day 0 followed by 
liposomal clodronate (100µl) i.t. on day 21.  Mice were culled on day 25.  As shown in 
Figure 4.11, A, B and C, depletion of lung macrophages leads to a reduction in TIMP1 
and MMP13 gene expression with no effect on MMP2 gene expression.  There is a 
suggestion in Figure 4.11D that the average protein quantity of TIMP1 in lung tissue, as 
determined by western blotting, is reduced following lung macrophage depletion as 
compared to non-depleted bleomycin controls.  This was not however formally 
quantified.  In addition, the GAPDH controls are not of a sufficient standard for firm 
conclusions to be drawn.  Standard curves for the qPCR analyses are shown in Figure 
4.11, E-G.  Overall, these results are consistent with the possibility that macrophages 
may create a matrix-promoting microenvironment within lung tissue.  Additional 
experiments that would have been performed, had time allowed, to add credibiltity to 
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Figure 4.11 
Lung macrophages create a matrix-promoting microenvironment within lung 
tissue 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl) +/- liposomal 
clodronate (LC) i.t. (100µl) on day 21 and culled on day 25.  qPCR (A)-(C) and western 
blotting (D) were performed on lung homogenates .  Following lung macrophage 
depletion there is (A) a significant reduction in TIMP1 gene expression (bleomycin 
alone vs. bleomycin, B, plus LC on day 21, *p=0.0381), (B) no effect on MMP2 gene 
expression (bleomycin alone vs. B plus LC on day 21, p=ns) and (C) a significant 
reduction in MMP13 gene expression (bleomycin alone vs. B plus LC on day 21, 
*p=0.0485). (D) Following lung macrophage depletion there is a suggestion that the 
average protein quantity is reduced compared to bleomycin positive controls.  
Representative standard curves used in qPCR analysis are shown for (E) TIMP1, 
bleomycin treated lung, (F) MMP2, bleomycin treated lung, (G) MMP13, bleomycin 

















Lung macrophages create a matrix-degrading microenvironment within the 
alveolar space 
Within the alveolar space the main structure composed of matrix is the basement 
membrane (BM).  The main component of BM is type IV collagen (Nerlich 1995) which 
is believed to be degraded by the gelatinases MMP2 and MMP9.   I wished to determine 
the effects of depletion of lung macrophages on TIMP and MMP gene expression within 
the alveolar space and to determine if there were any differences compared with the 
expression pattern seen in lung tissue. 
 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl) on day 0 followed by 
liposomal clodronate i.t. (100µl) on day 21.  Mice were culled on day 22, 
bronchoalveolar lavage performed, alveolar macrophages isolated, and qPCR performed 
on this selective cell population, or mice were culled on day 25 and lung protein quantity 
assessed by western blotting.  As shown in Figure 4.12, A and B, depletion of lung 
macrophages leads to an increase in TIMP1 expression and TIMP1 protein levels in the 
BALF.  It is interesting to note that the increase in TIMP1, bleomycin versus 0.9% 
saline, is much more dramatic at the protein level than at the gene level.  The reason for 
this is unclear.  It is possible that TIMP1 is produced and stored, ready for secretion at 
an appropriate time.  This could partially explain the differences; further work is 
required to prove this hypothesis.  Moreover, formal quantification of the western blot 
by densitometry could confirm what is currently a visual representation rather than a 
firm quantifiable difference.  As shown in Figure 4.12C, depletion of lung macrophages 
leads to a decrease in MMP2 expression in alveolar macrophages within the alveolar 
space.  These are opposite to the effects seen in lung tissue, and taken together suggests 
that location-specific differences may exist with regard to MMP/TIMP expression 
during the pathogenesis of lung fibrosis.  It is important to state that no controls were 
used (such as GAPDH) in the western blot of bronchoalveolar lavage fluid (BALF).  In 
performing western blots of lung tissue, an absolute and equivalent amount of protein 
(determined by BCA assay [Materials & Methods, Chapter 2, 2.17]) is added to each 
well.  As such the western blot effectively demonstrates the amount of protein present, 
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previously corrected per unit weight of lung tissue, and in that setting the addition of a 
GAPDH control is appropriate.  In BALF specimens, it is not possible to correct the 
protein present to the total protein in BALF.  As such a GAPDH control may not be 
appropriate and for this reason was not used.  To control the experiment as far as 
possible it is imperative that equal volumes of BALF are added to each well to minimise 
variability, and this was performed, but it must be recognised that western blots on 
BALF samples are inherently difficult to control, and as such caution must be used in 
interpreting results. 
 
Next I established that the expression of MMP9 at day 22 following bleomycin 
instillation was lower than that found in the non-injured, 0.9% saline controls (Figure 
4.12D).  Furthermore following lung macrophage depletion, gene expression levels of 
MMP9 returned to the levels seen with the 0.9% saline controls.  As this was a 
somewhat unexpected finding I went on to perform gelatin zymography of BALF.  This 
suggested similar findings; activity of MMP9 within the BALF appeared to decrease 
subsequent to bleomycin-induced pulmonary fibrosis, but returned to control levels 
following lung macrophage depletion (Figure 4.12E).  While the overall trend for this 
can be seen, it is obvious that there is variability within the lanes.  This limitation could 
have been overcome by repeating the zymogram and by using greater n numbers, and 
this would have been performed had time allowed.  It has previously been shown using 
the bleomycin model that transgenic mice over-expressing MMP9 in alveolar 
macrophages have less fibrosis compared with their littermate wild-type controls 
(Cabrera et al., 2007), suggesting that MMP9 expression by alveolar macrophages in the 
alveolar space has a “reparative” role with respect to lung fibrosis. This finding has 
parallels with my apparent result as I have suggested that MMP9 gene expression is 
increased during lung repair (bleomycin plus liposomal clodronate compared to 
bleomycin alone).  Interestingly a previous study showed that MMP9 knockout mice had 
similar levels of fibrosis but impaired bronchiolisation compared to wild-type in 
response to bleomycin (Betsuyaka et al., 2000), again suggesting a reparative role for 
MMP9 expression within the alveolar space.  This is contrast to MMP2 which is 
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damaging to the alveolar space as a result of BM degradation.   It makes logical and 
biological sense that the gelatinases (MMP2 and MMP9), in spite of having similar 
enzymatic activity, may have counter-regulatory and overlapping properties so as to 
allow for tissue homeostasis to be controlled at many levels, and ensure that the 
microenvironment may be modified appropriately in response to external stimuli. 
 
This is therefore, to my knowledge, the first demonstration of the possibility that 
location or compartmental specific effects of MMPs/TIMPs exist during lung fibrosis.  
Furthermore I suggest for the first time the possible differential effects exhibited by 
MMP2 and MMP9 within the alveolar space.  It is clear however that considerable work 
will be required before clear conclusions about these possibilities can be made.  
However, my work has suggested that there is an ever increasing complexity to the 
nature of MMP/TIMP biology, and that further new insights will undoubtedly produce 
exciting, and possibly surprising, results. 
 







































































































































Lung macrophages create a matrix-degrading microenvironment within the 
alveolar space 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl) +/- liposomal 
clodronate (LC) (100µl) i.t. on day 21 and culled on day 22 (qPCR) or day 25 (western 
blotting, gelatin zymography).  qPCR was performed on lysed alveolar macrophages 
(A), (C), (D).  Western blotting was performed on bronchoalveolar lavage fluid (BALF) 
(B).  Gelatin zymography was performed on BALF (E).  (A) Following lung 
macrophage depletion there is a significant increase in TIMP1 gene expression 
(bleomycin alone vs. bleomycin, B, plus LC on day 21, ***p<0.001).  This was 
confirmed by western blotting (B).  (C) Following lung macrophage depletion there is a 
trend to reduction in MMP2 gene expression (bleomycin alone vs. B plus LC on day 21, 
p=ns, trend to reduction).  (D) Following bleomycin administration there is a reduction 
in expression of MMP9 by alveolar macrophages, compared to 0.9% saline controls, 
which is restored following lung macrophage depletion (bleomycin alone vs. B plus LC 
on day 21, **p=0.0087). (E)  Following bleomycin administration there is a reduction in 
activity of MMP9 within the alveolar space, which returns to control levels following 
lung macrophage depletion.  Representative standard curves used in qPCR analysis are 
shown for (F) TIMP1, BALF macrophages from bleomycin treated mice, (G) MMP2, 
BALF macrophages from bleomycin treated mice, (H) MMP9, BALF macrophages from 
bleomycin treated mice.  (I) 18S, BALF macrophages from bleomycin treated mice.  
(A), (C), (D) n = 5 for each group except 0.9% saline which represents a pooled sample.  
(D) n = 3 per group.  (E) Bleomycin and B + LC day 21,    n = 4; 0.9% saline, n = 2.  










Using a validated murine model of lung fibrosis, the bleomycin model, interrogated by 
two lung macrophage depletional strategies, and backing up my findings with an 
independent second model, I have demonstrated that lung macrophages appear to be 
important for lung fibrogenesis and lung fibrosis resolution.  
 
As discussed previously, interest in the role of macrophages in lung fibrosis is not new.  
Several papers in the 1980s highlighted their potential importance (Rennard et al., 1981; 
Bitterman et al., 1983; Bitterman et al., 1984; Lacronique et al., 1984; Bitterman et al., 
1986; Rennard et al., 1988; Nagaoka et al., 1990).  However research in this area has not 
progressed, in part as a consequence of the lack of benefit of corticosteroids in treating 
fibrotic lung diseases (Turner-Warwick et al., 1980b).  Investigation into the 
pathogenesis of pulmonary fibrosis has focussed on the aberrant wound healing model 
(Selman et al., 2001; Selman & Pardo 2006).  Importantly, it has been demonstrated that 
corticosteroids actually induce alternative activation of macrophages (Gratchev et al., 
2001; Gratchev et al., 2005), and a recent study has suggested that alternatively 
activated macrophages may regulate myofibroblasts in vitro (Prasse et al., 2006).  In 
addition, corticosteroids have previously been shown to induce lung fibroblast 
proliferation (Warshamana et al., 1998) through up-regulation of the PDGF-α receptor.  
I have discussed previously that PDGF is up-regulated in alveolar macrophages of 
patients with IPF (Nagaoka et al., 1990), as mentioned above alternatively activated 
macrophages regulate myofibroblasts in vitro (Prasse et al., 2006).  Several other papers 
have suggested the potential importance of macrophages (Mora et al., 2006; Prasse et 
al., 2006; Okuma et al., 2004).  My study is the first to thoroughly investigate the role of 
macrophages in pulmonary fibrosis. 
 
Previous studies have attempted to ascertain the role of macrophages in lung fibrosis but 
they have all used models that have methodological concern (Zhang-Hoover et al., 2000; 
Misson et al., 2004; Bem et al., 2008).  The study by Bem and colleagues (Bem et al., 
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2008) looked at the effect of depleting lung macrophages, also using liposomal 
clodronate, during a lung injury protocol.  This study showed that depletion of lung 
macrophages, prior to the initiation of lung injury protocol, did not prevent Fas-mediated 
lung injury in mice.  The Fas-mediated lung injury model has been used as a model of 
lung fibrosis (Matute-Bello et al., 2007).  It is produced by administration of the Fas-
activating antibody Jo2, which induces apoptosis of alveolar epithelial cells and 
consequent fibrosis.  Importantly, fibrosis only occurs after long-term administration of 
Jo2 (Matute-Bello et al., 2007). Short term administration induces lung injury 
characterised by inflammation, not fibrosis (Matute-Bello et al., 2007).  The study by 
Bem and colleagues used short-term administration and therefore is not a model of lung 
fibrosis per se.  They showed that depletion of resident lung macrophages pre-
administration of the Jo2 antibody had no effect on lung injury as shown by lung 
histology.  In fact their histological analysis of lungs actually showed a worsening of 
lung injury.  Furthermore, it is questionable whether depletion of lung macrophages pre-
administration of the fibrosis-inducing agent has any relevance to the role of lung 
macrophages during injury.  The study by Zhang-Hoover and colleagues (Zhang-Hoover 
et al., 2000) analysed the effect of depleting lung macrophages in a model of hapten 
immune pulmonary interstitial fibrosis induced by a recall cell-mediated immune 
response against the hapten 2,4,6-trinitrobenzene sulphonic acid (TNBS) in the lung.  
This model has not been well characterised, and it is questionable whether it is a model 
of lung fibrosis per se and as such no comparisons can be made with my own study nor 
with IPF.  The study by Misson and colleagues (Misson et al., 2004) did not find any 
relationship between macrophage activation state and the promotion of lung fibrosis.  
However, in their study they used silica to induce lung fibrosis.  It is known that silica is 
toxic to macrophages, so any effect that macrophages may have during lung fibrogenesis 
would have been confounded by their model itself.  Furthermore, the granulomatous 
lesions produced by silica have a strong lymphocyte and mast cell component to their 
response, which probably has a strong immunogenic component, and as such limits the 
usefulness of silica as a model of lung fibrosis, particularly with regard to the 
investigation of macrophages. 
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Recent work by many groups has shown the heterogeneity that macrophages exhibit, 
culminating in an attempt to categorise macrophages into subtypes, or activation states, 
according to protein and RNA expression patterns, function, and the stimuli required to 
induce these activation states (Wynn et al., 2004; Gordon & Taylor 2005).  Borne out of 
this classification are alternatively activated macrophages.  As discussed previously, 
they have anti-inflammatory properties, but it is suggested that their major effects are 
likely to be in the control of wound healing and repair, and as a result alternatively 
activated macrophages may stimulate extra-cellular remodeling and fibrogenesis 
(Gordon 2003; Varin & Gordon 2009). 
 
I have shown that lung macrophages do not appear to be involved in the early 
inflammatory phase of bleomycin-induced lung fibrosis, but show using two 
independent macrophage depletional strategies that they are important during the 
subsequent progressive fibrotic phase.  Moreover I demonstrate the importance of lung 
macrophages in the adenoviral-TGFβ-mediated model of progressive lung fibrosis.  
TGFβ is widely recognized to be a “master” molecule during the development of lung 
fibrosis (Munger et al., 1999; Sheppard 2006) and the fact that lung macrophage 
modulation limits induced lung fibrosis emphasises their importance.  It is likely that by 
using the CD11c-DTR mouse there will be an inherent depletion of lung dendritic cells 
as well as lung macrophages.  However, it has been demonstrated that lung macrophages 
are the predominant CD11c+ cell type in the lung and within the alveolar space 
(Landsman & Jung 2007), and it has been shown that DT depletes interstitial and 
alveolar macrophages (Landsman & Jung 2007).  Furthermore, and as has already been 
discussed, the distinctions between macrophages and dendritic cells are becomingly 
increasingly blurred (Hume 2008) 
 
For the first time, I have assessed the importance of lung macrophages during the 
resolving phase of bleomycin-induced lung fibrosis; it is compelling that lung 
macrophages are required for the resolution of fibrosis.  This is in keeping with recent 
work which has shown that alveolar macrophages are involved in the removal of 
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accumulated collagen (Atabai et al., 2009).  This result is novel in two ways: I am not 
aware of any publications looking at the biology of the resolution phase of bleomycin-
induced pulmonary fibrosis, and secondly, I have not only demonstrated for the first 
time the important role that lung macrophages play in the progression of pulmonary 
fibrosis, I have also shown that they exhibit distinct and opposing effects during the 
resolution of pulmonary fibrosis.  This data is in keeping with the findings in 
experimental liver fibrosis where it has been established that macrophages promote liver 
fibrogenesis, but in contrast they also facilitate liver fibrosis resolution (Duffield et al., 
2005). 
  
My study demonstrates the novel finding that i.t. instillation of bleomycin induces up-
regulation of the alternative macrophage markers Ym1 and arginase1, and that following 
lung macrophage depletion, gene expression and protein levels are reduced for both of 
these markers.  Ym1 is an archetypal murine marker of alternatively activated 
macrophages (Raes et al., 2002).  The absolute function of Ym1, also called chitinase 3-
like protein 3, is uncertain.  Recent work, however, has suggested that it is a marker of 
oxidative stress, known to be important in the pathogenesis of lung fibrosis (Walters et 
al., 2008).  No human homologue has been identified as yet; however, YKL-40 (also 
called chitinase 3-like protein 1) is a member of the chitinase family of proteins.  
Circulating levels (Johansen et al., 1997; Johansen et al., 2000; Zheng et al., 2005) and 
liver tissue staining (Johansen et al., 2000) of YKL-40 have been found to be elevated in 
patients with liver fibrosis and it has  recently been proposed that it has a role in tissue 
remodeling and fibrosis (Lee & Elias 2010).  Arginase1 is another characteristic marker 
of alternative macrophage activation.  It is necessary for the conversion of L-arginine to 
L-ornithine.  L-ornithine is subsequently converted to proline which is required for the 
formation of collagen (Gordon 2003).  As such arginase1 has been implicated in wound 
healing, repair and fibrogenesis.  Importantly arginase1 is known to be up-regulated in 
patients with IPF (Mora et al., 2006).   
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I have demonstrated that alternatively activated lung macrophages are present in patients 
with IPF.  This lends support to my suggestion that the alternatively activated 
macrophage phenotype is important for lung fibrogenesis.  It is important to note some 
limitations of this work.  I have shown that depletion of macrophages leads to 
amelioration of lung fibrosis, and that this is associated with a reduction in alternative 
macrophage markers.  I have not shown directly that alternatively activated 
macrophages are depleted per se.  Furthermore, I have not looked specifically at the 
quantitites or proportions of macrophages subtypes during lung fibrogenesis, and as a 
result have not categorically delineated the overriding macrophage phenotype present 
during lung fibrogenesis.  It may be argued that if macrophages are effectively depleted, 
and a major resultant effect is reduction in alternative macrophage markers (as opposed 
to classically activated macrophage markers), that alternatively activated macrophages 
are most likely the predominant macrophage subtype; however, absolute confirmation of 
this would undoubtedly add extra credibility to my assertions.  A further limitation is 
that this work has not taken specific account of the other cell types present and their 
possible effects.  However, the specific aims of this thesis were to assess the role of 
macrophages during lung fibrogenesis, which I believe I have gone some way to 
addressing.  The role of other “immune-type” cells is obviously of paramount 
importance, and requires proper investigation, but was not able to be properly assessed 
within the limitations of this thesis.  What is important to say, particularly in the context 
of bleomycin-induced lung fibrosis, is that monocytes and macrophages become the 
predominant infiltrating cell as the disease progresses through to the fibrotic stage 
(Izbicki et al., 2002; Higashiyama et al., 2007). 
 
The potential importance of location-specific functions of matrix metalloproteinases 
(MMPs) and their inhibitor, tissue inhibitor of matrix metalloproteinases (TIMP1) has 
recently been highlighted (Pardo et al., 2008).  TIMP1 is known to be up-regulated in 
bleomycin induced pulmonary fibrosis (Swiderski et al., 1998; Madtes et al., 2001); a 
finding replicated by myself.  I sought to identify whether lung macrophages promote 
lung fibrosis by mechanisms that rely on compartmental specific expression and 
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function of MMPs and their inhibitor.  I demonstrate that this appears to be true, as 
depletion of lung macrophages results in a reduction in TIMP1 gene expression within 
lung tissue, but an increase (in gene expression and protein) in the alveolar space.  
MMP2 is primarily active against type IV collagen, the major constituent of basement 
membrane (BM), and has a weak ability to degrade interstitial fibrillar collagens (types I 
and III) (Aimes et al., 1995; Patterson et al., 2001).  It is up-regulated early in bleomycin 
induced pulmonary fibrosis and it has been postulated that MMP2 production may 
disrupt the BM and aid in the progression of bleomycin induced pulmonary fibrosis 
(Swiderski et al., 1998) and IPF (Pardo & Selman 2006).  I found no change in MMP2 
gene expression following lung macrophage depletion in lung tissue, albeit at a later 
time-point than that evaluated by Swiderski and colleagues.  However, as TIMP1 gene 
expression was reduced, the MMP/TIMP1 balance favoured matrix degradation 
following lung macrophage depletion. However, within the alveolar space, where 
MMP2 possibly mediates its major effects during lung fibrosis due to its predilection for 
collagen type IV, I found a reduction in MMP2 gene expression, findings in keeping 
with the hypothesis that MMPs and TIMP1 have location-specific functions during 
pulmonary fibrosis.  MMP13 (collagenase 3) has a similar structure and enzymatic 
properties to MMP1 (collagenase 1, human collagenase) but has been shown, like 
TIMP1, to be up-regulated in fibroblasts in response to TGFβ (Uria et al., 1998).  
Furthermore, MMP13 has been shown to be up-regulated in a murine model of lung 
fibrosis induced by asbestosis (Shukla et al., 2006) and in models of liver fibrosis 
(Uchinami et al., 2006; Fallowfield et al., 2007).  I show that MMP13 gene expression is 
reduced following lung macrophage depletion, in keeping with lung macrophages 
producing a matrix-promoting micro-environment within lung tissue during lung 
fibrosis. The role of MMP9 in pulmonary fibrosis is more complicated.  Studies have 
shown that MMP9 gene expression is up-regulated in tissues of patients with IPF (Zuo et 
al., 2002).  Furthermore immunoreactive studies have shown that MMP9 is active on 
alveolar, but not interstitial macrophages (Selman et al., 2000).  This combined with the 
fact that MMP9 has activity against collagen type IV, the major component of BM, lead 
investigators to speculate that MMP9 is involved in the pathogenesis of IPF through its 
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ability to degrade BM.  However, MMP9 knockout mice do not exhibit reduced fibrosis 
in response to bleomycin, but instead exhibit impaired bronchiolisation (Betsuyaku et 
al., 2000).  Alveolar bronchiolisation is the appearance of terminal airway-like epithelial 
cells in areas of injured alveoli.  This phenomenon can be seen in response to many 
types of alveolar injury, and is believed to be a sign of terminal airway epithelial cell 
migration to these areas of injury and not a defect in alveolar epithelial cell 
differentiation.  With this in mind it has been proposed that MMP9 plays a role in 
epithelial repair and not in alveolar fibrosis (Atkinson & Senior 2003).  Indeed a recent 
study in which transgenic mice over-expressing MMP9 in alveolar macrophages were 
exposed to bleomycin showed that these mice had less fibrosis compared to wild-type 
(Cabrera et al., 2007), supporting a potential role for alveolar-macrophage-produced-
MMP9 in facilitating BM repair, rather than degradation.  Furthermore, in patients with 
cryptogenic organising pneumonia (COP), a condition with considerable reversibility, 
the MMP9/TIMP1 ratio in BALF is considerably higher than in patients with IPF (Choi 
et al., 2002).  I show that gene expression of MMP9 in alveolar macrophages is reduced 
in the late phase of bleomycin-induced pulmonary fibrosis, but returns to baseline levels 
following liposomal clodronate administration.  This effect was confirmed by gelatin 
zymography for MMP9, and adds support to the proposal that MMP9 plays a protective 
rather than injurious role within the alveolar space in response to fibrotic lung injury.  
Taken together, I have shown for the first time the opposing effects that gelatinases may 
exhibit within the alveolar space in response to fibrotic lung injury.  These novel 
findings highlight the increasing complexity of control and function of MMPs/TIMPs in 
lung tissue and within the alveolar space in response to fibrotic lung injury, and may 
require that we re-evaluate our understanding of MMP and TIMP biology. 
 
Aside from the effects on MMP/TIMP biology, it is tempting and important to speculate 
on other mechanisms by which macrophages may promote fibrogenesis and facilitate 
lung fibrosis resolution.  During lung fibrogenesis I anticipate that macrophages release 
soluble factors that are important for both myofibroblast survival and epithelial 
activation.  The paper by Prasse and colleagues demonstrated that culture supernatants 
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of alveolar macrophages from patients with IPF increased collagen production by 
normal lung fibroblasts partly mediated via CCL18, a marker of alternative macrophage 
activation (Prasse et al., 2006).   
 
Another candidate soluble factor is IGF-1.  Secretion of IGF-1 by alternatively activated 
macrophages protects myofibroblasts from apoptosis (Wynes et al., 2004).  It is well 
established that both lung tissue and BAL levels of IGF-1 are increased in patients with 
IPF, as well as bleomycin-induced pulmonary fibrosis (Rom et al., 1988; Homma et al., 
1995; Maeda et al., 1996; Moestrup & Møller 2004).  In a study of lung biopsy samples 
from patients with IPF it was found that there was a correlation between IGF-1 
expression by interstitial lung macrophages and parameters of disease severity (Uh et 
al., 1998).  Furthermore antibody blockade of the murine IGF-1 receptor during the 
inflammatory and fibrotic phases, or initiated part-way through and onwards from the 
inflammatory phase of the bleomycin-induced lung fibrosis model improves outcome 
and decreases fibrosis (Choi et al., 2009). 
 
The importance of TGFβ as a master regulator of fibrosis is well described (Sheppard 
2006).  It has been demonstrated that alveolar macrophages from patients with IPF, but 
not from normal patients, secrete active TGFβ and are likely to be its major source 
(Khalil et al., 1989).  In addition it has been proposed that TGFβ may induce epithelial 
to mesenchymal transition in patients with IPF (Willis et al., 2005).  Interestingly a 
study of patients with IPF using in situ hybridisation demonstrated that TGFβ1 mRNA 
was present in macrophages adjacent to fibroblastic foci, but that the foci themselves 
showed no signal for TGFβ1 mRNA (Broekelmann et al., 1991).   
 
I would speculate therefore that in patients with IPF the initial insult results from 
interactions between not only epithelia and fibroblasts, but through a much more 
complicated and concerted interplay between macrophages, epithelium and 
fibroblasts/myofibroblasts.  I propose that once the fibroblastic focus has been set up as 
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the driver of matrix production, the macrophages continue to surround and feed this 
cellular hotspot with a variety of soluble mediators and engage in cell-cell interaction. 
 
 In summary therefore I have demonstrated for the first time in vivo that alternatively 
activated lung macrophages are required for lung fibrogenesis in a murine model of lung 
fibrosis and are present in the human form of the disease.  I do not believe my findings 
detract from prevailing hypotheses regarding the pathogenesis of pulmonary fibrosis but 
believe they add a further layer of complexity.  My finding of decreased resolution of 
pulmonary fibrosis subsequent to lung macrophage depletion is an intriguing one.  I 
believe it will open up a new dimension in lung fibrosis biology and suggests a potential 
therapeutic strategy of macrophage-mediated fibrosis resolution.  Further work will need 
to be performed to complete the knowledge of the role of lung macrophages in fibrotic 
lung disease, both during progression and resolution.  New insights into pathogenesis 
will allow new approaches to be adopted, enabling new therapies to be produced.  With 
the rapidly increasing research into monocyte/macrophage based cell therapy, 
therapeutic manipulation of the activation state of alveolar and interstitial macrophages 




















As there has been much controversy regarding the role of lung macrophages in 
pulmonary fibrosis it is no surprise that there has been little interest in the role of 
circulating monocytes, the precursors of tissue macrophages, in the pathogenesis of 
pulmonary fibrosis.  Using in vivo depletional strategies and adoptive transfer techniques 
I have demonstrated for the first time the important role that circulating monocytes have 
in the development of pulmonary fibrosis.  I have identified the Ly6C
hi
 monocyte as the 
subtype responsible for the fibrosis-promoting effect.  Recent work suggests that these 
cells may have an “alternatively activated” phenotype, and in keeping with this I have 
demonstrated that Ly6C
hi
 monocyte depletion leads to a reduction in gene and protein 
expression of markers of alternative activation within lung tissue.  By defining a new 
cell type of significant importance to the development of pulmonary fibrosis, I envisage 
that this work will enable new targets to be produced and hopefully allow for effective 















Pulmonary fibrosis has already been described as a devastating disorder for which there 
are no effective therapies.  The only treatment option that has been cited as life-
prolonging is lung transplantation, but as the majority of patients are over 60 by the time 
that they develop this lung condition then it is not surprising that very few patients with 
pulmonary fibrosis actually get assessed for lung transplant.  In addition 50% patients on 
the transplant list are still waiting for a transplant 1 year after being placed on the list 
(Transplant activity in the UK 2007-2008) and as the median survival of IPF is 
approximately 3 years (Bjoraker et al., 1998) then it is not surprising that patients with 
IPF have the highest rate of death amongst patients awaiting a lung transplant 
(Hosenpud et al., 1998).  In fact, as a means of trying to avert this occurrence, patients in 
the USA with IPF are given a three month waiting advantage over patients with 
emphysema (Dark 1998).  As such it is imperative that attempts are made to better 
understand the natural history and pathogenesis of pulmonary fibrosis to allow new 
therapies to be developed. 
 
With the advent of cell therapy, it has become appealing to attempt to identify cell types 
involved in the development of disease with the ultimate aim of manipulating cellular 
function to alter disease outcomes.  In this thesis I have hypothesised that lung 
macrophages play a role in the promotion of pulmonary fibrosis.  As bone-marrow and 
circulating monocytes are believed to be the precursors of tissue macrophages (Hunter et 
al., 2009), then it would seem logical to attempt to define the monocytes that may be the 
precursors of these tissue fibrosis-promoting macrophages.   
 
In the last few years there has been an expansion in the knowledge of blood monocyte 
origin and differentiation.  Currently there are believed to be two major types of 














, respectively (Geissmann et al., 2003).  It has long been suggested that there is a 
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monocyte subset termed the “inflammatory” monocyte (van Furth et al., 1973), and it is 
becoming increasingly clear that the Ly6Chi marker defines this population of cells 
(Gordon & Taylor 2005). 
 
I set out to establish whether depletion of circulating monocytes would have any effect 
on pulmonary fibrosis as illustrated using the bleomycin and AdTGFβ models.  I 
demonstrate that depletion of circulating monocytes leads to a reduction in pulmonary 
fibrosis in both these models.  I establish that it is the Ly6C
hi
 population of cells that is 
depleted in experiments where there is a reduction in fibrosis, and show that adoptive 
transfer of these cells leads to a worsening of fibrosis using the bleomycin model.  
Finally, I demonstrate that depletion of circulating monocytes leads to a reduction in the 
expression of markers of alternatively activated macrophages within the lung tissue, and 
as such suggest that Ly6Chi monocytes may represent the precursors of lung tissue 




















Bleomycin time course 
I have already demonstrated in chapters 3 and 4 that fibrosis peaks around 28 (to 32) 
days in the bleomycin model and around 14 days in the AdTGFβ model.  In addition I 
have shown that at 18 days there is early fibrosis.  These findings are summarised in 
Figure 5.1, A-D.  Interestingly, there is a significant increase in peri-vascular collagen 
deposition at 28 days in mice treated with bleomycin, compared to mice treated with 
bleomycin and culled at 18 days, or mice treated with 0.9% saline (Figure 5.1, D, C and 
B, respectively), which in itself as an observation suggests that the circulation may be a 




























































Female C57Bl/6 mice were given 0.033mg bleomycin intra-tracheally (i.t., 50µl) and 
culled on day 18 or 28.  0.9% saline was given i.t. (50µl) as a control.  Fibrosis was 
measured by Sircol assay (A), or visualised by Masson’s trichrome staining of 
representative lung sections (B)-(D).  (A) Mice were given 0.9% saline or bleomycin by 
i.t. instillation, culled during early lung fibrosis (day 18) or progressive fibrosis (day 28) 
and lung collagen assessed.  Significant differences in lung collagen were found between 
0.9% saline-treated and bleomycin-treated groups at both 18 days (**, p=0.0051) and 28 
days (***, p<0.001).  (B) Masson’s trichrome stain, 0.9% saline-treated mice, culled on 
day 18.  (C) Masson’s trichrome stain, bleomycin-treated mice, culled on day 18. (D) 




















Circulating monocytes are not necessary for the inflammation initiation of fibrosis 
To assess the role of circulating monocytes during the inflammatory phase of 
bleomycin-induced lung fibrosis, I administered a single i.t. instillation of 0.033mg 
bleomycin and culled mice after 18 days.  Liposomal clodronate (400µl) was given 
intra-peritoneally (i.p.) to deplete circulating monocytes on three consecutive days, 
either days 2, 3, 4 or 6, 7, 8 or 10, 11, 12 or 14, 15, 16.  As controls, bleomycin alone or 
0.9% saline (50µl) were given i.t. on day 0 and mice culled on day 18.  As shown in 
Figure 5.2A, depletion of circulating monocytes has no effect on the inflammatory phase 
and early induction of lung fibrosis as measured by Sircol assay.  This lack of effect was 
confirmed by Masson’s trichrome staining on lung sections as can be seen in 
























































Bleomycin B + LC day 2,3,4 




Circulating monocytes are not necessary for the inflammation initiation of fibrosis 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl) and culled on day 18.  
In addition to bleomycin, groups of mice were also given liposomal clodronate by intra-
peritoneal injection (i.p.) (400µl) on three consecutive days at various stages post-
bleomycin instillation.  All mice were culled on day 18.  Fibrosis was measured by 
Sircol assay.  0.9% saline (50µl) was given i.t. as a control and mice culled on day 18.  
(A) A significant difference in fibrosis was found between bleomycin and control (0.9% 
saline vs. bleomycin, **p=0.0051), but there were no differences, compared with 
bleomycin positive control (B), when liposomal clodronate (LC) was given in 
combination with bleomycin.  (B)-(G) Masson’s trichrome staining on representative 
lung sections of mice treated with: (B) 0.9% saline alone, (C) Bleomycin alone, (D) 
Bleomycin plus LC i.p. on days 2,3,4.  (E) Bleomycin plus LC i.p. on days 6,7,8. (F) 
Bleomycin plus LC i.p. on days 10,11,12.  (G) Bleomycin plus LC i.p. on days 14,15,16.  

















Depletion of circulating monocytes during the inflammatory phase of bleomycin-
induced pulmonary fibrosis has no effect on subsequent pulmonary fibrosis  
To assess whether circulating monocytes present during the inflammatory phase of 
bleomycin-induced lung fibrosis play in a role in the subsequent development of 
pulmonary fibrosis, I administered a single i.t. instillation of 0.033mg bleomycin and 
culled mice after 28 days.  Liposomal clodronate (400µl) was given intra-peritoneally 
(i.p.) on three consecutive days, 13, 14 and 15.  As shown in Figure 5.3A, depletion of 
circulating monocytes during the inflammatory phase of bleomycin-induced pulmonary 
fibrosis has no effect on the subsequent development of pulmonary fibrosis, as measured 
by Sircol assay.  This lack of effect was confirmed by Masson’s trichrome staining on 

























































Depletion of circulating monocytes during the inflammatory phase of bleomycin-
induced pulmonary fibrosis has no effect on subsequent pulmonary fibrosis  
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl).  In addition to 
bleomycin, a group of mice were also given liposomal clodronate (LC) intra-peritoneally 
(i.p.) (400µl) on three consecutive days: 13, 14 and 15.  All mice were culled on day 28.  
Fibrosis was measured by Sircol assay.  (A) No difference in fibrosis was found 
following circulating monocyte depletion (bleomycin vs. bleomycin, B, plus LC on days 
13, 14, 15, p=ns).  (B) and (C) Masson’s trichrome staining on representative lung 
sections of mice treated with: (B) bleomycin alone or (C) bleomycin plus LC i.p. on 





















Liposomal clodronate preferentially depletes “inflammatory” circulating 
monocytes 
Administration of liposomal clodronate is a well established method of selectively and 
effectively depleting circulating monocytes (van Rooijen & Sanders 1994; Getts et al., 
2008; Jaiswal et al., 2009).  Female C57Bl/6 mice were given 0.033mg bleomycin i.t. 
(50µl), liposomal clodronate by intra-peritoneal (i.p.) injection (400µl) on days 21, 22 
and 23, and culled on day 24 or day 28.  Control groups of mice were given 0.033mg 
bleomycin i.t. (50µl) and culled on day 24 or day 28.  Using flow cytometric analysis of 
mouse whole blood I have demonstrated that 24 hours after the final injection of 
liposomal clodronate there is depletion of circulating monocytes, as defined by dual 
CD11b and CD115 positivity (Figure 5.4, A, B and C).  After a further 96 hours levels 
of circulating monocytes are returning to control levels (Figure 5.4, A, D and E).   
 
As discussed in the introduction, populations of mouse monocytes have recently been 




 (Gordon & Taylor, 2005).  
The Ly6Clo group has been further classified as Ly6Clo, CX3CR1hi, CCR2-, 7/4mid.  They 
may play a role in patrolling non-inflamed tissues and differentiate into tissue-resident 
macrophages (Geissmann et al., 2003; Taylor et al., 2003; Auffray et al., 2007; Westcott 
et al., 2009).  The Ly6C
hi









.  They are also termed “inflammatory” monocytes as they appear to be 
preferentially recruited to sites of tissue inflammation (Taylor et al., 2003; Gordon & 




 monocytes, I 
demonstrate that liposomal clodronate preferentially depletes the 7/4
hi
 “inflammatory” 
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Liposomal clodronate preferentially depletes “inflammatory” circulating 
monocytes 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl).  In addition to 
bleomycin, groups of mice were also given liposomal clodronate (LC) intra-peritoneally 
(i.p.) (400µl) on days 21, 22 and 23.  Mice were culled on day 24 or day 28.  Single cell 
suspensions were produced from mouse whole blood and analysed by flow cytometry 
(A)-(E).  (A)-(C) Monocytes are significantly depleted 24 hours after the final injection 
of liposomal clodronate (bleomycin, B, cull day 24 (A), (B) vs. bleomycin, B, plus LC 
on days 21, 22, 23, cull on day 24 (A), (C)).  (A), (D) and (E) A further 96 hours later 
monocyte levels are almost back to control levels (bleomycin, B, cull day 28 (A), (D) vs. 





 monocytes (F)-(H).  There is complete depletion of 7/4
hi
 
“inflammatory” monocytes (F)-(H) (bleomycin, B, cull day 24 (F), (G) vs. bleomycin, 
B, plus LC on days 21, 22, 23, cull on day 24 (F), (H)) and a relative increase in 7/4
mid 
















Systemic depletion of circulating monocytes reduces the proportion of lung 
macrophages 
Having established that systemic administration of liposomal clodronate depletes 
circulating monocytes, I wished to establish the effect on the lung macrophage 
population.  To address this question, female C57Bl/6 mice were given 0.033mg 
bleomycin i.t. (50µl), liposomal clodronate by intra-peritoneal (i.p.) injection (400µl) on 
days 21, 22 and 23, and culled on day 24 or day 28.  Control groups of mice were given 
0.033mg bleomycin i.t. (50µl) and culled on day 24 or day 28.  Using flow cytometric 
analysis of mouse whole lung digests I demonstrate that 24 hours after the final injection 
of liposomal clodronate there is a reduction in the proportion of lung macrophages as 
defined by dual CD11c and CD11b positivity, Figure 5.5, A, B and C.  This can be seen 
visually in cytospins created from lung digests, Figure 5.5, F and G.  After a further 96 
hours the proportion of lung macrophages have almost returned to those of control 
(Figure 5.5, A, D and E).  Again this can be seen visually in cytospins created from lung 
digests, as shown in Figure 5.5, H and I. 
 
As discussed previously, the F4/80 antigen is a macrophage-restricted marker. As further 
confirmation of lung macrophage reduction following circulating monocyte depletion, I 
performed F4/80 immunohistochemistry on lung sections of mice treated as follows:  
female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl), liposomal clodronate 
by intra-peritoneal (i.p.) injection (400µl) on days 21, 22 and 23, and culled on day 25.  
A control group of mice were given 0.033mg bleomycin i.t. (50µl) and culled on day 25.  
As demonstrated in Figure 5.5, J, lung macrophages stain with F4/80 25 days after 
bleomycin instillation.  When in addition liposomal clodronate is given i.p. (400µl) on 
days 21, 22 and 23, there is a significant reduction in lung fibrosis and in the degree of 
F4/80 staining (Figure 5.5K).  As shown in Figure 5.5, L-O, there is no staining when an 
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Systemic depletion of circulating monocytes reduces the proportion of lung 
macrophages 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl).  In addition to 
bleomycin, groups of mice were also given liposomal clodronate (LC) intra-peritoneally 
(i.p.) (400µl) on days 21, 22 and 23.  Mice were culled on day 24 (A)-(C), (F), (G), day 
25 (J)-(O) or day 28 (A), (D), (E), (H), (I).  Single cell suspensions were produced from 
mouse whole lung digests and analysed by flow cytometry (A)-(E), or cytospins created 
(F)-(I).  Immunohistochemistry was performed lung sections (J)-(O).  (A)-(C), (F), (G) 
There is a reduction in the proportion of lung macrophages 24 hours after the final 
injection of liposomal clodronate (Bleomycin, B, cull day 24 (A), (B), (F) vs. bleomycin, 
B, plus LC on days 21, 22, 23, cull on day 24 (A), (C), (G)).  A further 96 hours later the 
proportion of lung macrophages are almost back to those of control (bleomycin, B, cull 
day 28 (A), (D), (H) vs. bleomycin, B, plus LC on days 21, 22, 23, cull on day 28 (A), 
(E), (I)).  (J)-(K) Lung macrophages, as identified by F4/80 staining, are reduced 
following circulating monocyte depletion.  (L)-(M) There is no staining in mice treated 
with bleomycin +/- liposomal clodronate when an isotype control is used instead of the 
F4/80 primary antibody.  (N)-(O) There is no staining in mice treated with bleomycin +/- 
liposomal clodronate when a no primary control is used instead of the F4/80 primary 
antibody.  (A)-(I) n=3 per group, (J)-(O) n=5 per group.  Data are presented as mean +/- 










Systemic depletion of circulating monocytes reduces the proportion of 
bronchoalveolar lavage fluid macrophages 
Having established thus far that systemic administration of liposomal clodronate causes 
depletion of circulating monocytes and leads to a reduction in the proportion of lung 
macrophages, I wished to establish whether depletion of circulating monocytes had any 
effect on the proportion of macrophages in the BALF.  As a result, female C57Bl/6 mice 
were given 0.033mg bleomycin i.t. (50µl), liposomal clodronate by intra-peritoneal (i.p.) 
injection (400µl) on days 21, 22 and 23, and culled on day 24 or day 28.  Control groups 
of mice were given 0.033mg bleomycin i.t. (50µl) and culled on day 24 or day 28.  
Using flow cytometric analysis of bronchoalveolar lavage fluid I demonstrate that 24 
hours after the final injection of liposomal clodronate there is a reduction in the 
proportion of BALF macrophages as defined by dual CD11c and CD11b positivity, 
Figure 5.6, A, B and C.  This can be seen visually in cytospins created from BALF, 
Figure 5.6, F and G, where there is a reduction in the proportion of “foamy” 
macrophages and an increase in mononuclear cells (macrophages and lymphocytes) 
following liposomal clodronate administration.  After a further 96 hours the proportion 
of BALF macrophages have almost returned to those of control (Figure 5.6, A, D and E).  
Again this can be seen visually in cytospins created from BALF as shown in Figure 5.6, 
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Systemic depletion of circulating monocytes reduces the proportion of 
bronchoalveolar lavage fluid macrophages 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl).  In addition to 
bleomycin, groups of mice were also given liposomal clodronate (LC) intra-peritoneally 
(i.p.) (400µl) on days 21, 22 and 23.  Mice were culled on day 24 (A)-(C), (F), (G), or 
day 28 (A), (D), (E), (H), (I).  Single cell suspensions were produced from mouse 
bronchoalveolar lavage fluid (BALF) and analysed by flow cytometry (A)-(E), or 
cytospins created (F)-(I).  (A)-(C), (F), (G) There is a reduction in the proportion of 
BALF macrophages 24 hours after the final injection of liposomal clodronate 
(Bleomycin, B, cull day 24 (A), (B), (F) vs. bleomycin, B, plus LC on days 21, 22, 23, 
cull on day 24 (A), (C), (G)).  A further 96 hours later the proportion of BALF 
macrophages are almost back to those of control (bleomycin, B, cull day 28 (A), (D), 
(H) vs. bleomycin, B, plus LC on days 21, 22, 23, cull on day 28 (A), (E), (I)).  n=3 per 

















Circulating monocytes regulate the progressive fibrotic phase of pulmonary 
fibrosis in the bleomycin model    
Next I wished to evaluate the role of circulating monocytes during the progressive phase 
of pulmonary fibrosis (day 18 onwards).  In our bleomycin model, fibrosis peaks around 
28-32 days (Chapter 3, Figure 3.2, A and G, and Figure 3.5, A, B and G).  Consequently, 
female C57Bl/6 mice were given 0.033mg bleomycin i.t. on day 0 and culled on day 28 
or day 32.  Circulating monocytes were depleted by giving liposomal clodronate (400µl) 
by i.p. injection on days 21, 22 and 23.  As shown in Figure 5.7, A and B, depletion of 
circulating monocytes significantly reduces the degree of pulmonary fibrosis that 
develops as measured by Sircol assay, when mice are culled on either day 28 (Figure 
5.7A) or day 32 (Figure 5.7B).  This reduction in fibrosis is confirmed when lung 
sections are stained by Masson’s trichrome, as shown in Figure 5.7, C, D and E, where 
mice were given 0.9% saline and culled on day 28 (Figure 5.7C), bleomycin alone and 
culled on day 28 (Figure 5.7D) or bleomycin plus liposomal clodronate i.p. on days 21, 
22 and 23 and culled on day 28 (Figure 5.7E).  Furthermore, qPCR performed on lung 
homogenates 25 days after bleomycin instillation demonstrated a reduction in expression 
of the surrogate markers of fibrosis α-smooth muscle actin (α-SMA) and Col1A1 after 
depletion of circulating monocytes (on days 21, 22 and 23) (Figure 5.7, F and G, 
respectively).  Standard curves for the qPCR analyses are shown in Figure 5.7, H-J. 
 
To ensure that this result was mediated by circulating monocyte depletion per se rather 
than being a liposomal effect, I set up an independent experiment where female C57Bl/6 
mice were given 0.033mg bleomycin i.t. alone or 0.033mg bleomycin i.t. on day 0 plus 
liposomal phosphate-buffered saline (LP) i.p. (400µl) on days 21, 22 and 23 and culled 
on day 32.  As shown in Figure 5.7, K, there is in fact a trend to worsening of pulmonary 
fibrosis, as measured by Sircol assay, following liposomal PBS injection.  Masson’s 
trichrome staining of lung sections (Figure 5.7, L and M) demonstrates that there is 
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Circulating monocytes regulate the progressive fibrotic phase of pulmonary 
fibrosis in the bleomycin model  
 Depletion of circulating monocytes ameliorates lung fibrosis.  Female C57Bl/6 mice 
were given 0.033mg bleomycin i.t. (50µl) +/- liposomal clodronate (400µl) by intra-
peritoneal (i.p.) injection on days 21, 22 and 23 and culled on day 28 (A), (D), (E), day 
32 (B), or day 25 (F), (G).  0.9% saline was given i.t. (50µl) as a control and mice culled 
on day 28 (C).  Bleomycin 0.033mg (50µl) +/- liposomal PBS (LP) i.p. (400µl) on days 
21, 22 and 23 were administered to female C57Bl/6 mice in an independent experiment 
(K)-(M) as a further control, and mice culled on day 32.  (A), (B) Mice were given 0.9% 
saline, bleomycin alone, or bleomycin, B, plus liposomal clodronate i.p. (400µl) during 
progressive fibrosis and culled at peak lung fibrosis (day 28, (A) or day 32 (B)).  
Depletion of circulating monocytes reduces lung fibrosis as measured by Sircol assay 
(bleomycin, B, alone vs. bleomycin plus liposomal clodronate (LC) on days 21, 22, 23, 
cull day 28 (A), *p=0.0185; bleomycin, B, vs. bleomycin, B, plus LC on days 21, 22 and 
23, cull day 32 (B), *p=0.0052).  (C)-(E) Masson’s trichrome staining on representative 
lung sections of mice treated with 0.9% saline (C),    bleomycin alone (D) or bleomycin 
plus LC on days 21, 22 and 23 (E).  (F) and (G) Female C57Bl/6 mice were given 
bleomycin 0.033mg (50µl) i.t. +/- LC i.p. (400µl) on days 21, 22 and 23 and culled on 
day 25.  qPCR was performed on lung homogenates.  (F) Depletion of circulating 
monocytes leads to a reduction in α-SMA gene expression, p=ns.  (G) Depletion of 
circulating monocytes leads to a reduction in Col1A1 gene expression, p=ns.  
Representative standard curves used in qPCR analysis are shown for (H) αSMA, 
bleomycin treated lung, (I) Col1A1, bleomycin treated lung, and (J) 18S, bleomycin 
treated lung.  (K)-(M) Female C57Bl/6 mice were given 0.033mg bleomycin i.t.(50µl) 
alone, or bleomycin, B, plus liposomal PBS (LP) i.p. (400µl) on days 21, 22 and 23 and 
culled on day 32.  (K) Administration of bleomycin plus liposomal PBS does not reduce 
fibrosis as measured by Sircol assay, but leads to a trend in worsening of pulmonary 
fibrosis.  (L)-(M) Masson’s trichrome staining on representative lung sections of mice 
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treated with bleomycin alone (L) or bleomycin, B, plus liposomal PBS (LP) (days 21, 22 
and 23) (M).  (A), (C), (D), (E) n=4-5, (B) n=6-8.  (F)-(G) n=4-5.  (K)-(M) n=5  Data are 





























Circulating monocytes regulate the progressive fibrotic phase of pulmonary 
fibrosis in the AdTGFβ model    
Having established that circulating monocytes regulate the progressive fibrotic phase of 
bleomycin-induced pulmonary fibrosis, I wished to back up our findings using a second 
model.  As a result I next sought to determine the effect of depletion of circulating 
monocytes during the progressive phase of fibrosis in the AdTGFβ model.  As discussed 
earlier, previous work using this model in mice has established that peak fibrosis occurs 
at around 14 days (Warshamana et al., 2002).  Our dose finding study (Chapter 3, Figure 
3.6B) identified 1x108 pfu of AdTGFβ (50µl) as the optimal dose that could be given to 
induce significant lung fibrosis without causing undue harm.  As a result female 
C57Bl/6 mice were given 1x10
8
 pfu (50µl) of AdTGFβ (AdT) i.t. on day 0 and culled on 
day 14.  In addition mice were given liposomal clodronate (LC) (400µl) i.p. or liposomal 
phosphate-buffered saline (LP) (400µl) i.p. on days 9, 10 and 11.  Empty adenoviral 
vector (AdDL70-3, 1x10
8
 pfu (50µl)) was given i.t. as a control and did not induce 
fibrosis (Figure 5.8, A and B).  Depletion of circulating monocytes leads to a reduction 
in pulmonary fibrosis as measured by Sircol assay (Figure 5.8A).  This was confirmed 
by Masson’s trichrome staining of lung sections as can be seen in representative images 
shown in Figure 5.8, C and D.  Administration of liposomal control (liposomal PBS, LP) 
instead of liposomal clodronate did not reduce pulmonary fibrosis as measured by Sircol 
assay (Figure 5.8A).  In fact there was a suggestion of a worsening of pulmonary fibrosis 
when lung sections stained by Masson’s trichrome were visualised (Figure 5.8E).  
Furthermore, qPCR performed on lung homogenates demonstrated a significant 
reduction in expression of the surrogate marker of fibrosis Col1A1 (Figure 5.8F).  There 
was a non-significant reduction in another surrogate marker of fibrosis, α-smooth muscle 
actin (α-SMA) (Figure 5.8G), after depletion of circulating monocytes (on days 9, 10 
and 11).  Representative standard curves for the qPCR analyses are shown in Figure 5.8, 
H and I. 
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These results back up our findings in the bleomycin model and add further evidence that 
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Circulating monocytes regulate the progressive phase of pulmonary fibrosis in the 
AdTGFβ model    
Depletion of circulating monocytes ameliorates lung fibrosis in the AdTGFβ model.  
Female C57Bl/6 mice were given 1x10
8
 pfu of AdTGFβ i.t. (50µl) and fibrosis 
quantified by Sircol assay (A).  AdDL70-3 (1x10
8
 pfu/50µl) was given as a control.  
Masson’s trichrome staining was performed on lung sections (B)-(E).  qPCR was 
performed on lung homogenates (F)-(G).  (A) Mice were given AdDL70-3, AdTGFβ 
alone, AdTGFβ (AdT) plus liposomal clodronate (LC) i.p. (400µl) on days 9, 10 and 11, 
or  AdTGFβ (AdT) plus liposomal PBS (LP) i.p. (400µl) on days 9, 10 and 11, and 
culled at peak lung fibrosis (day 14).  Depletion of circulating monocytes reduces lung 
fibrosis as measured by Sircol assay (AdTGFβ alone vs. AdT plus LC on days 9, 10 and 
11, **p=0.0091).  Administration of liposomal PBS as a control instead of liposomal 
clodronate does not reduce lung fibrosis.  (B) AdDL70-3 does not induce significant 
fibrosis at 14 days.  (C) AdTGFβ induces significant fibrosis by 14 days.  (D) Depletion 
of circulating monocytes ameliorates lung fibrosis.  (E) Administration of liposomal 
PBS does not reduce fibrosis.  (F) Depletion of circulating monocytes leads to a 
reduction in Col1A1 gene expression, p=ns.  (G) Depletion of circulating monocytes 
leads to a trend in reduction in α-SMA gene expression, p=ns.  Representative standard 
curves used in qPCR analysis are shown for (H) Col1A1, AdTGFβ treated lung, and (I) 
αSMA, AdTGFβ treated lung.  (A)-(E) n=5-7, (F)-(G) n=5-6.  Data are presented as 









Circulating monocyte depletion using the CD11b-DTR system does not regulate the 
progressive phase of pulmonary fibrosis in the bleomycin model    
So far in this chapter I have used liposomal clodronate to deplete circulating monocytes.  
I wished to establish whether use of another depletional strategy would have the same 
effect.  The CD11b-DTR transgenic mouse was generated as a means of studying 
macrophage function in vivo (Cailhier et al., 2005; Duffield et al., 2005).  It relies on the 
fact that the mouse diphtheria toxin (DT) receptor (DTR) binds DT poorly (Naglich et 
al., 1992).  A construct was generated in which the CD11b promoter was upstream of 
the DTR-eGFP fusion gene (Duffield et al., 2005).  Downstream of these elements was 
part of the human growth hormone gene, inserted specifically to provide the necessary 
splicing and poly-adenylation sequences.  CD11b is expressed on both macrophages and 
granulocytes, but DT administration to CD11b-DTR mice does not deplete granulocytes 
(Cailhier et al., 2005), possibly as a result of their lower levels of protein synthesis 
(Cailhier et al., 2005).  The CD11b-DTR transgenic system therefore allows for 
conditional and specific depletion of monocytes and macrophages.  The CD11b-DTR 
mice were kindly supplied by Dr Jeremy Hughes, MRC/University of Edinburgh Centre 
for Inflammation Research, Edinburgh. 
 
Female C57Bl/6 CD11b-DTR mice were given 0.033mg bleomycin i.t. (50µl).  In 
addition to this one group of mice was also given DT 10ng/g body weight i.p. on day 21.  
Mice were culled on day 28.  As demonstrated in Figure 5.9, A, B and C, depletion of 
circulating monocytes does not affect pulmonary fibrosis as quantified by Sircol assay 
(Figure 5.9A), or as visualised by Masson’s trichrome staining of lung sections (Figure 













































Circulating monocyte depletion using the CD11b-DTR system does not regulate the 
progressive phase of pulmonary fibrosis in the bleomycin model    
Female C57Bl/6 CD11b-DTR mice were given 0.033mg bleomycin i.t. (50µl) +/- DT 
i.p. (10ng/g body weight) on day 21.  All mice were culled on day 28.  Fibrosis was 
quantified by Sircol assay (A).  Masson’s trichrome staining was performed on lung 
sections (B)-(C).  (A) Depletion of circulating monocytes by DT has no effect on lung 
fibrosis as measured by Sircol assay (bleomycin alone vs. bleomycin plus DT on day 21, 
p=ns).  (B) and (C) Depletion of circulating monocytes by DT does no affect the degree 
of pulmonary fibrosis (bleomycin alone (B) vs. bleomycin plus DT on day 21 (C)).  (A)-





















Adoptive transfer of Ly6C
hi
 monocytes exacerbates pulmonary fibrosis in the 
bleomycin model 
Our earlier experiments have shown that liposomal clodronate administration i.p. 
preferentially depletes circulating “inflammatory” monocytes (Figure 5.4).  I wished to 
establish whether adoptive transfer of bone marrow Ly6C
hi
 “inflammatory” monocytes 
would have any effect on the degree of fibrosis in mice already treated with low-dose 
bleomycin.  Ly6C is expressed on both monocytes and granulocytes, whereas only 
granulocytes also express Ly6G (Tacke & Randolph 2006).  Female C57Bl/6 mice were 
given 0.0167mg bleomycin i.t. (50µl), 1x106 Ly6Chi monocytes by tail-vein injection on 
day 21 and culled on day 28.  Ly6Chi monocytes were purified from bone marrow using 
a BD FACS Aria II (Special order system).  As shown in Figure 5.10, live cells were 
sorted (A), Ly6G
+
 cells subsequently positively sorted to eliminate granulocytes (B), 
then Ly6Chi monocytes were sorted from this negatively sorted population (C).  As 
shown in Figure 5.10D, adoptive transfer of these Ly6C
hi
 monocytes exacerbates 
pulmonary fibrosis as quantified by Sircol assay, and as visualised by Masson’s 
trichrome staining of lung sections (Figure 5.10, E and F).  It is interesting to point out 
that there appears to be profound peri-vascular (as well as interstitial) fibrosis, as shown 
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Figure 5.10 
Adoptive transfer of Ly6C
hi
 monocytes exacerbates pulmonary fibrosis in the 
bleomycin model 
Female C57Bl/6 mice were given 0.0167mg bleomycin i.t. (50µl).  Ly6Chi cells were 
sorted from bone marrow; live cells were first gated (A) and Ly6G+ granulocytes 
positively excluded (B).  From the resulting negative fraction Ly6C
hi
 monocytes were 
positively sorted (C).  1x10
6
 cells were injected into the tail vein of mice on day 21.  A 
control group of mice were injected with media only into the tail vein on day 21.  All 
mice were culled on day 28.  Fibrosis was quantified by Sircol assay (D) and visualised 
by Masson’s trichrome staining on lung sections (E), (F).  (D) Mice injected with Ly6Chi 
monocytes have enhanced fibrosis when compared with control (bleomycin plus media 
vs. bleomycin, B, plus Ly6C
hi
 monocytes on day 21, *p=0.0304).  (E) and (F) Mice 
injected with Ly6Chi monocytes have more fibrosis, as visualised on Masson’s trichrome 
stained lung sections, than mice injected with media alone.  (D)-(F) n=6-8.  Data are 

















CX3CR1-null mice develop pulmonary fibrosis similar to wild-type 
The different monocyte populations in mice have already been described in detail.  

















 populations.  I have already established that the Ly6C
hi
 
population enhances pulmonary fibrosis in the bleomycin model.  I wished to establish 
whether CX3CR1-null mice had an altered lung fibrotic response to bleomycin.  These 
mice were kindly supplied by Professor Christopher Gregory, MRC/University of 
Edinburgh Centre for Inflammation Research, Edinburgh.  Female C57Bl/6 CX3CR1-
null mice were given 0.033mg bleomycin i.t. (50µl) and culled on day 32.  Wild-type 
littermates were used as a control.  There was no difference in fibrosis between the two 
groups, as measured by Sircol assay (Figure 5.11A).  In addition, there was no obvious 
difference in fibrosis as visualised by Masson’s trichrome staining of lung sections 
























































CX3CR1-null mice develop pulmonary fibrosis similar to wild-type 
Female C57Bl/6 CX3CR1-null mice and their wild-type (WT) littermates were given 
0.033mg bleomycin i.t. (50µl) and culled on day 32.  Fibrosis was quantified by Sircol 
assay (A).  Masson’s trichrome staining was performed on lung sections (B)-(C).  (A) 
CX3CR1-null mice develop pulmonary fibrosis to a similar degree to their wild-type 
littermates.  (B) and (C) No significant difference in fibrosis was observed when lung 
sections were stained by Masson’s trichrome; wild-type mice (B) compared with 























Alternatively activated macrophages characterise the progressive fibrotic phase of 
pulmonary fibrosis in mice  
I have demonstrated in chapter 4 that depletion of lung macrophages results in a 
reduction in markers of alternative macrophage activation at both the gene and protein 
level.  It has recently been shown that Ly6C
hi
 monocytes have increased expression of 
alternative macrophage markers in both mice (Ym1 [chitinase 3-like protein 3, Chi3l3]) 
and humans (CD163) (Ingersoll et al., 2010).  I have shown that CD163 is up-regulated 
on human alveolar macrophages in patients with IPF, and furthermore it has just been 
published that in patients with an exacerbation of IPF there is an increase in the number 
of CD14
+
 monocytes that express CD163 compared to healthy controls (Murray et al., 
2010). 
 
I wished to establish whether there was any correlation between depletion of (Ly6C
hi
) 
circulating monocytes and alternative macrophage activation state within the lungs.  
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. on day 0 with or without 
liposomal clodronate (400µl) i.p. on days 21, 22 and 23, and culled on day 28.  0.9% 
saline (50µl) was given i.t. as a control.  Quantitative immunohistochemical analysis on 
lung sections demonstrated a reduction in Ym1 protein expression following circulating 
monocyte depletion (Figure 5.12, A, B and C).  Isotype control and no primary control 
showed no positive staining in the context of bleomycin-induced lung fibrosis (Figure 
5.12, C and D). 
 
Having established an effect at the protein level, I wished to establish whether this effect 
was also seen at the RNA level.  Female C57Bl/6 mice were given 0.033mg bleomycin 
i.t. on day 0, with or without liposomal clodronate (400µl) i.p. on days 21, 22 and 23, 
and culled on day 25.  qPCR was performed on lung homogenates for markers of 
alternative macrophage activation.  As shown in Figure 5.12, F and G, depletion of 
circulating monocytes leads to a reduction in gene expression of characteristic markers 
of alternative macrophage activation, Ym1 and Arginase1, respectively.  Representative 
standard curves for the qPCR analyses are shown in Figure 5.12, H and I. This data 
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suggests that there is an association between Ly6C
hi
 monocytes and the development of 
an alternatively activated macrophage environment within the lung during the 



























































B + LC day 21, 22, 23 Bleomycin 










































Alternatively activated macrophages characterise the progressive fibrotic phase of 
pulmonary fibrosis in mice 
Female C57Bl/6 mice were given bleomycin i.t. (50µl).  Liposomal clodronate (LC) was 
given i.p. (400µl) on days 21, 22 and day 23.  Mice were culled on day 28 
(immunohistochemistry) or day 25 (qPCR).  0.9% saline was given i.t. as a control.  
Immunohistochemistry (IHC) was performed on lung sections (A)-(E).  qPCR was 
performed on lung homogenates (F)-(G).  (A)-(C) Ym1 expressing lung macrophages 
are reduced following circulating monocyte depletion (bleomycin alone (A), (B) vs. 
bleomycin, B, plus LC on days 21, 22 and 23, *p=0.0310 (A), (C)).  (D) There is no 
positive staining when an isotype control is used instead of primary antibody.  (E) There 
is no positive staining when a no primary control is used instead of primary antibody.   
(F) Ym1 gene expression is reduced following circulating monocyte depletion 
(bleomycin alone vs. bleomycin, B, plus LC on days 21, 22 and 23, p=ns).  (G) 
Arginase1 (Arg1) gene expression is reduced following circulating monocyte depletion 
(bleomycin alone vs. B plus LC on days 21, 22 and 23, p=ns).  Representative standard 
curves used in qPCR analysis are shown for (H) Ym1 and (I) Arg1.  (A)-(E) n=4-6, (F)-














Circulating monocytes contribute towards creating a matrix-promoting micro-
environment within lung tissue 
As discussed previously the MMP/TIMP ratio is known to be critical for ensuring an 
appropriate wound healing response and contributes significantly to promotion and 
resolution of pulmonary fibrosis.  I demonstrated in chapter 4 that lung macrophages 
create a matrix-promoting micro-environment in lung tissue. I wished to establish 
whether circulating monocytes contributed to the matrix micro-environment within lung 
tissue, and if so, what effects they have.   
 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. on day 0 followed by 
liposomal clodronate (400µl) i.p. on days 21, 22 and 23.  Mice were culled on day 25.  
As shown in Figure 5.13, A and B, depletion of circulating monocytes leads to a 
reduction in TIMP1 gene expression and an increase in MMP2 gene expression, creating 
a micro-environment favouring matrix degradation.  Representative standard curves for 
the qPCR analyses are shown in Figure 5.13, C and D.  This suggests that circulating 
monocytes contribute towards the creation of a micro-environment that favours matrix-
production within lung tissue during the progressive fibrotic phase of bleomycin-

















































Circulating monocytes contribute towards creating a matrix-promoting 
microenvironment within lung tissue 
Female C57Bl/6 mice were given 0.033mg bleomycin i.t. (50µl) +/- liposomal 
clodronate (LC) i.p. (400µl) on days 21, 22 and 23, and culled on day 25.  qPCR was 
performed on lung homogenates .  Following circulating monocyte depletion there is (A) 
a reduction in TIMP1 gene expression (bleomycin alone vs. bleomycin, B, plus LC on 
days 21, 22 and 23, p=ns), and (B) an increase in MMP2 gene expression (bleomycin 
alone vs. bleomycin, B, plus LC on days 21, 22 and 23, p=ns).  Representative standard 
curves used in qPCR analysis are shown for (C) TIMP1 and (D) MMP2.  n = 4-5 per 























Having previously shown that lung macrophages are important for the promotion of 
pulmonary fibrosis, I have now shown using two models that circulating monocytes are 
also important for the development of pulmonary fibrosis.  I have identified the Ly6C
hi
 
monocyte as the cell responsible for this effect, and I have data to suggest that these 
Ly6Chi monocytes are the precursors of the alternatively activated lung macrophages. 
 
As discussed previously, there has some been interest in the role of tissue macrophages 
in the pathogenesis of pulmonary fibrosis, but there has been little interest in the role of 
circulating monocytes.  I have already mentioned that  there have been two very recent 
reports suggesting the importance of circulating monocytes in the pathogenesis of 
pulmonary fibrosis, specifically in relation to IPF (Murray et al., 2010) and systemic 
sclerosis-related interstitial lung disease (Mathai et al., 2010). 
 
I have demonstrated that circulating monocytes are important for the development of 
pulmonary fibrosis and that their depletion leads to a reduction in the proportion of lung 
and BALF macrophages.  This suggests that during pulmonary fibrosis circulating 
monocytes may be the precursors of interstitial lung and BALF macrophages.  This is 
not surprising as it has been shown that circulating monocytes can be the precursors of 
lung and BALF macrophages (Landsman & Jung 2007).  This however is the first 
descriptive evidence that in the context of (bleomycin-induced) pulmonary fibrosis, this 
phenomenon may occur.  Furthermore, I go on to show that depletion of circulating 
monocytes leads to a reduction in gene expression and protein quantity of markers of 
alternative macrophage activation.  This indirectly implicates circulating monocytes as 
the precursors of alternatively activated lung macrophages, and ties in with our findings 
discussed in chapter 4.  Moreover, I have shown in chapter 4 that intra-tracheal 
instillation of alternatively activated bone marrow-derived macrophages subsequent to 
lung macrophage depletion did not restore the fibrotic phenotype.  This may reflect the 
fact that bone marrow-derived macrophages cannot replicate the effects of in situ 
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alternatively activated lung macrophages, or it might add further evidence to our 
suggestion that alternatively activated lung macrophages are indeed descended from 
circulating monocytes. 
 
Fibrocytes have been identified in the blood of mice and humans developing pulmonary 
fibrosis and have been implicated in their pathogenesis (Phillips et al., 2004; Andersson-
Sjöland et al., 2008; Mehrad et al., 2009; Moeller et al., 2009).  Furthermore, it has 














 monocyte cell population that was depleted by liposomal 
clodronate in our experiments.  It is also identical to the monocyte population of cells 
that I adoptively transferred into bleomycin-exposed mice with a consequent worsening 
of pulmonary fibrosis.  I have shown that CX3CR1-null mice do not display a difference 
in pulmonary fibrosis compared to wild-type.  Ly6C
hi
 monocytes are CX3CR1
lo
, and so 
this data complements our results implicating the Ly6C
hi 
monocyte as the promoter of 
pulmonary fibrosis.  Furthermore, it has been recently been published that this Ly6C
hi
 
(CD14+CD16- in humans) population of monocytes exhibit up-regulation of markers of 
alternative macrophage activation, Ym1 (chitinase 3-like protein 3) in mice and CD163 
in humans (Ingersoll et al., 2010).  My experiments show that depletion of Ly6C
hi
 
monocytes reduces the numbers of Ym1 positive macrophages in lung.  Moreover, in 
chapter 4 I demonstrated that CD163 is up-regulated on BALF macrophages from 
patients with IPF, but not in elderly healthy volunteers.  I may have therefore provided 
the first link between fibrocytes, Ly6C
hi
 monocytes, alternatively activated macrophages 
and pulmonary fibrosis.  It is interesting to note as previously discussed that 
corticosteroids actually induce the alternatively activated phenotype (Gratchev et al., 
2001; Gratchev et al., 2005), and this in part would explain the resistance of patients 
with IPF to corticosteroid therapy.  Our findings therefore bring together a whole host of 
experimental data from different sources, complemented by our own original data that 
hopefully clears up one of the long unanswered questions and highly contentious areas 
in pulmonary fibrosis research. 
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It is interesting to note that I demonstrated that depletion of circulating monocytes in the 
CD11b-DTR transgenic mouse did not result in reduced pulmonary fibrosis.  This may 
be explained by 2 factors.  Firstly, having worked with this transgenic mouse it is clear 
that depletion of monocytes may have significant effects on other tissues of the body, 
such as the monocytes patrolling the gastro-intestinal mucosa.  These mice become 
increasingly unwell as time progresses post-DT administration, and this may confound 
any effects produced by depletion of circulating monocytes per se, particularly where 
mice survive for many days beyond DT administration, as was the case in our studies.  
Secondly, recent unpublished work from our own group (Prakash Ramachandran, 
personal communication) appears to show that DT predominantly and preferentially 
depletes Ly6C
lo
 monocytes.  As such this would instantly explain why no reduction in 
fibrosis was seen using the CD11b-DTR mouse. 
 
I went on to examine the effects of depletion of circulating monocytes on MMP/TIMP 
gene expression within lung tissue.  Depletion of circulating monocytes lead to a 
reduction in TIMP1 gene expression and an increase in MMP2 gene expression.  These 
results are in keeping with those demonstrated by lung macrophage depletion, as 
highlighted in chapter 4, where depletion of monocytes/macrophages produces an 
MMP/TIMP ratio that favours lung tissue matrix degradation. 
 
In summary, I have shown the importance of circulating monocytes in the pathogenesis 
of pulmonary fibrosis.  I have identified the Ly6Chi monocyte as the promoter of 
pulmonary fibrosis and possibly the precursor of lung alternatively activated 
macrophages.  My data further highlights the importance of MMPs and their inhibitor, 
TIMP1, to the promotion and resolution of pulmonary fibrosis.  Finally, and most 
importantly, having provided a possible link between fibrocytes, Ly6C
hi
 monocytes, 
alternatively activated lung macrophages, pulmonary fibrosis and steroid resistance, I 
hope to have informed greater understanding of what remains a devastating and 
untreatable condition.  By doing so, I would hope that new targets are identified, 
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effective therapies produced, and some hope is brought back into the life of patients with 






























CONCLUDING REMARKS AND FUTURE STUDIES 
 
During this PhD thesis I have investigated the role of circulating monocytes and lung 
macrophages in the pathogenesis of pulmonary fibrosis.  I have demonstrated that they 
are not important for the inflammation initiation of fibrosis, and that their depletion 
during the inflammation stage has no effect on consequent pulmonary fibrosis in the 
bleomycin model.  However, I have established that circulating monocytes and lung 
macrophages are important during the progressive fibrotic phase of lung fibrogenesis, 
and that lung macrophages have important but opposite effects during lung fibrosis 
resolution.  I hypothesised that pro-fibrotic alternatively activated macrophages may be 
the key macrophages that promote fibrosis, and I have established that this indeed 
appears to be the case in mice, and that alternatively activated macrophages characterise 
the human form of disease.  Furthermore, my work has identified that Ly6C
hi
 circulating 
monocytes may be the precursors of alternatively activated lung macrophages, but even 
if they are not, they are important in the pathogenesis of lung fibrosis.  Finally, this work 
has suggested that matrix metalloproteinases may have compartmental-specific 
functions during lung fibrogenesis. 
 
It is important to state that there are obvious limitations of this work.  While the 
bleomycin and AdTGFβ models are undoubtedly the best models in which to study the 
molecular mechanisms of pulmonary fibrosis, there remains debate as to their direct 
applicability to the human forms of fibrotic lung disease.  While there are pulmonary 
conditions that undoubtedly progress through an inflammatory phase which may 
ultimately develop into fibrosis, such as fibrotic NSIP (Kligerman et al., 2009) and 
chronic hypersensitivity pneumonitis (Olson et al., 2008), the direct applicability of 
these models to IPF, per se, remains controversial (Gauldie & Kolb 2008).   
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The methods used to explore the roles of macrophages in pulmonary fibrosis have 
limitations in themselves.  There is no doubt that liposomal clodronate depletes lung 
macrophages (Thepen et al., 1989), and my work has shown that in the context of 
bleomycin-induced  lung fibrosis, macrophages are effectively depleted.  However, other 
off-target effects of liposomal clodronate in the context of bleomycin-induced, and 
AdTGFβ-induced pulmonary fibrosis are not established and could have confounding 
effects.  The specificity of the CD11c-DTR transgenic mouse in depleting macrophages 
has potential issues, particularly if one believes that CD11c-positive cells are dendritic 
cells.  However, CD11c is used to “define” both lung macrophages (Gordon & Taylor 
2005; van Rijt et al., 2005) and lung dendritic cells (Bar-On & Jung 2010), and as lung 
macrophages are the predominant cell type in the lungs (Landsman & Jung 2007), then it 
is more likely that the effect of CD11c cellular targetting is depletion of lung 
macrophages.  Importantly, however, I have shown consistent effects of “macrophage” 
depletion on lung fibrosis in different models, and using different depletional strategies, 
and it would seem less likely that in each case the outcomes are merely down to off-
target effects.  In any case, as has been previously mentioned, prominent macrophage 
biologists have suggested that dendritic cells and macrophages are in fact part of the 
same group of mononuclear phagocytic cells (Hume 2008), and that the distinctions are 
more blurred than has been previously been proposed.  What may become more 
important is not to argue about whether the effects are manifested by CD11c-positive 
macrophages versus CD11c-positive dendritic cells, but what subtype of CD11c-positive 
mononuclear phagocyte is important.     
 
I believe this work has expanded the knowledge and understanding of pulmonary 
fibrosis.  By identifying new key cellular players, it may enable new treatment strategies 
to be developed, either in the form of drugs or cellular manipulation.  However, it has 
also generated many interesting and exciting questions.  Importantly, I show that it is the 
modulation of “immune-type” cells, monocytes and macrophages, during fibrogenesis 
that effect the ultimate end-point of fibrosis.  While criticisms might remain about the 
applicability of models that have an inflammatory component, the potential strength of 
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this work is that the effects are manifested during the post-inflammatory fibrogenic 
phase, and  this does have potential translatability to the human diseases, such as IPF, if 
inflammation  (in its broadest sense) plays only a minor role in its disease pathogenesis.  
This then begs the question as to whether we should talk about inflammation, or whether 
we should be more specific and talk about “immune-type cells”.  I believe that this is 
where the potential translation of my work may exist.  Maybe we should be discussing 
the benefit of “immune-type” drugs that have specific cellular targets during particular 
phases of pulmonary fibrosis, rather than broadly discussing the benefits of generic 
“anti-inflammatory” drugs versus generic anti-fibrotic drugs.  I would suggest that my 
work informs the need to be clear in the forms of therapy that we use in treating 
“fibrotic” lung diseases, and that we need to be clear at what stages of disease we use 
particular generic anti-inflammatory drugs, specific “immune-type” cell modulatory 
drugs, and specific anti-fibrotic drugs.  My work raises the potential disheartening issue 
that steroids could have detrimental effects during fibrotic lung disease.  If steroids do in 
fact induce a pro-fibrotic alternative activation state in monocytes and macrophages, 
then it is conceivable that steroids will hasten any natural switch in 
monocytes/macrophages to a more pro-fibrotic phenotype, to the detriment of the 
patient.  At the practical level, clinicians still use steroids in fibrotic lung disease in an 
attempt to “eliminate” any underlying additional inflammation.  I think this raises 
several questions: 
 
1.) Should we continue to use steroids to dampen any pre-existing inflammation, 
while recognising and accepting that they may hasten fibrogenesis, and that 
therefore we need to use an additional “protective” agent in addition to an anti-
fibrotic agent? 
2.) Should we stop using steroids, but instead use more specific drugs which have 
specific effects on particular “immune-type” cells but no fibrosis-enhancing 
effects, in addition to an anti-fibrotic agent? 
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3.) How many drugs should we be using?  Should we adopt an “oncogenic” 
approach and use several drugs aimed at targeting the disease process at many 
levels? 
4.) Should we be phenotyping patients more rigorously so that we know what stage 
of their disease they are at so that specific drugs may be used best tailored to the 
stage of the disease, with the best predicted response to therapy and outcome? 
 
These are but a few questions that can be asked.  There are likely to be many more. 
 
In addition, it remains to be established how circulating monocytes and lung 
macrophages exert their effects.  I believe it will be important to perform in vitro co-
culture experiments to identify the interactions between macrophages and epithelial cells 
or fibroblasts/myofibroblasts, what soluble factors may enhance these interactions, and 
what, if any, signalling pathways direct the changes in cellular behaviour?  Many 
strategies could be employed to tease out the answers.  My supervisors are in the process 
of directing research into the interactions between macrophages and epithelial cells; the 
effect macrophage activation state has on the process, the importance of cell contact in 
these interactions, and what changes occur at the protein and RNA levels in each of the 
different cells?  A combination of targeted and broader-based interrogation techniques 
will likely be needed to gain some mechanistic insights. 
 
I have demonstrated that Ly6Chi monocytes are important in the pathogenesis of 
pulmonary fibrosis and suggested that they may be the precursors of alternatively 
activated lung macrophages.  Together with my supervisors we have instigated a series 
of experiments to ascertain whether this is the case.  By adoptively transferring bone 
marrow-derived Ly6C
hi
-sorted monocytes from CD45.1 mice to CD45.2 mice treated 
with intra-tracheal bleomycin, we should be able to identify whether this hypothesis is 
true, and the manner in which this occurs; does it occur through a Ly6C
lo
 intermediate or 
not?   
 
 228 
We don’t know whether the Ly6C
hi
 monocytes facilitate the switch of resident lung 
macrophages to the alternative activation macrophage phenotype, or whether they 
engraft and become these cells.  This is important therapeutically.  If we can target these 
influxing cells at the level of the blood then any therapy may be ostensibly easier.  If 
however the circulating monocytes facilitate a switch within resident lung macrophages 
then therapies that prevent Ly6C
hi
 infiltration to lung and effect alternatively activated 
lung macrophages will likely be more difficult.  It is important that these possibilities are 
explored, and that knowledge is informed, so that appropriate and effective therapies are 
designed with potential efficacy. 
 
Preliminary work with collaborators has suggested that CD204
+
 (macrophage scavenger 
receptor-1+) circulating monocytes may be up-regulated during pulmonary fibrosis in 
humans.  It has recently been shown that CD163
+
 monocytes are up-regulated in blood 
from patients with IPF (Murray et al., 2010), and my own work has shown that CD163 
characterises lung macrophages isolated from BALF of patients with IPF.  By further 
defining and phenotyping the circulating monocytes that are important during lung 
fibrogenesis, we may be better able to target important cell populations, and in the future 
even enable their manipulation.  Should we target them by blocking/depletion/facilitate 
apoptosis, or should we attempt to induce a switch away from pro-fibrotic.  These are 
some of the potential options that exist.  With further research, more necessary 
knowledge may be obtained, and inform directed therapeutic approaches.  It is possible 
that expansive and difficult experiments will need to be performed before this potential 
promise becomes a real possibility.    
 
My research has produced very preliminary data to suggest that matrix 
metalloproteinases may exhibit compartmental-specific functions during lung 
fibrogenesis.  Tissue-specific targeted approaches using a combination of molecular 
inhibitors or conditional knockouts may further advance understanding.  The potential 
differential effects of MMP2 and MMP9 needs to be investigated.  If my initial 
observations are true, do they reflect changes in secreted or cell-membrane bound 
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molecules?  If MMP9 does facilitate alveolar re-epithelialisation, how does it do so and 
what cells does it signal to?; is it the case that type II alveolar epithelial cells facilitate 
this renewal, or is it due to other local, nearby or circulating progenitor cells?  All of 
these questions are important and many approaches to answer these questions could be 
used.  It is important to highlight the limitations of the MMP/TIMP data.  This has 
already been touched on in previous chapters.  I have suggested that in the broad context 
of MMP/TIMP behaviour within the lung versus the alveolar space that compartmental 
differences may exist.  The data to suggest this is very provisional and needs firming up 
with further experiments.  The potential sources of the various MMPs/TIMP have not 
been explored.  Is it epithelia, macrophages, or possibly polymorphonuclear cells, such 
as neutrophils?  Not only from an understanding, but from a potential therapeutic point 
of view, the sources of the described MMPs and TIMP are important.  A previous study 
evaluated the clinical behaviour and survival of patients with IPF (Selman et al., 2007).  
Patients were classified as “‘rapid” or “‘slow” progressors according to the duration of 
symptoms before diagnosis. The “rapid” progressors did not have more BALF 
neutrophils or eosinophils than slow progressor, however, BALF from “rapid” 
progressors showed a 2-fold increase of active MMP9.  The possible role of neutrophils, 
eosinophils and other polymorphonuclear cells has not been addressed or discussed.  It is 
known for example that neutrophils (Veeraraghavan et al., 2003; Kinder et al., 2008) 
and eosinophils (Veeraraghavan et al., 2003) are increased in the BALF of patients with 
IPF.  The significance of this is unknown.  I have alluded to potential roles of other 
“immune-type” cells throughout the thesis; their specific roles and effects were not the 
subject of my thesis, and thus were not explored.  However it is clearly an area where 
research needs to be performed before a comprehensive understanding of the 
pathogenesis of fibrotic lung disease can be realised. 
 
Finally, my finding that lung macrophages facilitate resolution of lung fibrosis during 
the reversible phase is a tantalising one.  It leaves many unanswered questions.  It 
remains to be determined what phenotype of macrophage produces this effect.  Are they 
produced from local populations or are they recruited from the circulation?  What 
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interactions do they have and what is their mechanism of action?  Can we manipulate 
these “good” macrophages for positive effect and do they have a human counterpart?  A 
limitation of this finding is that in humans fibrosis does not appear to reverse, so where 
is the direct translatability?  Inflammation and organising pneumonia can reverse, but 
they are not indicative of fibrosis per se.  As a result, there will undoubtedly be a group 
of people who believe that my finding of macrophages regulating the reversible phase of 
fibrosis as of no direct applicability to humans.  Strictly speaking this is true.  However, 
if we can gain some mechanistic insight inot how macrophages may help facilitate 
fibrosis resolution in the mouse, then we may be able to design and produce therapies 
that can be studied in humans.  It may produce real promise.  There is no doubt that any 
translatability to humans is a long way off, but I believe that this is an area where 
research should be taken forward. 
 
In summary, my research has produced some answers and generated many questions.  I 
believe my research has enabled a better understanding of a devastating disease and I 
hope new efficacious therapies may be developed so that patients with fibrotic lung 
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